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Abstract
Chapter 1. Introduction to Non-Traditional Platinum Compounds for Improved
Uptake, Oral Bioavailability, and Tumor Targeting
The path to more potent platinum anticancer drugs with fewer side effects lies in the
exploration of non-traditional platinum compounds, which do not necessarily contain the
canonical ligand set of two labile leaving groups and two am(m)ine ligands. Cationic,
platinum(IV), and multinuclear complexes are considered. Advances in tumor targeting
using platinum complexes are also discussed.
Chapter 2. Structure-Activity Relationship for the Uptake of Platinum(ll)
Compounds by Human Organic Cation Transporters
Although the platinum-based anticancer drugs cisplatin, carboplatin, and oxaliplatin form
similar adducts on DNA, only oxaliplatin is active in colorectal cancer. Human organic
cation transporters hOCT1 and hOCT2 markedly increase oxaliplatin, but not cisplatin
or carboplatin, accumulation and potency in cells. These transporters are also present
in human colorectal cancers and are likely to play an important role in the efficacy of
oxaliplatin.
Chapter 3. Synthesis of Pt(llI) and Pt(IV) Compounds for Uptake by the Organic
Cation Transporters: Extension of Structure-Activity Relationships
A structure-activity relationship for the cellular accumulation of platinum compounds due
to the organic cation transporters was developed and extended to design cationic
compounds as particularly potent colorectal cancer drugs.
Chapter 4. Pyriplatin, cis-[Pt(NH3)2(pyridine)CI]CI, a Monofunctional, Cationic
Platinum(llI) Antitumor Agent
A cationic, monofunctional platinum(II) complex, cis-[Pt(NH3)2(py)CI]CI or pyriplatin, was
synthesized and found to be an excellent substrate for the human organic cation
transporters 1 and 2. Pyriplatin displays what appears to be a unique mechanism of
action in cancer cells. The repair of DNA damage induced by pyriplatin and the
inhibition of RNA polymerase II by pyriplatin-DNA adducts are implicated in the
mechanism.
Chapter 5. Characterization of the Role of HMGBI in Cellular Response to
Cisplatin
Cisplatin-DNA adducts are recognized by the nuclear protein and cytokine HMGB1. The
contribution of HMGB1 to the potency of cisplatin is explored in the presence of
androgens, retinoic acid, or under reducing conditions. HMGB1 binds more tightly to
cisplatin-DNA adducts in the presence of 10 mM DTT.
Chapter 6. Pre-Clinical Evaluation of Pyriplatin
Pyriplatin was evaluated in human cancer cell lines for the purpose of gathering
information for future Phase I trials. Pyriplatin has a unique cytotoxicity profile that is
distinct from that of either the "platinum dach" class of compounds or cisplatin. The
distinct profile suggests a significantly different mechanism of action than either
oxaliplatin or cisplatin. Pyriplatin is about 10-fold less potent than either oxaliplatin or
cisplatin. Although the compound shows synergy in combination with taxol or cisplatin in
vitro, the drug is unlikely to be developed clinically due to its low potency.
Chapter 7. Pre-Clinical Evaluation of Mitaplatin
Mitaplatin, c,c,t-[Pt(NH3)2C12(O2CCHC 2)2], was evaluated as a drug for potential Phase I
clinical trials. The cytotoxicity profile, cell cycle inhibition results, and potential predictive
factors (correlation of mRNA levels vs. IC50 values) suggest that mitaplatin acts very
similarly to cisplatin. The results are supported by a correlation factor of 0.719 between
the two compounds, found using the NClI's COMPARE algorithm. Although it is a
promising dual functional platform for the delivery of both cisplatin and dichloroacetic
acid, the results obtained closely resemble those for cisplatin and advantages of the
dichloroacetic acid delivery are not apparent in data collected in this work.
Appendix A. Examination of the Platination of Plasmid DNA in Carbonate Buffer
Appendix B. Cellular Properties of a Cell-Permeable Zn2+-Sensitive MRI Contrast
Agent and the Effect of Zinc Chelators on Cisplatin Cytotoxicity
Thesis Supervisor: Stephen J. Lippard
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Goals and Organization of the Thesis
The purpose of this thesis is to venture into a new area of research for the lab,
the investigation of cellular accumulation of platinum drugs and design of compounds
that will preferentially accumulate in cancer cells. Chapter one reviews some
considerations for producing cationic compounds, which are not traditionally used in
cancer treatment due to the difficulty of passing the lipophilic cell membrane. In chapter
two, a structure-activity relationship is developed for the design of platinum compounds
as substrates for the organic cation transporters. In chapter 3, the synthesis and
biochemical testing of compounds designed along this structure-activity relationship is
described, and extensive biochemical testing of one of the new compounds, pyriplatin is
presented in chapter 4. Chapter 6 and 7 describe preclinical testing of pyriplatin and
mitaplatin and study of these compounds in a 10-cell line panel.
The desire to produce platinum compounds that affect only cancer cells has also
led to investigations in an area of research that has also been the subject of past and
ongoing work in the Lippard lab. Cisplatin is a drug that is highly effective in testicular
cancer, but less effective in other cancer types. In chapter 5, we have identified
intracellular redox potential as a factor that could play a role in the variation in potency
of cisplatin across cell types. The nuclear protein and cytokine, HMGB1, can form a
disulfide bond under oxidizing cellular conditions, which reduces its affinity for DNA.
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Chapter 1
Introduction to Non-Traditional Platinum Compounds for Improved Uptake, Oral
Bioavailability and Tumor Targeting
I. Status of clinically useful platinum compounds
The first and most effective platinum-based drug is cisplatin, which is currently
sold in the United States as Platinol. Initially approved by the FDA in December 1978, it
is currently approved for use in bladder, non-small cell lung cancer, squamous cell
carcinoma of the head and neck, and advanced ovarian, .,cervical and testicular cancer.
Cisplatin is curative in nearly all cases of testicular cancer. In the three years prior to
generic entry in 1999, net annual sales of cisplatin ranged from $100 to $250 million for
Bristol-Myers Squibb.' Carboplatin (Chart 1.1), marketed as Paraplatin by Bristol-Myers
Squibb, was the second FDA-approved platinum-based drug and is approved for use in
advanced ovarian cancer and non-small cell lung cancer.2 Sales of carboplatin were
$769 million in 2003 and, like cisplatin, it is currently not patent protected.
H2  0
OPt Pt PtH3 N/  CI H3N 0O O H2 0Cisplatin Carboplatin Oxaliplatin
0
H3N\ O O 7 NH2 O (
H3N ' NH2  0 -
Nedaplatin Lobaplatin
Chart 1.1. Platinum compounds in clinical use.
One drug similar to both cisplatin and carboplatin, nedaplatin, is marketed in Japan.
Oxaliplatin, marketed as Eloxatin by Sanofi-Aventis, generated over $1.4 billion in sales
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in 2004. When combined with 5-fluorouracil, oxaliplatin is approved by the FDA for
treatment of stage III colon cancer and advanced colorectal cancer. Lobaplatin, which
has a structure similar to that of oxaliplatin, is marketed in China as a diastereomeric
mixture.
II. Mechanisms of action
The activity of platinum(ll) anticancer compounds lies in the reaction of the
platinum center with nuclear DNA. Aquation yields cationic, highly electrophilic species
that react with various nucleophiles in the cell, including amino acid sulfhydryl groups
and nitrogen donor atoms on nucleic acids.3 Reactions with sulfhydryl groups are
implicated in platinum resistance.4 Reactions with DNA, the most nucleophilic site of
which is in the major groove at the N7 position of guanine bases, are the crucial
anticancer interactions and induce major distortions in the DNA.5
The predominant lesion formed by both cisplatin and carboplatin is the 1,2-
d(GpG) intrastrand adduct. 6 7 This adduct, which has been structurally characterized on
dodecamer DNA by x-ray crystallography, locally unwinds the double helix by 250 and
both widens and flattens the minor groove.8 The GG lesion formed by oxaliplatin on
dodecamer DNA is very similar to that of cisplatin: both have similar helix bend angles
of about 300 and a hybrid A/B-DNA conformation. 9
The distortion of DNA induced by platinum lesions disrupts vital cellular
processes, such as replication and transcription, and elicits a cellular defense response.
The cell is capable of several responses to platinum-induced DNA damage. Four types
of pathways that assist the cell in managing DNA damage have been identified.10 DNA
can be repaired by one of several repair mechanisms, which restores the DNA to its
undamaged state. Secondly, the cell cycle can be arrested by activation of a DNA
damage checkpoint, a process that allows the cell time to repair the damage.
Additionally, changes in the transcription of genes in response to DNA damage can aid
cell survival. Finally, cells that have sustained significant damage undergo apoptosis, or
programmed cell death.
Damage that involves covalent modifications of DNA are processed by DNA
repair and recombination pathways. These pathways can be divided into five
categories: direct repair, base excision repair, nucleotide excision repair, double-
stranded break repair, and repair of interstrand cross-links. 10
Cell cycle arrest is triggered upon detection of DNA damage by damage sensors.
Among other proposed damage sensor proteins, RNA polymerase II (RNAP II) has
been identified as especially important.11' 1 2 The particular suitability of RNAP II as a
damage sensor is that it is not only highly specific, with the ternary RNAP II-RNA-DNA
complex found at sites of UV-induced thymine dimers having a half-life of -20 h, 13 but
also constantly transcribes the genome, except during cell division. The close
interaction of RNAP II with a large portion of the genome suggests that the protein can
act as an inspector of the genome, which allows for a rapid detection of and response to
DNA damage.
The downstream events that evolve following identification of DNA damage and
lead to cell cycle arrest are dependent on the damage type. Cisplatin damage results in
a delay of the cell cycle in S phase, eventually progressing to a block in G2 phase. 14 15
While the cell cycle is paused, changes in gene transcription that allow the cell to
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respond to DNA damage occur. Many genes that are involved in DNA repair are not
transcribed at a high level until DNA damage is detected. Upon detection of damage,
the transcription of genes associated with repair is increased and the capability of the
cell to repair damage is enhanced. 16 These changes include increased transcription of
genes associated with repair. Finally, if the cell fails to respond sufficiently, it succumbs
to the damage and apoptosis is triggered. Designing drugs that cause damage to DNA
but do not induce cancer cells to mount a checkpoint response or begin DNA repair is
crucial to the improvement of anticancer therapy.10
III. Nucleotide Excision Repair
Nucleotide excision repair (hereafter "excision repair") is the repair pathway by
which the major product of cisplatin-induced DNA damage, the intrastrand d(GpG)
lesion,6,7 is repaired. 7 DNA lesions formed by cisplatin are repaired by excision repair,
and cells in which this pathway is disrupted, such as in patients with xeroderma
pigmentosum, 18 are particularly sensitive to cisplatin damage.
The process of nucleotide excision repair begins with cellular recognition of
damage and formation of an open complex.19 An excision complex is then formed,
which involves the proteins RPA, XPA, XPG, and XPF/ERCC1, and a DNA fragment of
24 to 32 nucleotides (length dependent on species) is excised. 19 The structural details
of the protein-protein interaction between XPA to the ERCC1 subunit of the
XPF/ERCC1 complex show that only a small portion of XPA is involved in the
interaction.20
23
Excision repair of 1,2- and 1,3-intrastrand cisplatin cross-links in human tumors
results in oligomeric excision products of 27 to 29 nucleotides. 17 Conversely, interstrand
cisplatin-DNA cross-links produce no excision products.21
Much investigation has been based on the fact that the high mobility group box 1
protein (HMGB1) binds 1,2-intrastrand cross-links and blocks the nucleotide excision
repair of these adducts under in vivo conditions.17 21 HMGB1 is a highly abundant
protein that can be found associated with chromatin or in the cytosol acting- as a
cytokine (see section X, below). When associated with nuclear DNA, the protein
protects intrastrand 1,2-d(GpG) and 1,2-d(ApG) cisplatin-DNA lesions from repair, but
not the 1,3-d(GpTpG) adduct.2 1 The interaction of a testicular cell-specific high mobility
group protein with platinated DNA has also been of particular interest because of the
high efficacy of cisplatin in testicular cancer. Work on mouse testicular teratocarcinoma
extracts revealed deficient repair of 1,2-intrastrand cross-links, which was hypothesized
to be due to shielding of the adducts by tsHMG.22
Other proteins that interact with cisplatin-damaged DNA include the TATA-
binding protein, which also protects 1,2-intrastrand cross-links from repair in in vitro
assays.2 3 The tumor suppressor protein p53 also recognizes DNA with the cisplatin 1,2-
d(GpG) cross link, but not the 1,3-d(GpTpG), interstrand, or monofunctional adducts. 24
Poly(ADP-ribose) polymerase 1 (PARP-1), a protein that responds to DNA damage by
modifying other key proteins with poly(ADP-ribose), also has affinity to 1,2-d(GpG)
adducts.25 2 6 Additionally, the nucleosome has also been shown to inhibit nucleotide
excision repair of the major d(GpG) intrastrand cross-links by about 30%.27
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IV. Transcription Inhibition
After platinum compounds cross the cell membrane and form adducts with DNA,
the ultimate consequences of the DNA lesions are mediated by the proteins that first
arrive at the damaged site.2 8 In many cases, the damage is initially recognized and then
repaired by proteins involved in the nucleotide excision repair pathway.17 Other proteins
that may quickly appear at the adduct side include those capable of facilitating DNA
repair, interfering with DNA repair, or otherwise affecting the processing of damaged
DNA.2 8 Cellular processing of the adduct and the eventual fate of cancer cells depends
on the proteins that associate quickly with the newly damaged site.
One group of proteins that encounter cisplatin-DNA adducts soon after lesion
formation are the transcriptional factors. Unlike DNA polymerases, which briefly pause
at and then bypass cisplatin cross-links, presumably without major down-stream
effects,29-31 RNA polymerases are greatly affected by the presence of cisplatin adducts.
Transcription by the phage T7 RNA polymerase is strongly inhibited by both cisplatin
1,2-intrastrand cross-links and oxaliplatin 1,3-intrastrand cross-links.32 The progress of
human RNA polymerase II (Pol II) along the DNA strand is almost completely blocked
by platinum DNA adducts. 33 Furthermore, Pol II does not resume transcription after
stalling,33 and the stalled polymerase becomes ubiquitylated, triggering various signal
cascades in the cell.33 ,34 In particular, the arrest and ubiquitylation of Pol II is believed to
be involved in initiation of a repair pathway called transcription-coupled repair, which is
a subpathway of nucleotide excision repair.34 Investigations of proteins involved in
transcription will lead to a greater understanding of the mechanisms by which cells cope
with and become resistant to platinum-DNA adducts.
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V. Traditional structure-activity relationships
All five compounds in clinical use (Chart 1.1), conform to the structure-activity
relationship developed coincidently with the discovery of cisplatin.35 These compounds
are all neutral, platinum(ll) species with two am(m)ine ligands or one bidentate chelating
diamine, and two ligands that can be replaced by aquation reactions, eventually leading
to the formation of a bifunctional adduct on DNA.
As we learn more about cellular interactions with platinum compounds, the
canonical structure activity relationships that guide the design of new platinums must
constantly be revisited. Exciting areas of development in the platinum anticancer
community include insights on ways to improve uptake, oral bioavailability, and tumor
targeting of platinum compounds.
VI. Non-traditional compounds in clinical trials
The three year interval between initial testing of cisplatin in mouse tumor models
by the National Cancer Institute in 1968 to clinical trials with terminal cancer patients,
which began in 1971, is unusually short by today's standards. Discomfort over the use
of heavy metals in medicine and the novelty of the class of compounds were overcome
in favor of rapid introduction of the promising new treatment.3 6 The platinum compounds
currently in clinical trials that violate the canonical structure-activity relationship have
also overcome significant barriers on their way to the clinic, and the lag between
benchtop and clinical use has been considerably longer than that of cisplatin.
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Compounds that have entered clinical trials include platinum(IV) compounds
such as satraplatin, or c,c,t-[Pt(NH3)2(cyclohexylamine)CI(COOCH 3)2 (also known as
JM216), the first orally administered platinum compound to undergo active clinical
investigation, multinuclear compounds of the form [{PtCIm(NH 3)3-m 2 (H2N-R-NH 2 )]2 (2 -m)+
(m = 0-3) and R is a linear or substituted aliphatic linker), and picoplatin, cis-[Pt(NH 3)(2-
picoline)C121 (also known as AMD473) (Chart 1.2).
The first patient received satraplatin, the first oral dose of platinum anticancer
treatment, in 1993. A phase II trial in patients with hormone-refractory prostate cancer
showed a median overall survival of 14.9 months for the patients receiving satraplatin
and prednisone and a survival of 11.9 months for patients receiving prednisone alone
and a phase III trial in patients with similar cancer profiles also showed that patients on
the combination therapy had an improved prognosis for disease progression.37
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Chart 1.2. New and non-traditional compounds in clinical trials.
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Satraplatin was considered by the FDA in 2007 as a treatment for hormone-
resistant prostate cancer and, despite having entered into a "special protocol
assessment" with the FDA, was not approved. According to Forbes magazine, the
confidential panel convened on satraplatin concluded that the FDA had agreed to most
of the trial, but not to one key measure of pain, which was the basis for rejection, 38
although other sources disagree on the reasons for rejection. Satraplatin's development
is under the control of Spectrum Pharmaceuticals in the United States, where it is
currently under investigation for the treatment of non-small-cell lung cancer and GPC
Biotech in Europe, where it is in phase II trials in patients with hormone-refractory
prostate cancer.
The dose-limiting side-effect to satraplatin is myelosuppression, specifically, a:
reduction in the production of white blood cells and platelets. Biotransformation of
satraplatin in the body produces several products, but the major product is the result of
biological reduction to platinum(lII), cis-[PtCI2(NH3)(cyclohexylamine)] (JM118)-.3 9 The
DNA adducts formed by this reduced and activated form of satraplatin are similar to
those formed by cisplatin40 and are repaired by the nucleotide excision repair
pathway.41 A comparison of excision repair for cisplatin, oxaliplatin, and JM118, the
reduced form of oxaliplatin, revealed only modest differences for the rate of in vitro
repair. The percent excision after 60 minutes was about 2.0% for 1,2-d(GpG) adducts of
JM118, about 1.5% for cisplatin and about 1.0% for oxaliplatin GG adducts.
Picoplatin, a drug in development under the control of Poniard Pharmaceuticals,
was designed with additional steric bulk around the platinum center to reduce
inactivation by cellular thiols, such as glutathione.3 9 In fact, the binding of cisplatin to
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DNA is significantly more inhibited relative to the binding of picoplatin to DNA in the
presence of 5 mM glutathione, and cells that are resistant to cisplatin, such as
A2780cis, are not cross-resistant to picoplatin.42 Picoplatin also exhibits synergistic
behavior when administered as a combination therapy with paclitaxel, as does cisplatin.
Phase II clinical trials of picoplatin demonstrated a survival benefit for patients with
small cell lung cancer who were treated with picoplatin after relapsing within six months
of initial therapy with other drugs. The phase III trial of picoplatin, SPEAR (Study of
Picoplatin Efficacy After Relapse) is underway in Europe and India and is also focused
on patients with small cell lung cancer. A phase I trial in colorectal cancer (combination
therapy with 5-fluorouracil) and a phase II trial in prostate cancer (combination therapy
with docetaxel and prednisone) are also underway.
VII. Cationic non-traditional compounds.
Cationic Compound in Clinical Trials, BBR3464
The trinuclear compound BBR3464, or [{trans-PtCI(NH 3)2 2{p-trans-
Pt(NH 3)2(H2N(CH 2)6NH2)2 }]4 , is composed of two trans-{PtCI(NH 3)2} units linked by the
bridging tetra-amine trans-{Pt(NH 3)2{H2N(CH2 )6NH2}2} 2+ (Chart 1.2) and is undergoing
phase II clinical trials. The platinum atoms at either end of this compound react in a
monofunctional manner with non-adjacent DNA bases to form a variety of adducts and it
is not clear which adduct, if any, predominates in vivo. 43 The charge on the internal
platinum atom is important to the anticancer activity of the complex and is linked to
increased cellular accumulation postulated to be due to polyamine transporters.44 The
dose-limiting suppression of blood cell production in the bone marrow and
gastrointestinal side effects, which reduce the maximum-tolerated dose below that of
cisplatin, limit the potency of the drug and may prevent it from entering phase Ill trials.
Trials in patients with advanced gastric or gastroesophageal adenocarcinomas resulted
in 5 of 7 patients receiving 1.1 mg/m 2 every four weeks experiencing side effects
requiring a reduction in dose. Of 17 patients on a reduced dose of 0.9 mm/m2 , only 1
showed a significant response.45
Cationic Drug Candidates
Cationic platinum compounds are not commonly thought of as active species due
to their inability to diffuse through the neutral, hydrophobic lipid bilayer. Having identified
platinum compounds as potential substrates for cation transporters in cell membranes,
investigations into the cationic platinums have been reignited.
Once inside the cell, the cationic nature of these compounds lends them
immediate affinity for the negative charge of DNA, similar to the interaction of the
aquated, cationic form of cisplatin with DNA. As a practical advantage, cationic platinum
compounds are significantly more soluble in water than their neutral relatives, which
aids in drug formulation. Also, unlike some organic drugs, they are unlikely to partition
into or stick to the hydrophobic plastics used in common clinical and cell culture
practice.
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Chart 1.3. Structural frameworks for cationic platinum(ll) complexes with antitumor activity.
Strategies for the design of active cationic complexes fall into several categories.
An early successful Pt(ll) framework that produced a number of active complexes
involved complexes with three non-labile nitrogen donor ligands and one chloride
leaving group (Chart 1.3, A).46 A variation on this structure involves linking two such
monofunctional complexes to form binuclear, bifunctional, 47 or trinuclear, bifunctional
(Chart 1.3, F)48 complexes. Instead of three nitrogen donor ligands, ligand sets such as
a bidentate (Chart 1.3, B) or tridentate (Chart 1.3, C) nitrogen donor ligand plus a
halogen, thiourea,4 9'50 or sulfoxide also yield cationic complexes. Another framework
involves replacement of one ammine on cisplatin or trans-[Pt(NH 3)2C 2] with a positively
charged non-labile nitrogen donor ligand, such as piperazine (Chart 1.3, D and E).s
The replacement on cisplatin tends to result in a compound with reduced cytotoxicity
compared with cisplatin, whereas the corresponding replacement on trans-[Pt(NH 3)2CI2]
tends to enhance cytotoxicity.
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Chart 1.4. Three cationic platinum(ll) anticancer drug candidates.
Monofunctional platinum-acridine complexes bind to N3 of adenine in the minor
groove due to an intercalator-mediated minor groove association at adenine-containing
base pair steps.52 The IC50 for the most cytotoxic member of this series (Pt-ACRAMTU,
Chart 1.4) was 16.0 pgM in the human leukemia cell line HL-60 and was 2.4 M in the
human lung carcinoma cell line NCI-H460. 53
Another cationic series of compounds showing significant cytotoxicity have the
general formula trans-[PtCl 2(Am)(pip-pip)] HCI (pip-pip = 4-piperidinopiperidine) (Chart
1.4).54 Of the seven compounds of this series and cisplatin, the compound with Am =
NH3 was the most cytotoxic in the cisplatin-resistant ovarian cancer cell lines
A2780cisR, CHlcisR, and 41McisR. In the murine carcinoma line C-26, cellular
accumulation of trans-[PtCI2(NH 3)(pip-pip)I HCI was 10- to 25-fold greater than cisplatin,
Table 1.1. Structural parameters for some cationic complexes designed as antitumor drugs.
N2  /N 3
Pt
Compound L, L2 L3 X1 Pt-L1 Pt-L2 Pt-L 3 Pt-X1 N2-Pt-N1 N2-Pt-N 3 N1-Pt-X1
cis-[Pt(NH3)2(N3-
cytosine)CI]CI 46
cis-[Pt(NH 3)2(N1-
pyridine)CI]CI 55
[Ptl(Me 2phen)(AmPIC)Il 56
[Pt 3(HPTAB)C13](CIO04)3 57(trinuclear compound w/ 3
monofunctional Pt centers)
[PtCl(en)(C19H 23N4)](NO 3)2 53
[PtCI(en)(PICAC-N)] 58
(neutral form, only closed
form is cationic)
[Pt(bampy)Cl]+ 59
[PtCl(dach)(tmtu)]NO3 49
NH3  NH3
NH3  NH3
2,9-dimethyl-
1,10-
phenanthroline
cytosine CI 2.045(7) 2.059(7) 2.033(7) 2.309(2) 90.1(3)0 90.1(3)0 91.5(2)0
pyridine Cl 2.054(13) 2.028(13) 2.002(13) 2.312(4)
6-amino-2-
picoline
2,2'-bis(pyridylmethyl)amine
N-[2-(acridin-9-
ylamino)ethyl]-
N-
methylpropion
amidine
en (methylpyridin-
2-yl)acetate
C-(6-aminomethylpyridin-2-
yl)methylamine
dach
1,1,3,3-
tetramethylthio
urea
89.9(6)0 89.2(5)' 89.7(4)0
I 2.044(6) 2.079(6) 2.036(6) 2.592(1) 80.9(2) °  96.7(2)0 98.8(2)0
Cl 1.986(8) 2.027(8) 2.001(8) 2.283(2) 81.8(3)0 85.1(3) 96.6(2)0
CI 2.013(7) 2.025(7) 2.023(3) 2.313(2) 83.3(3)0 90.9(2) 90.5(2)0
CI 2.033(3) 2.047(3) 2.048(3) 2.3093(9) 83.78(13)0 93.82(12) 91.96(10) °
Cl 2.033(6) 1.936(5) 2.040(6) 2.308(2) 83.2(2)0 81.4(2)0 97.4(2)0
CI 2.080(6) 2.042(6) 2.281(2) 2.298(2) 83.2(2) 92.3(2) 92.7(2)
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although the level of platinum bound to DNA was roughly the same. The charged
complexes also bind DNA up to 10-fold more quickly than neutral complexes such as
cisplatin and trans-[Pt(NH 3)2C 21 .60
A summary of structural parameters for eight known cationic, monofunctional
platinum(ll) complexes is shown in Table 1.1. The weakening of the Pt-X 1 bond can be
seen in the variance of bond length, but this value does not relate to the cytotoxicity of
the complexes. The 19 5 Pt NMR chemical shift for these complexes does not scale with
cytotoxicity either.
VIII. Influx transporters and platinum compounds
The mechanisms by which platinum anticancer compounds accumulate in cells
have been of interest since the early work on cisplatin, where it was already suspected
that cisplatin enters the cell by passive diffusion through the cell membrane.3 6 Although
the small, neutral cisplatin may not need to take advantage of an active transport
system, new drug candidates that are either sterically bulky, charged, or both, have
been shown to interact with influx and efflux transporters.
Human genes that encode transporters make up 3.0% of all open reading frames
and code for a predicted 841 transporter proteins.61 Solute transporters are divided into
four major classes, according to the transporter classification system.6 2 Channels move
water, ions, or hydrophilic small molecules down a gradient. Primary active transporters
utilize ATP hydrolysis to drive the transport process. Transport in secondary
transporters is driven by an ion or solute electrochemical gradient. Finally, group
transporters are characterized by their requirement for modification of the substrate,
such as by phosphorylation, during transport.6 1 In humans, the percentages of
channels, primary transporters, secondary transporters, and phosphotransferases are
43.3, 14.9, 38.9, and 0, respectively.61
As a group, secondary transporters accept a wide variety of substrates, including
sugars, lipophilic molecules, cations and anions, and nucleosides. Organic cation
transporters (OCTs) are members of the solute carrier family of secondary transporters
(SLC22A) with a broad range of substrate specificity. Of greatest interest for drug
metabolism, they are found, among other organs, in the intestine, liver, and kidney
63-65
and facilitate the movement of endogenous and xenobiotic substrates across cell
membranes. The presence of these transporters in the intestine facilitates drug uptake
from the gastrointestinal tract, while presence in the liver and kidney affects excretion of
drugs and can give rise to renal and nephrotoxicity. Examples of drugs that are organic
cations can be found among antihistamines, P-adrenergic antagonists, calcium channel
blockers, and skeletal muscle relaxants.66 Examples of endogenous substrates of the
organic cation transporters include guanidine, a small molecule formed during protein
metabolism, and thiamine, which is needed for the metabolism of carbohydrates and
lipids.67
The presence of OCTs in the intestine allows for both desirable and undesirable
biomedical effects. Organic cations that would otherwise not be orally bioavailable are
removed from the intestine by organic cation transporters and passed into the
bloodstream. Certain foods may interfere with the uptake of organic cations, as has
been shown for caffeine and the uptake of the OCT substrate MPP (1-methyl-4-
phenylpyridinium).68 Changes in the pH of the contents of the small intestine may also
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affect the uptake of some drugs. Additionally, mutations of the transporters may lead to
variability in drug accumulation among patients.6 9 Studies of the colorectal
adenocarcinoma cell line Caco-2 under conditions that simulate the in vivo environment
and allow differentiation between apical and basolateral membranes have clarified the
location of OCTs under polarized conditions.6 5 The transporter hOCT1 is localized to the
basolateral membrane and plays a role in uptake and efflux at the interstitium (Figure
1.1). Uptake of cations occurs under a normal membrane potential of -60 mV.
Alternately, efflux of a particular cation can occur if the intracellular concentration
becomes much higher than the extracellular concentration.
Sluminall I basolateral
OC +'00 i
OCTN2
Na* and carnitine +
OCTN1 C OCT1
SOC+
MDR1
Figure 1.1. Transporters of organic cations in enterocytes of the human small intestine. Figure is
based on a figure in Koepsell, et. al., 2007.69 OCT1 transports cations in either direction depending
on the electrochemical potential. In the presence of a normal membrane potential (-60 mV), cation
uptake (thick arrows) is preferred. Efflux can occur if the intracellular concentration of the cation
is 10 times higher inside the cell than outside the cell.
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IX. Other connections between transport and platinum sensitivity
Besides organic cation transporters, other transporters that have proven
influential in the efficacy of platinum anticancer drug candidates. Folate receptor-a,
which is overexpressed on the cell membrane of a variety of human tumors, has been
targeted using platinum-folate constructs. An early example carboplatin was modified
with a folic acid-PEG construct to produce a complex that efficiently entered folate
receptor-positive cells, but seemed to then be sequestered in a way that prevented
reaction of the platinum with nuclear DNA.70 In a more successful example, a platinum
(IV) complex modified with folic acid derivative at one axial position and a single-walled
carbon nanotube at the second axial position.71 The Pt(IV) construct undergoes
reductive release of cisplatin inside the cell, producing increased platinum-DNA adducts
in and selective destruction of folate receptor-positive cells.
The homeostasis of copper ions in the human body is mediated for the most part
by the copper transporter CTR1 (SLC31A1) and this transporter has been linked to the
accumulation of platinum compounds in cancer cells.72 The presence of copper
increases the uptake, but decreases the potency of cisplatin and increases both uptake
and potency of BBR3464.73
Other transporters that have been associated with the efficacy of platinum
anticancer drugs and drug candidates include steroid receptors. Targeting cancer cells
using platinum complexes tethered to estrogen derivatives has met with success in pre-
clinical experiments.74 76 The combination of estrogen and platinum complexes is of
interest because estrogen potentiates the upregulation of HMGB1,7 7 a protein that binds
with high affinity to platinum-DNA adducts.
X. Influence of HMGB1 on cellular processes
The high-mobility group box-1 protein is an abundant, highly conserved protein
that is a critical component of a wide variety of cellular processes. It binds to cisplatin-
modified DNA with a specificity between 10- and 100-fold over unmodified DNA with a
Kd values from 0.3-370 nM.7 8 At a concentration of 8 pM, HMGB1 inhibits the overall
repair of cisplatin-DNA adducts by over 70% ( where [DNA substrate] = 20 pM). 17 This
finding suggested that tumors with high levels of HGMB1 may have increased
susceptibility to cisplatin due to decreased excision repair of cisplatin adducts. In
support of this hypothesis, the cytotoxicity of cisplatin is potentiated by pretreatment of
breast and cervical cancer tumor cells with estrogen and progesterone,7 7 a protocol that
increases the level of HMGB1 in the nucleus.79'80
Paradoxically, increased expression of HMGB1 is also linked to enhanced
resistance seen in cisplatin-resistant cells. Activity in the HMGB1 promoter region was
3- to 10-fold higher in cisplatin-resistant KB-CP20 cells than in the parent KB cell line.81
These data and other connections between HMGB1 and the evolution of cancer have
led to an alternate hypothesis: the possibility that cisplatin-modified DNA sequesters
HMGB1 from its role in the progression of cancer and that cisplatin acts as an anti-
HMGB1 agent in a way that is key to its activity as an anticancer drug.82
The reason for the two hypotheses is the dual nature of HMGB1: it acts both as a
transcription factor in the nucleus, but also as a cytokine in the cytosol.
HMGB 1 in the Nucleus
In resting, healthy cells, HMGB1 is found in the nucleus and acts as a
transcription factor and as a chromatin remodeler. Two nuclear localization signal
sequences (amino acids 28-44 and 180-185) are present in the amino acid sequence of
human HMGB1.83 In its role as a transcription factor, HMGB1 is involved in the
regulation of gene transcription of a limited number of genes. Steroid receptors, for
example, including the progesterone and estrogen receptors, are activated upon steroid
binding and bind to DNA at sites that contain hormone response elements of target
genes, thereby stimulating transcription of those genes. HMGB1 establishes a protein-
protein interaction with these steroid receptors and, upon binding DNA, induces a
structural distortion of the DNA that stabilizes the steroid receptor-DNA interaction.
HMGB1 therefore enhances the interaction of the steroid receptor and its hormone
response element, which leads to increased transcription of the associated genes.80
HMGB1 also interacts in a non-gene-specific way with chromatin. The basic unit
of chromatin is the nucleosome, which is composed of DNA and an octamer of histones,
consisting of two copies of each of four histone proteins. Each nucleosome in eukaryotic
cells also contains one of a fifth type of histone, H1, which is transiently associated with
chromatin. H1 modulates chromatin function depending on the length of time it is
associated with the nucleosome and its competition with nuclear proteins that also bind
to nucleosomal DNA. 84'85 HMGB1 competes with histone H1 and weakens its interaction
with chromatin. The replacement of H1 with HMGB1 creates the possibility for
transcription regulatory factors to access chromatin. 85
HMGB1 as a Cytokine
In addition to activity in the nucleus, HMGB1 can also be released into the
cytosol and into the extracellular environment by both active and passive mechanisms.
Movement into the nucleus occurs in cells dying a deregulated, necrotic death and not
in cells that succumb to apoptosis. Migration into the cytosol may be mediated by post-
translational modification of either Cys1068 6 or several of the 43 lysine residues.8 3
Phosphorylation has also been investigated as a signal for migration between the
cytosol and nucleus, and other post-translational modifications of HMGB1, including
ADP ribosylation, glycosylation, and methylation, may also be involved.87 ,88
Following localization into the cytosol, HMGB1 switches roles to facilitate immune
response to cell death and microbial invasion. Necrotic cells have leaky cell
membranes, which allows cytosol-localized HMGB1 to escape into the extracellular
milieu. HMGB1 then causes an inflammatory response, which brings macrophages to
the necrotic site to clean up the aftermath of necrotic cell death and prevent infection
and causes neighboring tissue to initiate repair.89 Immune cells such as monocytes and
macrophages, can actively release HMGB1 via secretory vesicles, in effect mimicking
necrotic cell death and bringing about a similar immune response. The signaling
capabilities of HMGB1 require partner target receptors, which include the receptor for
advanced glycation end products (RAGE), Toll-like Receptor 2 and 4 (TLR2 and TLR4),
syndecan, phosphacan/protein-Tyr phosphatase y/p, and plasminogen.82 Much of the
work linking HMGB1 to cancer has focused on the interactin of HMGB1 and RAGE.
RAGE is a member of the immunoglobulin superfamily, which is composed of proteins
that act as cytokine or antigen receptors, or are involved in the binding, or adhesion of
cells. Most members of the Ig superfamily play a role in the immune system. 89 RAGE is
expressed by monocytes and macrophages, dendritic cells, endothelial cells, and
vascular smooth muscle cells. Levels of RAGE are low in normal tissues, but the level
increases in areas where HMGB1 accumulates. 90 Increased expression of either
HMGB1 or RAGE has been identified in breast, colon, melanoma, metastatic prostate,
and metastatic pancreatic cancer cells. One exception has been found in lung tissue, in
which RAGE and HMGB1 are down-regulated.82
The relevance of the inflammation-inducing, cytokine properties of HMGB1 to
cancer is based on the realization that tumor cells, which undergo messy, necrotic cell
death, use HMGB1 to promote the growth of the surrounding non-necrotic, viable
portions of the tumor. The RAGE-HMGB1 interaction has also been linked to proteins
involved in the cytoskeletal remodeling process required for cell movement. 91
Importantly, inhibition of the interaction of RAGE and HMGB1 decreases the growth and
metastasis of tumors in mice.92
HMGB4
Besides HMGB1, other members of the HMG family exist and differ mostly in
which organs they are expressed. A new member of the family, HMGB4 (NCBI
Reference Sequence: NP_660206.2), has recently been characterized. 93 It is expressed
in the testis and in sperm cells, which is of interest because of the particular efficacy of
cisplatin in testicular cancer. The sequence alignment (Chart 1.5) indicates that the
disulfide bond formed in HMGB1 between Cys23 and Cys45 cannot be formed in
HMGB4 due to the absence of a cysteine at position 23.
HMGB4 : EIQLM"XVBHLFQQKHMGBI1: EGDPKWG FQT EHK S S
HMGB4: S E SIRDPE
HMGB1: P
HMGB4:
HMGB1: I SF L 
S
TEKST
L~EEMIHYRO
_ 
_,~eb~ ~b
1,G
HMGB4: FLELQCRKK ARNRCR QS ------------
HMGB1: I KGK DA- EK~ EEEDEEDEEDEE
HMGB4: -----------------
HMGB1: EEEDEEDEDEEEDDDDE
Chart 1.5. Sequence alignment of human HMGB4 and human HMGB1. Identical residues are highlighted in
black, similar residues are highlighted in grey, and the Phe38, Cys23, and Cys45 residues are underlined.
Additionally, the acid C-terminal residues found in HMGB1, which reduce the affinity of
HMGB1 for DNA 94 are not found in HMGB4. The binding affinity of HMGB4 for cisplatin-
modified DNA is unknown and, given the lack of disulfide bond formation and inhibitory
acidic tail in HMGB4, the interaction may be of great relevance for the repair of cisplatin-
modified DNA in testicular cancer.
References
(1) "Generic Drug Entry Prior to Patent Expiration: An FTC Study," Federal Trade
Commission, July 2002.
(2) National Cancer Institute.
(3) B. Lippert (2000). Multiplicity of metal ion binding patterns to nucleobases. Coord.
Chem. Rev., 200-202, 487-516.
(4) M. Kartalou and J. M. Essigmann (2001). Mechanisms of resistance to cisplatin.
Mutat. Res., 478, 23-43.
(5) E. R. Jamieson and S. J. Lippard (1999). Structure, Recognition, and Processing of
Cisplatin-DNA Adducts. Chem. Rev., 99, 2467-2498.
(6) A. M. J. Fichtinger-Schepman, R. A. Baan, A. Luiten-Schuite, M. Van Dijk and P. H.
M. Lohman (1985). Immunochemical quantitation of adducts induced in DNA by cis-
diamminedichloroplatinum(ll I) and analysis of adduct-related DNA-unwinding. Chem.
Biol. Interact., 55, 275-288.
ATDL~s
(7) A. M. Fichtinger-Schepman, A. T. van Oosterom, P. H. Lohman and F. Berends
(1987). cis-Diamminedichloroplatinum(l I)-induced DNA adducts in peripheral leukocytes
from seven cancer patients: quantitative immunochemical detection of the adduct
induction and removal after a single dose of cis-diamminedichloroplatinum(ll). Cancer
Res., 47, 3000-3004.
(8) P. M. Takahara, C. A. Frederick and S. J. Lippard (1996). Crystal Structure of the
Anticancer Drug Cisplatin Bound to Duplex DNA. J. Am. Chem. Soc., 118, 12309-
12321.
(9) B. Spingler, D. A. Whittington and S. J. Lippard (2001). 2.4 A... Crystal Structure of
an Oxaliplatin 1,2-d(GpG) Intrastrand Cross-Link in a DNA Dodecamer Duplex. Inorg.
Chem., 40, 5596-5602.
(10) A. Sancar, L. A. Lindsey-Boltz, K. Onsal-Kacmaz and S. Linn (2004). Molecular
mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev.
Biochem., 73, 39-85.
(11) B.-B. S. Zhou and S. J. Elledge (2000). The DNA damage response: putting
checkpoints in perspective. Nature, 408, 433-439.
(12) L. A. Lindsey-Boltz and A. Sancar (2007). RNA polymerase: The most specific
damage recognition protein in cellular responses to DNA damage? Proc. Natl. Acad.
Sci. U. S. A., 104, 13213-13214.
(13) C. P. Selby, R. Drapkin, D. Reinberg and A. Sancar (1997). RNA polymerase II
stalled at a thymine dimer: footprint and effect on excision repair. Nucleic Acids Res.,
25, 787-793.
(14) C. M. Sorenson and A. Eastman (1988). Mechanism of cis-
diamminedichloroplatinum(ll)-induced cytotoxicity: role of G2 arrest and DNA double-
strand breaks. Cancer Res., 48, 4484-4488.
(15) C. M. Sorenson and A. Eastman (1988). Influence of cis-
diamminedichloroplatinum(ll) on DNA synthesis and cell cycle progression in excision
repair proficient and deficient Chinese hamster ovary cells. Cancer Res., 48, 6703-
6707.
(16) S. A. Jelinsky and L. D. Samson (1999). Global response of Saccharomyces
cerevisiae to an alkylating agent. Proc. Natl. Acad. Sci. U. S. A., 96, 1486-1491.
(17) J.-C. Huang, D. B. Zamble, J. T. Reardon, S. J. Lippard and A. Sancar (1994).
HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the
anticancer drug cisplatin by human excision nuclease. Proc. Natl. Acad. Sci. U. S. A.,
91, 10394-10398.
(18) M. F. Pera, F. Friedlos, J. Mills and J. J. Roberts (1987). Inherent sensitivity of
cultured human embryonal carcinoma cells to adducts of cis-
diamminedichloroplatinum(llI) on DNA. Cancer Res., 47, 6810-6813.
(19) J. Q. Svejstrup (2002). Mechanisms of transcription-coupled DNA repair. Nature
Reviews Molecular Cell Biology, 3, 21-29.
(20) 0. V. Tsodikov, D. Ivanov, B. Orelli, L. Staresincic, I. Shoshani, R. Oberman, O. D.
Schaerer, G. Wagner and T. Ellenberger (2007). Structural basis for the recruitment of
ERCC1-XPF to nucleotide excision repair complexes by XPA. EMBO J., 26, 4768-4776.
(21) D. B. Zamble, D. Mu, J. T. Reardon, A. Sancar and S. J. Lippard (1996). Repair of
Cisplatin-DNA Adducts by the Mammalian Excision Nuclease. Biochemistry, 35, 10004-
10013.
(22) D. B. Zamble, Y. Mikata, C. H. Eng, K. E. Sandman and S. J. Lippard (2002).
Testis-specific HMG-domain protein alters the responses of cells to cisplatin. J. Inorg.
Biochem., 91, 451-462.
(23) Y. Jung, Y. Mikata and S. J. Lippard (2001). Kinetic studies of the TATA-binding
protein interaction with cisplatin-modified DNA. J. Bio/. Chem., 276, 43589-43596.
(24) J. Kasparkova, S. Pospisilova and V. Brabec (2001). Different recognition of DNA
modified by antitumor cisplatin and its clinically ineffective trans isomer by tumor
suppressor protein p53. J. Bio/. Chem., 276, 16064-16069.
(25) C. X. Zhang, P. V. Chang and S. J. Lippard (2004). Identification of Nuclear
Proteins that Interact with Platinum-Modified DNA by Photoaffinity Labeling. J. Am.
Chem. Soc., 126, 6536-6537.
(26) E. R. Guggenheim, D. Xu, C. X. Zhang, P. V. Chang and S. J. Lippard (2009).
Photoaffinity isolation and identification of proteins in cancer cell extracts that bind to
platinum-modified DNA. ChemBioChem, 10, 141-157.
(27) D. Wang, R. Hara, G. Singh, A. Sancar and S. J. Lippard (2003). Nucleotide
Excision Repair from Site-Specifically Platinum-Modified Nucleosomes. Biochemistry,
42, 6747-6753.
(28) S. D. Cline and P. C. Hanawalt (2003). Who's on first in the cellular response to
DNA damage? Nature Reviews Molecular Cell Biology, 4, 361-373.
(29) W. J. Heiger-Bernays, J. M. Essigmann and S. J. Lippard (1990). Effect of the
antitumor drug cis-diamminedichloroplatinum(ll I) and related platinum complexes on
eukaryotic DNA replication. Biochemistry, 29, 8461-8466.
(30) K. M. Comess, J. N. Burstyn, J. M. Essigmann and S. J. Lippard (1992).
Replication inhibition and translesion synthesis on templates containing site- specifically
placed cis-diamminedichloroplatinum(ll) DNA adducts. Biochemistry, 31, 3975-3990.
(31) A. L. Pinto and S. J. Lippard (1985). Sequence-dependent termination of in vitro
DNA synthesis by cis- and trans-diamminedichloroplatinum(ll). Proc. Nat. Acad. Sci. U.
S. A., 82, 4616-4619.
(32) Y. Jung and S. J. Lippard (2003). Multiple States of Stalled T7 RNA Polymerase at
DNA Lesions Generated by Platinum Anticancer Agents. J. Biol. Chem., 278, 52084-
52092.
(33) Y. Jung and S. J. Lippard (2006). RNA Polymerase II Blockage by Cisplatin-
damaged DNA: stability and polyubiquitylation of stalled polymerase. J. Biol. Chem.,
281, 1361-1370.
(34) K.-B. Lee, D. Wang, S. J. Lippard and P. A. Sharp (2002). Transcription-coupled
and DNA damage-dependent ubiquitination of RNA polymerase II in vitro. Proc. Natl.
Acad. Sci. U. S. A., 99, 4239-4244.
(35) M. J. Cleare and J. D. Hoeschele (1973). Studies on the Antitumor Activity of
Group VIII Transition Metal Complexes. Part I. Platinum(ll) Complexes. Bioinorg.
Chem., 2, 187-210.
(36) B. Rosenberg (1980). Clinical aspects of platinum anticancer drugs. Met. Ions Biol.
Syst., 11, 127-196.
(37) C. N. Sternberg, P. Whelan, J. Hetherington, B. Paluchowska, P. H. T. J. Slee, K.
Vekemans, P. Van Erps, C. Theodore, O. Koriakine, T. Oliver, D. Lebwohl, M. Debois,
A. Zurlo and L. Collette (2005). Phase iil Trial of Satraplatin, an Oral Platinum plus
Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer.
Oncology, 68, 2-9.
(38) M. Herper In Forbes; Online Edition. Available at:
http://www.forbes.com/2008/08/06/pharmaceuticals-fda-biz-healthcare-
cx mh 0807fda.html ed., 2008.
(39) L. Kelland (2007). The resurgence of platinum-based cancer chemotherapy. Nat.
Rev. Cancer, 7, 573-584.
(40) A. P. Silverman, W. Bu, S. M. Cohen and S. J. Lippard (2002). 2.4-.ANG. Crystal
Structure of the Asymmetric Platinum Complex {Pt(ammine)(cyclohexylamine)}2+
Bound to a Dodecamer DNA Duplex. J. Biol. Chem., 277, 49743-49749.
(41) J. T. Reardon, A. Vaisman, S. G. Chaney and A. Sancar (1999). Efficient
nucleotide excision repair of cisplatin, oxaliplatin, and bis-acetoammine-dichloro-
cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer
Res., 59, 3968-3971.
(42) J. Holford, S. Y. Sharp, B. A. Murrer, M. Abrams and L. R. Kelland (1998). In vitro
circumvention of cisplatin resistance by the novel sterically hindered platinum complex
AMD473. Br. J. Cancer, 77, 366-373.
(43) N. Farrell In Metal Ions in Biological Systems.; Sigel, H., Ed.; Marcel Dekker Inc.,
New York: New York, 2004; Vol. 42, pp 251-296.
(44) J. D. Roberts, J. Peroutka, G. Beggiolin, C. Manzotti, L. Piazzoni and N. Farrell
(1999). Comparison of cytotoxicity and cellular accumulation of polynuclear platinum
complexes in L1210 murine leukemia cell lines. J. Inorg. Biochem., 77, 47-50.
(45) D. I. Jodrell, T. R. J. Evans, W. Steward, D. Cameron, J. Prendiville, C. Aschele, C.
Noberasco, M. Lind, J. Carmichael, N. Dobbs, G. Camboni, B. Gatti and F. De Braud
(2004). Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients
with gastric or gastro-oesophageal adenocarcinoma. Eur. J. Cancer, 40, 1872-1877.
(46) L. S. Hollis, A. R. Amundsen and E. W. Stern (1989). Chemical and biological
properties of a new series of cis-diammineplatinum(II) antitumor agents containing three
nitrogen donors: cis-[Pt(NH3)2(N-donor) CI]+. J. Med. Chem., 32, 128-136.
(47) T. Kapp, A. Dullin and R. Gust (2006). Mono- and Polynuclear
[Alkylamine]platinum(lI) Complexes of [1,2-Bis(4-
fluorophenyl)ethylenediamine]platinum(ll): Synthesis and Investigations on Cytotoxicity,
Cellular Distribution, and DNA and Protein Binding. J. Med. Chem., 49, 1182-1190.
(48) N. Farrell, Y. Qu, U. Bierbach, M. Valsecchi and E. Menta (1999). Structure-activity
relationships within di- and trinuclear platinum phase-I clinical anticancer agents.
Cisplatin, 479-496.
(49) U. Bierbach, T. W. Hambley and N. Farrell (1998). Modification of Platinum(ll)
Antitumor Complexes with Sulfur Ligands. 1. Synthesis, Structure, and Spectroscopic
Properties of Cationic Complexes of the Types [PtCl(diamine)(L)]NO3 and
[{PtCl(diamine)}2(L-L)](NO3)2 (L = Monofunctional Thiourea Derivative; L-L =
Bifunctional Thiourea Derivative). Inorg. Chem., 37, 708-716.
(50) U. Bierbach, J. D. Roberts and N. Farrell (1998). Modification of Platinum(lI)
Antitumor Complexes with Sulfur Ligands. 2. Reactivity and Nucleotide Binding
Properties of Cationic Complexes of the Types [PtCl(diamine)(L)]N03 and
[{PtCl(diamine)}2(L-L)](NO3)2 (L = Monofunctional Thiourea Derivative; L-L =
46
Bifunctional Thiourea Derivative) in Relation to Their Cytotoxicity. Inorg. Chem., 37,
717-723.
(51) Y. Najajreh, J. M. Perez, C. Navarro-Ranninger and D. Gibson (2002). Novel
Soluble Cationic trans-Diaminedichloroplatinum(ll) Complexes that Are Active against
Cisplatin Resistant Ovarian Cancer Cell Lines. J. Med. Chem., 45, 5189-5195.
(52) Z. Ma, G. Saluta, G. L. Kucera and U. Bierbach (2008). Effect of linkage geometry
on biological activity in thiourea- and guanidine-substituted acridines and platinum-
acridines. Bioorg. Med. Chem. Lett., 18, 3799-3801.
(53) Z. Ma, J. R. Choudhury, M. W. Wright, C. S. Day, G. Saluta, G. L. Kucera and U.
Bierbach (2008). A Non-Cross-Linking Platinum-Acridine Agent with Potent Activity in
Non-Small-Cell Lung Cancer. J. Med. Chem., 51, 7574-7580.
(54) Y. Najajreh, E. Khazanov, S. Jawbry, Y. Ardeli-Tzaraf, J. M. Perez, J. Kasparkova,
V. Brabec, Y. Barenholz and D. Gibson (2006). Cationic Nonsymmetric Transplatinum
Complexes with Piperidinopiperidine Ligands. Preparation, Characterization, in Vitro
Cytotoxicity, in Vivo Toxicity, and Anticancer Efficacy Studies. J. Med. Chem., 49, 4665-
4673.
(55) K. S. Lovejoy, R. C. Todd, S. Zhang, M. S. McCormick, J. A. D'Aquino, J. T.
Reardon, A. Sancar, K. M. Giacomini and S. J. Lippard (2008). cis-
diammine(pyridine)chloroplatinum(ll), a monofunctional platinum(llII) antitumor agent:
uptake, structure, function, and prospects. Proc. Natl. Acad. Sci. U. S. A., 105, 8902-
8907.
(56) N. Margiotta, G. Natile, F. Capitelli, P. Fanizzi Francesco, A. Boccarelli, P. De
Rinaldis, D. Giordano and M. Coluccia (2006). Sterically hindered complexes of
platinum(ll) with planar heterocyclic nitrogen donors. A novel complex with 1-methyl-
cytosine has a spectrum of activity different from cisplatin and is able of overcoming
acquired cisplatin resistance. J. Inorg. Biochem., 100, 1849-1857.
(57) Y. Zhao, W. He, P. Shi, J. Zhu, L. Qiu, L. Lin and Z. Guo (2006). A positively
charged trinuclear 3N-chelated monofunctional platinum complex with high DNA affinity
and potent cytotoxicity. J. Chem. Soc., Dalton Trans., 2617-2619.
(58) Y. Ma, C. S. Day and U. Bierbach (2005). Synthesis, structure, and reactivity of
monofunctional platinum(llI) and palladium(ll) complexes containing the sterically
hindered ligand 6-(methylpyridin-2-yl)acetate. J. Inorg. Biochem., 99, 2013-2023.
(59) S. W. Annie Bligh, A. Bashall, C. Garrud, M. McPartlin, N. Wardle, K. White, S.
Padhye, V. Barve and G. Kundu (2003). Reaction of (C-(6-aminomethyl-pyridin-2-
yl)methylamine)chloroplatinum(ll) with nucleosides and its biological activity. J. Chem.
Soc., Dalton Trans., 184-188.
(60) Y. Najajreh, Y. Ardeli-Tzaraf, J. Kasparkova, P. Heringova, D. Prilutski, L. Baiter, S.
Jawbry, E. Khazanov, J. M. Perez, Y. Barenholz, V. Brabec and D. Gibson (2006).
Interactions of Platinum Complexes Containing Cationic, Bicyclic, Nonplanar
Piperidinopiperidine Ligands with Biological Nucleophiles. J. Med. Chem., 49, 4674-
4683.
(61) Q. Ren and I. T. Paulsen (2005). Comparative analyses of fundamental differences
in membrane transport capabilities in prokaryotes and eukaryotes. PLoS Comput. Biol.,
1, 190-201.
(62) W. Busch and M. H. Saier, Jr. (2002). The Transporter Classification (TC) system,
2002. Crit. Rev. Biochem. Mol. BioL, 37, 287-337. Database at http://www.tcdb.orq.
(63) M. J. Dresser, M. K. Leabman and K. M. Giacomini (2001). Transporters involved
in the elimination of drugs in the kidney: organic anion transporters and organic cation
transporters. J. Pharm. Sci., 90, 397-421.
(64) N. Kitada, K. Takara, T. Minegaki, C. Itoh, M. Tsujimoto, T. Sakaeda and T.
Yokoyama (2008). Factors affecting sensitivity to antitumor platinum derivatives of
human colorectal tumor cell lines. Cancer Chemother. Pharmacol., 62, 577-584.
(65) J. Muller, K. S. Lips, L. Metzner, R. H. H. Neubert, H. Koepsell and M. Brandsch
(2005). Drug specificity and intestinal membrane localization of human organic cation
transporters (OCT). Biochem. Pharmacol., 70, 1851-1860.
(66) L. Zhang, C. M. Brett and K. M. Giacomini (1998). Role of Organic Cation
Transporters in Drug Absorption and Elimination. Annu. Rev. Pharmacol. Toxicol., 38,
431-460.
(67) J. E. van Montfoort, B. Hagenbuch, G. M. M. Groothuis, H. Koepsell, P. J. Meier
and D. K. F. Meijer (2003). Drug uptake systems in liver and kidney. Curr. Drug Metab.,
4, 185-211.
(68) R. Monteiro, C. Calhau, F. Martel, A. Faria, N. Mateus and I. Azevedo (2005).
Modulation of MPP+ uptake by TEA and some of its components in Caco-2 cells.
Naunyn-Schmiedeberg's Arch. Pharmacol., 372, 147-152.
(69) H. Koepsell, K. Lips and C. Volk (2007). Polyspecific organic cation transporters:
structure, function, physiological roles, and biopharmaceutical implications. Pharm.
Res., 24, 1227-1251.
(70) 0. Aronov, A. T. Horowitz, A. Gabizon and D. Gibson (2003). Folate-Targeted PEG
as a Potential Carrier for Carboplatin Analogs. Synthesis and in Vitro Studies.
Bioconjug. Chem., 14, 563-574.
(71) S. Dhar, Z. Liu, J. Thomale, H. Dai and S. J. Lippard (2008). Targeted Single-Wall
Carbon Nanotube-Mediated Pt(IV) Prodrug Delivery Using Folate as a Homing Device.
J. Am. Chem. Soc., 130, 11467-11476.
(72) R. Safaei (2006). Role of copper transporters in the uptake and efflux of platinum
containing drugs. Cancer Lett., 234, 34-39.
(73) P. Kabolizadeh, J. Ryan and N. Farrell (2007). Differences in the cellular response
and signaling pathways of cisplatin and BBR3464 ([[trans-PtCl(N H3)(2)]2mu-(trans-
Pt(NH3)(2)(H2N(CH2)(6)-NH2)2)14+) influenced by copper homeostasis. Biochem.
Pharmacol., 73, 1270-1279.
(74) J. Altman, T. Castrillo, W. Beck, G. Bernhardt and H. Schoenenberger (1991).
Metal complexes with biologically important ligands. 62. Platinum(ll) complexes of 3-(2-
aminoethoxy)estrone and -estradiol. Inorg. Chem., 30, 4085-4088.
(75) 0. Gandolfi, H. C. Apfelbaum, Y. Migron and J. Blum (1989). Syntheses of cis-
dichlorodiammineplatinum analogs having steroidal hormones bound to the metal atom
via malonato bridges. Inorg. Chim. Acta, 161, 113-123.
(76) A. Jackson, J. Davis, R. J. Pither, A. Rodger and M. J. Hannon (2001). Estrogen-
derived steroidal metal complexes: agents for cellular delivery of metal centers to
estrogen receptor-positive cells. Inorg. Chem., 40, 3964-3973.
(77) Q. He, C. H. Liang and S. J. Lippard (2000). Steroid hormones induce HMG1
overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc. Natl.
Acad. Sci. U. S. A., 97, 5768-5772.
48
(78) Y. Jung and S. J. Lippard (2007). Direct Cellular Responses to Platinum-Induced
DNA Damage. Chem. Rev., 107, 1387-1407.
(79) K. Y. Chau, H. Y. P. Lam and K. L. D. Lee (1998). Estrogen treatment induces
elevated expression of HMG1 in MCF-7 cells. Exp. Cell. Res., 241, 269-272.
(80) V. Boonyaratanakornkit, V. Melvin, P. Prendergast, M. Altmann, L. Ronfani, M. E.
Bianchi, L. Taraseviciene, S. K. Nordeen, E. A. Allegretto and D. P. Edwards (1998).
High-Mobility Group Chromatin Proteins 1 and 2 Functionally Interact with Steroid
Hormone Receptors to Enhance Their DNA Binding in Vitro and Transcriptional Activity
in Mammalian Cells. Mol. Cell. Biol., 18, 4471-4487.
(81) G. Nagatani, M. Nomoto, H. Takano, T. Ise, K. Kato, T. Imamura, H. Izumi, K.
Makishima and K. Kohno (2001). Transcriptional activation of the human HMG1 gene in
cisplatin-resistant human cancer cells. Cancer Res., 61, 1592-1597.
(82) J. E. Ellerman, C. K. Brown, M. de Vera, H. J. Zeh, T. Billiar, A. Rubartelli and M. T.
Lotze (2007). Masquerader: High Mobility Group Box-1 and Cancer. Clin. Cancer Res.,
13, 2836-2848.
(83) T. Bonaldi, F. Talamo, P. Scaffidi, D. Ferrera, A. Porto, A. Bachi, A. Rubartelli, A.
Agresti and M. E. Bianchi (2003). Monocytic cells hyperacetylate chromatin protein
HMGB1 to redirect it towards secretion. EMBO J., 22, 5551-5560.
(84) M. Bustin, F. Catez and J.-H. Lim (2005). The dynamics of histone H1 function in
chromatin. Mol. Cell, 17, 617-620.
(85) F. Catez, H. Yang, K. J. Tracey, R. Reeves, T. Misteli and M. Bustin (2004).
Network of dynamic interactions between histone H1 and high-mobility-group proteins in
chromatin. Mol. Cell. Bio/., 24, 4321-4328.
(86) G. Hoppe, K. E. Talcott, S. K. Bhattacharya, J. W. Crabb and J. E. Sears (2006).
Molecular basis for the redox control of nuclear transport of the structural chromatin
protein Hmgbl. Exp. Cell Res., 312, 3526-3538.
(87) L. Ulloa and D. Messmer (2006). High-mobility group box 1 (HMGB1) protein:
Friend and foe. Cytokine Growth Factor Rev., 17, 189-201.
(88) Q. Zhang and Y. Wang (2008). High mobility group proteins and their post-
translational modifications. Biochim. Biophys. Acta Protein Proteonomics, 1784, 1159-
1166.
(89) I. E. Dumitriu, P. Baruah, A. A. Manfredi, M. E. Bianchi and P. Rovere-Querini
(2005). HMGB: guiding immunity from within. Trends Immunol, 26, 381-387.
(90) A. M. Schmidt, S. D. Yan, S. F. Yan and D. M. Stern (2001). The multiligand
receptor RAGE as a progression factor amplifying immune and inflammatory responses.
J. Clin. Invest., 108, 949-955.
(91) H. J. Huttunen, C. Fages and H. Rauvala (1999). Receptor for advanced glycation
end products (RAGE)-mediated neurite outgrowth and activation of NF-kB require the
cytoplasmic domain of the receptor but different downstream signaling pathways. J.
Bio/. Chem., 274, 19919-19924.
(92) A. Taguchi, D. C. Blood, G. Del Toro, A. Canet, D. C. Lee, W. Qu, N. Tanji, Y. Lu,
E. Lalla, C. Ful, M. A. Hofmann, T. Kislinger, M. Ingram, A. Lu, H. Tanaka, O. Hori, S.
Ogawa, D. M. Sternm and A. M. Schmidt (2000). Blockade of RAGE-amphoterin
signalling suppresses tumour growth and metastases. Nature, 405, 354-360.
(93) R. Catena, E. Escoffier, C. Caron, S. Khochbin, I. Martianov and I. Davidson
(2009). HMGB4, a novel member of the HMGB family, is preferentially expressed in the
49
mouse testis and localizes to the basal pole of elongating spermatids. Biol. Reprod., 80,
358-366.
(94) K.-B. Lee and J. O. Thomas (2000). The Effect of the Acidic Tail on the DNA-
binding Properties of the HMG1,2 Class of Proteins: Insights from Tail Switching and
Tail Removal. J. Mol. Biol., 304, 135-149.
Chapter 2
Structure-Activity Relationship for the Uptake of Platinum(ll) Compounds
by Human Organic Cation Transporters
This chapter consists of material from a published work (Cancer Research 2006,
66 (17), 8847-8857).1
Introduction
Platinum-based drugs are among the most active anticancer agents and
cisplatin represents one of the three most widely .used cancer
chemotherapeutics. 2 Although cisplatin is effective against a number of solid
tumors, especially testicular and ovarian cancer, its clinical use is limited
because of its toxic effects as well as the intrinsic and acquired resistance of
some tumors to this drug.3 To overcome these limitations, platinum, analogs with
lower toxicity and greater activity in cisplatin-resistant tumors:'. have been
developed and tested, resulting in the approval of carboplatin and oxaliplatin in
the United States (see Figure 2.1). Carboplatin has the advantage of being less
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Figure 2.1. Chemical structures of platinum compounds.
nephrotoxic, but its cross-resistance with cisplatin limits its application in
otherwise cisplatin-treatable diseases.3 Oxaliplatin, however, exhibits a different
anticancer spectrum from that of cisplatin.4' 5 It has been approved as the first or
second line therapy in combination with 5-fluorouracil/leucovorin for advanced
colorectal cancer, for which cisplatin and carboplatin are essentially inactive." In
spite of their distinct antitumor specificities, cisplatin and oxaliplatin, as well as
other platinum compounds, share similar mechanisms of action. In particular,
their cytotoxicity arises primarily from covalent binding to DNA after aquation to
form mono- and diaqua complexes.7'8 This chemistry initiates a series of
biochemical cascades, eventually leading to cell death.7'9
Because cisplatin and oxaliplatin target similar DNA sites for binding and
form similar types of DNA adducts, 10-12 mainly 1,2- and 1,3-intrastrand cross-links
involving purine nucleotides, the mechanisms responsible for their distinct tumor
specificities may involve events other than their interaction with and binding to
DNA. Studies aiming to identify such mechanisms have focused largely on the
cellular processing of cisplatin- and oxaliplatin-DNA adducts. 13' 1 4 However,
differences in the mechanism(s) controlling the cellular uptake and efflux of these
platinum compounds, although rarely investigated, could also be important, since
reduced intracellular accumulation is the most common observation in cisplatin-
resistant cells.1 5' 1 6
Recent studies suggest a direct involvement of the human copper influx
transporter, Ctrl, in the cellular uptake of cisplatin, carboplatin and oxaliplatin to
a varying extent.17 Studies in tumor cell lines suggest, however, that Ctrl may
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not affect the formation and corresponding cytotoxicity of cisplatin-DNA
adducts.18 The human copper efflux transporters, ATP7B and ATP7A, also
recognize these platinum compounds1 9' 20 and their elevated expression has been
associated with cisplatin resistance.2 1-24 The importance of these interactions in
modulating the differential activity and tumor specificity of the platinum
compounds is currently unknown.
The organic cation transporters (OCTs), OCT1 (solute carrier 22A1,
SLC22A1), OCT2 (SLC22A2), and OCT3 (SLC22A3) are in the class of plasma
membrane transporters belonging to the solute carrier (SLC) 22A family. The
OCTs mediate intracellular uptake of a broad range of structurally diverse
organic cations with molecular weights generally lower than 400 Da.2 5 Substrates
of OCTs include endogenous compounds, such as choline, creatinine and
monoamine neurotransmitters, and a variety of xenobiotics such as
tetraethylammonium (TEA, a prototypic organic cation), 1-methy-4-
phenylpyridinium (MPP', a neurotoxin) and clinically used drugs such as
metformin, cimetidine and amantadine. 25 In humans, OCT1 is primarily
expressed in the liver26'27 and less so in the intestine,28 whereas OCT2 is
predominantly expressed in the kidney."7 OCT3 is expressed in many tissues
including placenta, heart, liver and skeletal muscle. 2 9' 30 The expression of the
OCTs has also been detected in a number of human cancer cell lines. 31 The
interaction of cisplatin with human OCTs has been investigated and the results
are discordant.32'33 Previous studies suggest that cisplatin is not a substrate of
human OCT1 or OCT2,3 2 whereas more recent work indicates that the drug
interacts with human OCT2 but not OCT1.33 It is not known whether oxaliplatin or
carboplatin interacts with these transporters, however, or whether such
interactions contribute to their cytotoxicities and differential tumor specificities.
The goals of the present study were to characterize the interaction of
cisplatin, carboplatin and oxaliplatin with human OCT1, OCT2 and OCT3; to
determine whether the OCTs play a role in the cytotoxicity of these and related
platinum compounds; to determine whether interactions with OCTs contribute to
the differential antitumor specificity of oxaliplatin versus cisplatin; and to
understand in a broader context the underlying chemical principles that
determine these differences. Our data indicate that OCT1 and OCT2 play a
critical role in mediating the uptake and consequent cytotoxicity of oxaliplatin, but
not cisplatin or carboplatin. Structure-activity relationship studies suggest that the
1,2-diaminocyclohexane (DACH) moiety of oxaliplatin is an important
pharmacophore for its interaction with the OCTs and that an organic component
on the non-leaving portion of the platinum complexes is essential. Finally, our
experiments suggest that interactions with OCT1 and OCT2 are likely to be
important contributors to the sensitivity of colorectal cancer to oxaliplatin.
Results
OCT Expression and Function in Stably Transfected Cell Lines
The expression and function of human OCTs in the stably transfected
cells was confirmed by RT-PCR and by examining the uptake of the model OCT
substrates (TEA for OCT1 and OCT2, MPP' for OCT3). The expression of the
mRNA transcripts of OCT1, OCT2 and OCT3 and uptake of model compounds
were clearly much higher in OCT-transfected cells (MDCK-hOCT1, HEK-hOCT2
or HEK-hOCT3) in comparison to empty vector-transfected control counterparts
(MOCK cells) (Figures 2.7 and 2.8). OCT inhibitors (disopyramide (120 pM) for
OCT1, cimetidine (1.5 mM) for OCT2 and OCT3) substantially decreased the
uptake of the model compounds in the OCT-transfected cells (p < 0.001) (Figure
2.8).
Effect of OCTs on the Cytotoxicity of Cisplatin, Carboplatin and Oxaliplatin
The IC50 values of oxaliplatin, determined in MTT assays, in MDCK-MOCK
cells after different time periods (7, 24 and 72 hr) of drug exposure were all
significantly higher than those in MDCK-hOCT1 cells. Resistance factors (RF),
defined as the ratio of the IC50o value in MOCK cells to that in the corresponding
OCT-transfected cells, ranged from 5.73 to 8.48 (p < 0.01 or p < 0.001; Table
2.1A and Figure 2.2A). In contrast, the IC50 values of both cisplatin and
carboplatin were similar in the OCT1-transfected and in the MDCK-MOCK cells
with RF values close to unity (p > 0.05) (Table 2.1A). Co-incubation with a known
OCT1 inhibitor, disopyramide (150 pM), substantially increased the IC50 value of
oxaliplatin in MDCK-hOCT1 (control vs. disopyramide-treated: 3.79 ± 1.57 pM vs.
22.8 + 10.5 pM) by 6.01-fold (p < 0.05) with little effect in MDCK-MOCK (control
vs. disopyramide-treated: 30.4 + 9.28 vs. 32.2 + 13.0 pM, p > 0.05) tested in
parallel (Figure 2.2D). Disopyramide itself did not manifest any cytotoxicity up to
a concentration of 400 jM under the same test conditions (data not shown).
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A. Cytotoxicity, expressed as IC50 , of the platinum drugs
hOCT1 cells.
in MDCK-MOCK and MDCK-
Drug Exposure Time MDCK-MOCK MDCK-hOCT1
Platinum Drugs (hour) (pM) (pM) RF
cisplatin 7 19.6 + 7.56 15.4 + 2.84 1.27
carboplatin 7 258 + 86.3 227 _ 85.8 1.13
oxaliplatin 7 33.0 + 9.12 3.89 + 1.30 8.48***
oxaliplatin 24 14.3 _ 5.55 1.79 + 0.58 7.95**
oxaliplatin 72 9.64 _ 1.85 1.68 + 0.27 5.73***
B. Cytotoxicity, expressed as IC50 , of the platinum drugs in HEK-MOCK and HEK-hOCT2
cells.
Drug Exposure Time HEK-MOCK HEK-hOCT2
Platinum Drugs (hour) (pM) (pM) RF
cisplatin 7 2.95 + 0.23 1.32 ± 0.18 2.23***
carboplatin 7 110 + 46.3 61.6 ± 46.3 1.78
oxaliplatin 7 2.99 _ 1.51 0.039 ± 0.025 76.7**
oxaliplatin 24 1.50 + 0.69 0.02 _ 0.001 73.8*
oxaliplatin 72 0.93 + 0.056 0.019 _ 0.004 48.4***
C. Cytotoxicity, expressed as ICso, of the platinum drugs in HEK-MOCK and HEK-hOCT3
cells.
Drug Exposure Time HEK-MOCK HEK-hOCT3
Platinum Drugs (hour) (pM) (pM) RF
cisplatin 7 2.83 ± 0.90 2.44 ± 0.71 1.16
carboplatin 7 84.8 ± 9.71 48.1 ± 23.4 1.76
oxaliplatin 7 1.47 ± 0.28 2.22 ± 0.41 0.66
oxaliplatin 24 0.47 ± 0.05 0.62 ± 0.19 0.75
oxaliplatin 72 0.47 ± 0.12 0.69 ± 0.19 0.68
*: p < 0.05; **: p < 0.01 and ***: p < 0.001
Table 2.1. The ICso values (pM) of cisplatin, carboplatin and oxaliplatin in (A) human OCT1-
(B) OCT2- and (C) OCT3-transfected cell lines were determined in parallel with those in the
corresponding MOCK cells using MTT assay as described in the Experimental Procedures.
Briefly, the cells were seeded in 96-well plates at a density of 5,000 cells/well for the
transfected MDCK cells or 12,000 cells/well for the transfected HEK 293 cells. The platinum
drugs were added on the following day. After the specified time periods of drug exposure,
the drug-containing medium was replaced with fresh, drug-free medium, and the
incubation was continued for a total of 72 hours (starting from the time when the drug was
added). After incubation, the cell growth was determined by an MTT assay. Data are
expressed as mean ± SD from 3 to 6 independent experiments with each performed in
quadruplicate. The resistance factor (RF) was defined as the ratio of the mean IC50 value in
the MOCK cells to that in the OCT-transfected cells.
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These results indicate that OCT1 enhances the cytotoxicity of oxaliplatin, but not
that of cisplatin or carboplatin. A similar pattern of observations was obtained in
human OCT2-transfected cells, but the increase in oxaliplatin cytotoxicity was
A
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Figure 2.2. The cytotoxicity of oxaliplatin in (A) OCT1-, (B) OCT2- and (C) OCT3-transfected
cells (0) and in the corresponding MOCK cells ( 0 ) was determined as described in
the Experimental Procedures. Cells were seeded in 96-well plates at a density of 5,000
cells/well for the transfected MDCK cells and 12,000 cells/well for the transfected HEK 293
cells and exposed to the test compounds for 7 hours on the following day. After a total of
72 hours, cell growth was determined by an MTT assay. In addition, the cytotoxicity of
oxaliplatin in (D) OCT1- and (E) OCT2-transfected cells (open symbols) and in the
corresponding empty vector-transfected cells (MOCK cells) (solid symbols) in the
presence (squares) or absence (circles) of an OCT inhibitor (disopyramide for OCT1, and
cimetidine for OCT2) was also simultaneously determined in a similar fashion. When the
OCT inhibitors were used, disopyramide (150 pM) or cimetidine (1.5 mM) was added to the
incubation medium immediately before the addition of oxaliplatin. The lines represent the
predicted data obtained by fitting the observed data using WinNonlin as described in the
Experimental Procedures. Presented are the data from a typical experiment. Three to six
independent experiments were performed and similar results were obtained. For clarity,
the standard deviation bars in panel D and E were eliminated.
much more pronounced (Figure 2.2B). The IC50 values of oxaliplatin after
different time periods (7, 24 and 72 hr) of exposure were all markedly greater in
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HEK-MOCK cells than in HEK-OCT2 cells with RF values ranging from 48.4 to
76.7 (p < 0.05 to p < 0.001) (Table 2.1B and Figure 2.2B). However, the IC50
values of cisplatin and carboplatin were only slightly greater in HEK-MOCK cells
than in HEK-OCT2 cells with RF values around 2 after 7-hour drug exposure
(Table 2.1B). Co-incubation with an OCT inhibitor, cimetidine (1.5 mM),
dramatically increased the oxaliplatin IC5so (control vs. cimetidine-treated: 0.039 ±
0.025 !IM vs. 2.81 + 1.63 M) by 72-fold (p < 0.05) in HEK-hOCT2 cells, with only
a 3.18-fold increase in HEK-MOCK cells (control vs. cimetidine-treated: 2.99 ±
1.51 vs. 9.50 ± 2.95 jM, p < 0.05) (Figure 2.2E). Cimetidine itself did not exhibit
cytotoxicity up to a concentration of 5 mM under the same test conditions (data
not shown). These results indicate that OCT2 markedly enhances the cytotoxicity
of oxaliplatin with only slight effects on the cytotoxicities of cisplatin and
carboplatin. In contrast to OCT1 and OCT2, overexpression of human OCT3 did
not affect the cytotoxicity of any of the platinum drugs (Table 2.1C and Figure
2.2C).
Platinum Accumulation Rates in Cells After Exposure to Cisplatin, Carboplatin
and Oxaliplatin
The cellular platinum accumulation rate after two hours of exposure to
oxaliplatin (3 pM) was 2.90-fold higher (p < 0.001) in MDCK-hOCT1 cells (8.53 ±
0.52 pmol I (mg protein-hr)) than that in MDCK-MOCK cells (2.94 ± 0.11 pmol I
(mg protein-hr)) (Figure 2.3A). Co-incubation with disopyramide (150 jiM)
resulted in a two-fold decrease in the rate of platinum accumulation in MDCK-
hOCT1 cells (control vs. disopyramide-treated;
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Figure 2.3. Cellular accumulation of platinum after 2-hour exposure to cisplatin,
carboplatin and oxaliplatin. The cellular accumulation rates of platinum in (A) OCT1-, (B)
OCT2- and (C) OCT3-transfected cells and in the corresponding MOCK cells after
incubation with cisplatin, carboplatin and oxaliplatin in the presence (open bars) and
absence (solid bars) of an OCT inhibitor (disopyramide for OCT1, cimetidine for OCT2 and
OCT3) were determined as described in the Experimental Procedures. Briefly, (A) MDCK
cells were incubated in the antibiotic-free medium containing cisplatin (3 pM), carboplatin
(15 pM) or oxaliplatin (3 pM) at 370 C and 5% CO 2 for 2 hours. For the inhibitor studies, the
incubation medium also contained disopyramide (150 pM). (B) HEK 293 cells were
incubated in the antibiotic-free medium containing cisplatin (0.3 pM), carboplatin (10 pM)
or oxaliplatin (0.3 pM) at 370C and 5% CO2 for 2 hours. For the inhibitor studies, the
incubation medium also contained cimetidine (1.5 mM). (C) The study was performed
similarly as (B) except that the concentrations of cisplatin, carboplatin and oxaliplatin in
the incubation medium were 2 pM, 10 pM and 2 pM, respectively. After drug exposure, the
cells were washed with ice-cold PBS three times and harvested by scraping and
centrifugation. The cell-associated platinum was determined by ICP-MS and normalized for
protein content. Data are expressed as mean ± SD from a single experiment performed in
triplicate. Experiments were replicated for OCT1 and OCT2, and similar results were
obtained.
8.53 ± 0.52 vs. 4.04 ± 0.04 pmol I/ (mg protein-hr), p < 0.001) with little effect in
MDCK-MOCK cells (control vs. disopyramide-treated; 2.94 ± 0.11 vs. 3.23 ± 0.31
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pmol / (mg protein-hour), p > 0.05) (Figure 2.3A). However, the cellular
accumulation rates of platinum after 2-hr exposure to cisplatin (3 pM) or
carboplatin (15 pM) in MDCK-hOCT1 cells (cisplatin: 3.88 ± 0.15 pmol / (mg
protein-hr)); carboplatin: 2.77 ± 0.36 pmol / (mg protein-hr)) were not significantly
different from those in MDCK-MOCK cells (cisplatin: 3.70 ± 0.45 pmol / (mg
protein-hr)); carboplatin: 2.22 ± 0.07 pmol / (mg protein-hr)) and were not
inhibited by disopyramide (Figure 2.3A). These results indicate that human OCT1
contributes substantially to the uptake of oxaliplatin, but not cisplatin or
carboplatin in OCT1-transfected cells. The platinum accumulation rate in HEK-
hOCT2 (20.2 ± 1.54 pmol / (mg protein-hr)) was markedly higher (21.7-fold, p <
0.001) than that in HEK-MOCK cells and was substantially reduced in the
presence of cimetidine (control vs. cimetidine; 20.2 ± 1.54 vs. 1.80 ± 0.13 pmol /
(mg protein-hr)). However, the cellular accumulation rate of platinum in HEK-
hOCT2 cells after 2-hr exposure to cisplatin (0.3 pM) or carboplatin (10 pM)
(cisplatin: 0.738 ± 0.055 pmol / (mg protein-hr); carboplatin: 4.17 ± 0.18 pmol /
(mg protein-hr)) was only modestly higher (1.38-fold for carboplatin, p < 0.001;
2.08-fold for cisplatin, p < 0.01) than that in HEK-MOCK cells. Co-incubation with
cimetidine (1.5 mM) produced only a small decrease (less than 1.5-fold, p < 0.01)
in platinum accumulation rate after exposure of HEK-hOCT2 cells to either
cisplatin or carboplatin with little effect in HEK-MOCK cells. These results
indicate that OCT2 plays a critical role in the uptake of oxaliplatin in the
transfected cells with a much lower effect on the uptake of cisplatin or
carboplatin. In contrast to OCT1 and OCT2, OCT3 overexpression did not affect
the uptake of any of these platinum drugs (Figure 2.3C).
Platinum-DNA Adduct Formation after 2-hr Exposure to Oxaliplatin
To determine whether the oxaliplatin taken up by cells via the human
OCT1 and OCT2 transporters was available for DNA binding, we also measured
platinum-DNA adduct formation after a 2-hr exposure to oxaliplatin (Figure 2.4).
The platinum-DNA adduct level in MDCK-hOCT1 cells (0.0457 + 0.0011pmol / pg
DNA, rb (ratio of bound platinum atoms per nucleotide) = 1.51 + 0.04 x 10-5) was
4.15-fold greater (p < 0.001) than that in MDCK-MOCK cells (0.0110 ± 0.0010
pmol / pg DNA, rb = 3.63 ± 0.33 x 10-6) after exposure to oxaliplatin (Figure 2.4A).
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Figure 2.4. The content of platinum bound to DNA after 2-hr exposure to oxaliplatin in the
presence (open bars) or absence (solid bars) of an OCT inhibitor (disopyramide for OCT1,
cimetidine for OCT2) was determined as described in the Experimental Procedures.
Briefly, (A) Transfected MDCK cells were incubated in the antibiotic-free medium
containing oxaliplatin (10 rpM) with or without disopyramide (150 PM). (B) Transfected HEK
293 cells were incubated in the antibiotic-free medium containing oxaliplatin (0.6 pM) with
or without cimetidine (1.5 mM). After incubation at 370C and 5% CO 2 for 2 hours, the cells
were washed with ice-cold PBS three times and harvested. The genomic DNA was isolated
from the cells and the platinum content associated with DNA was determined by ICP-MS
and normalized for DNA content. Data are expressed as mean ± SD from a typical
experiment performed in triplicate. Two independent experiments were conducted and
similar results were obtained.
Co-incubation with disopyramide (150 pM) significantly decreased (2.11-fold, p <
0.001) platinum-DNA adduct formation in MDCK-hOCT1 cells (control vs.
disopyramide-treated; 0.0457 ± 0.0011 pmol / pg DNA, rb = 1.51 ± 0.04 x
10-5 vs. 0.0217 ± 0.0019 pmol / pg DNA, rb = 7.16 ± 0.63 x 10-6) with no effect in
MDCK-MOCK cells. The platinum-DNA adduct level in HEK-hOCT2 cells (0.0284
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+ 0.0020 pmol / pg DNA, rb = 9.37 ± 0.66 x 10-6) was 28.8-fold higher (p < 0.001)
than that in HEK-MOCK after exposure to oxaliplatin (Figure 2.4B) and was
markedly reduced by cimetidine (0.00216 + 0.00031 pmol / pg DNA, rb = 9.37 +
0.66 x 10-6 vs. 7.13 + 1.02 x 10-7). Cimetidine produced only a small decrease
(1.70-fold, p < 0.05) in HEK-MOCK cells.
Structure-Activity Relationships (SAR) for Platinum-OCT1 Interaction
To investigate the SAR for platinum-OCT1 interactions, the drug sensitivities
(IC50) and RF values of 9 platinum complexes (Figure 2.1) in both MDCK-MOCK
and MDCK-hOCT1 cells were determined (Table 2.2A): the higher the RF value,
the higher the interaction.
1. Nature of the non-leaving group(s): RF values less than two were obtained
for platinum complexes with diammine non-leaving groups including
cisplatin, carboplatin and [Pt(NH 3)2(trans-1,2-(OCO)2C 6Hlo], indicating that
platinum compounds with this purely inorganic non-leaving unit are poorly
recognized by OCT1 (Table 2.2A). However, when the non-leaving
group(s) contained an organic component as in [PtCI2(en)], which has two
methylene groups between the amine functionalities, the RF value
increased to 3.26. Moreover, with increasing size of the organic
component of the non-leaving group(s), the interaction of a platinum
compound with OCT1 increased. For example, the platinum compounds
cis-[Pt(NH 3)(Cy)CI2], the R,R- and S,S-isomers of oxaliplatin and
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[Pt(DACH)C12], which all have a 6-C cyclohexyl moiety as part of their non-
leaving group, had high RF values (9.02-28.4) (Table 2.2A). Therefore, it
appears that the structure of the non-leaving group(s) of a platinum
compound is an important determinant of its interaction with OCT1. Lastly,
different isomers of the 1,2-diaminocyclohexane-substituted platinum
complexes appear to interact similarly with OCT1. The R,R- and S,S-
isomers of oxaliplatin (R,R vs. S,S: 22.4 vs. 20.7) and [Pt(DACH)C12] (R,R
vs. S,S: 22.9 vs. 28.4) have similar RF values (Table 2.2A).
Table 2.2. Drug sensitivity of platinum compounds.
Table 2.2(A) Drug sensitivity of structurally diverse platinum complexes in OCT1-
transfected cells. The ICso0 values (pM) of all the 9 platinum complexes, except for
carboplatin, in MDCK-MOCK and MDCK-hOCT1 after 7 hours of drug exposure were
determined in parallel using an MTT assay as described in the Experimental Procedures.
Briefly, MDCK cells were seeded at a density of 5,000 cells/well in 96-well plates and
exposed to the test compounds for 7 hours on the following day. After incubation for a
total of 72 hours, the cell growth was determined by an MTT assay. The data for
carboplatin was taken from Table 2.1A and was not determined simultaneously with the
other compounds. The resistance factor (RF) was defined as the ratio of the mean IC50
value in MDCK-MOCK cells to that in MDCK-hOCT1 cells.
MDCK-MOCK MDCK-hOCT1
Platinum Complexes (pM) (pM) RF
cisplatin 6.32 ± 0.74 3.58 + 0.30 1.76**
carboplatin 258 + 86.3 227 + 85.8 1.13
[Pt(NH 3)2(trans-1,2-(OCO) 2C6Hlo] 21.4 ± 2.94 10.8 + 2.66 1.97***
[Pt(C12)(en)] 33.2 + 11.5 10.2 ± 4.76 3.26**
cis-[Pt(NH3)(Cy)C 21 1.42 ± 0.15 0.16 + 0.03 9.02***
oxaliplatin 10.9 + 3.66 0.48 + 0.19 22.4***
[Pt(S,S-DACH)oxalato] 30.0 + 14.2 1.45 + 1.16 20.7***
[Pt(R,R-DACH)C12] 15.0 + 3.24 0.65 + 0.26 22.9***
[Pt(S,S-DACH)C 2] 16.2 + 3.72 0.57 + 0.18 28.4***
**: p < 0.01; ***: p < 0.001.
65
Table 2.2(B) The sensitivity of the colon cancer cell lines to oxaliplatin and cisplatin in the
presence and absence of cimetidine. The IC50 values (FM) of oxaliplatin and cisplatin in the
colon cancer cell lines were determined in the presence or absence (control) of cimetidine
(1.5 mM) in a similar fashion. The cell seeding density was 6,000-, 8,000-, 6,000-, 15,000-
12,000- and 4,000 cells/well for HCT116, HT29, RKO, SW620, LS180 and DLD cells,
respectively. When cimetidine (1.5 mM) was used, it was added to the wells immediately
before the addition of the platinum drugs. The resistance factor (RF) was defined as the
ratio of the mean ICso value in the presence to that in the absence of cimetidine. Data are
expressed as mean + SD from six measurements for both (A) and (B), and each
measurement was performed in quadruplicate.
Oxaliplatin Cisplatin
Cimetidine- Cimetidine-
Cell Lines Control treated RF Control treated RF
HCT116a 2.37 ± 1.44 18.8 ± 6.19 7.93*** 5.42 ± 1.34 10.2 ± 3.23 1.88**
HT29a 4.56 ± 1.40 52.1 ± 18.5 11.4*** 12.4 ± 3.91 30.8 ± 11.0 2.47**
RKOa 1.64 ± 0.56 9.70 + 2.70 5.92*** 8.58 + 2.38 12.5 ± 4.44 1.46
SW620a 2.81 ± 1.00 14.2 ± 2.81 5.04*** 12.6 ± 1.95 22.2 ± 4.92 1.76**
LS180a 1.30 ± 0.41 8.39 ± 2.77 6.44*** 5.72 +± 1.75 8.27 ± 3.35 1.44
DLD 10.6 ± 5.99 71.3 ± 12.9 6.73*** 18.4 ± 7.58 32.3 ± 10.3 1.74*
*. p < 0.05; **" p < 0.07 and ***p < 0.001.
a: The IC50 value of oxaliplatin is significantly lower
cimetidine.
than that of cisplatin in the absence of
2. Nature of the leaving group(s): Changes in the leaving group did not
induce substantial changes in the RF values of platinum complexes. For
example, all the DACH compounds (R,R- and S,S-isomers of oxaliplatin
and [Pt(DACH)CI2]) had similar RF values (20.7-28.4, Table 2.2A),
although the leaving group of oxaliplatin (oxalate) is very different from
that of [Pt(DACH)CI21 (chloride) (Table 2.2A). In addition, cisplatin,
carboplatin and [Pt(NH 3)2(trans-1,2-(OCO) 2C6Hlo0 , all of which have
different leaving groups but identical non-leaving groups, had similar RF
values (1.13-1.97, Table 2.2A). Moreover, a cyclohexane ring, when
present in the non-leaving group(s) of a platinum complex, such as in
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those DACH compounds, markedly increases OCT1 interaction (RF:
20.7-28.4) in comparison to diammine ligands (RF : 1.13-1.97). However,
when the cyclohexane ring was incorporated into the leaving group, as in
[Pt(NH 3)2(trans-1,2-(OCO)2C6Hio], it had no effect on the OCT1
interaction, the RF value of [Pt(NH 3)2(trans-1 ,2-(OCO) 2C 6 Hio] being 1.97
(Table 2.2A).
Identification of the Chemical Form of Oxaliplatin that is the Substrate(s) of OCTi
Multiple chemical species exist in equilibrium when platinum complexes
are dissolved in an aqueous solution containing high concentrations of chloride
ion.34'35 Therefore, identification of the chemical species that are taken up by
OCT1 would contribute to our understanding of the SAR of platinum-OCT1
interactions. In chloride containing media, such as plasma ( [CI] - 103 mM) 35
and our cell culture medium, the oxalate leaving group of oxaliplatin can be
replaced by chloride, resulting in [Pt(R,R-DACH)C12]. The latter can be further
aquated to form the mono-, [Pt(R,R-DACH)(H 20)CI], and dicationic, [Pt(R,R-
DACH)(H 20) 2 ]2 , species. 36 The monoaqua and diaqua cations are the active
forms of oxaliplatin, which bind to DNA. Considering the general properties of
OCT substrates, which are positively charged small organic compounds, it is
likely that the mono- and / or diaqua chemical species, having one or two positive
charges, are the chemical forms taken up by OCT1.
To investigate experimentally the oxaliplatin-derived species taken up by
OCT1, we first measured the platinum-DNA adduct formation in both MDCK-
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hOCT1 and MDCK-MOCK cells after incubation with oxaliplatin (20 pM) in
chloride free buffer (PB-SO 4). In this buffer, oxaliplatin should remain
predominantly intact because the affinity of sulfate for platinum(ll) is much lower
than that of chloride. 35 Displacement of the oxalate group by water will be a
relatively slow process. In addition, we used short incubation times (25 min) to
minimize conversion of oxaliplatin to intermediate aquated species. Under these
conditions, the Pt-DNA adduct level in MDCK-hOCT1 cells (0.00398 ± 0.00089
pmol / pg DNA, rb = 1.31 ± 0.29 x 10-6) was similar to (p > 0.05) that in MDCK-
MOCK cells (0.00320 ± 0.00042 pmol I/ pg DNA, rb = 1.05 1 0.14 x 10-6) (Figure
2.5), suggesting that unmodified oxaliplatin is not an OCT1 substrate. Secondly,
to determine whether an aquated form of oxaliplatin was taken up by OCT1, we
0.025 -
I~,
in PB-iatin Olihtln [ PB-DACMO)in PB-SO, -in PB-CI in PB-ryO'
Figure 2.5. Platinum-DNA adduct formation after incubation with oxaliplatin or [Pt(R,R-
DACH)(H20) 2 2+ in PB-Cl or PB-SO4 buffer. Transfected MDCK cells were incubated with
oxaliplatin (20 pM) or [Pt(R,R-DACH)(H 20) 22 + (1 pM) in PB-CI or PB-SO4 buffer at 371C and
5% CO 2 for 25 min. Oxaliplatin was freshly prepared and was added to PB-SO4 buffer
immediately, and to PB-CI buffer half an hour before cell incubation. After incubation, the
cells were washed with ice-cold PBS three times and harvested. Genomic DNA was
isolated from the harvested cells and the DNA-associated platinum content was
determined by ICP-MS and normalized for the DNA content. Data are expressed as mean +
SD of three measurements.
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measured platinum-DNA adduct formation after incubation with oxaliplatin (20
pM) in the chloride-containing buffer, PB-CI, for 25 min. Under these conditions, it
is likely that conversion to the monochloro/monoaqua cation will occur, with
displacement of the oxalate ligand. The DNA-associated platinum level was
substantially higher (2.74-fold, p < 0.01) in MDCK-hOCT1 cells (0.00933 ±
0.00124 pmol / pg DNA, rb = 3.08 ± 0.41 x 10-6 ) than that in MDCK-MOCK cells
(0.00340 ± 0.00087 pmol / pg DNA, rb = 1.12 ± 0.29 x 10-6) (Figure 2.5)
consistent with this expectation. We also determined platinum-DNA adduct
formation after direct incubation with the diaqua compound, [Pt(R,R-
DACH)(H 20) 2 2+ (1 pM), in the PB-SO 4 buffer for 25 min. Under these conditions,
the platinum complex will be a mixture of diaqua (82.8 %) and aqua/hydroxo
(17.1%) species. Here the percentage was calculated based on the pKa values of
6.14 and 7.56 for the diaqua and aqua/hydroxo forms of oxaliplatin,
respectively,37 and the pH value of 7.4 for the incubation buffer). The DNA-
associated platinum level in MDCK-hOCT1 cells (0.0139 ± 0.0020 pmol / pg
DNA, rb = 4.59 ± 0.66 x 10-6) was similar to (p > 0.05) that in MDCK-MOCK cells
(0.0142 ± 0.0028 pmol / pg DNA, rb = 4.69 ± 0.92 x 10-6) (Figure 2.5), suggesting
that the diaqua form is not an OCT1 substrate. Whether or not the aqualhydroxo
form, which carries one positive charge, can be taken up by OCT1 remains
unclear. Taken together, these studies suggest that a monoaquated form of
oxaliplatin, either the chloro or hydroxo species, both of which carry one positive
charge, is the actual substrate of OCT1.
Expression of OCTI and OCT2 in Colon Cancer Cell Lines and Tissue Samples
Since oxaliplatin is currently approved for advanced colon cancer therapy,
we determined the expression of OCT1 and OCT2 in colon cancer cell lines and
tumor samples. As shown in Figure 2.6, expression of OCT1 mRNA was
detected in the six colon cancer cell lines tested in this study (LS180, DLD,
SW620, HCT116, HT29 and RKO) with the highest expression level in HT29
cells. Four normal colon tissue samples and twenty colon tumor samples
exhibited variable OCT1 expression levels. OCT2 was not detected in any of the
cell lines or in the normal colon tissue samples; however, 11 of the 20 tumor
samples demonstrated significant OCT2 expression (Figure 2.6).
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Figure 2.6. Expression of OCT1 and OCT2 in colon cancer cell lines and colon tissue
samples. Total RNA was isolated from colon cancer cells and normal or cancerous colon
tissues. The expression of OCT1 and OCT2 in these samples was detected by RT-PCR as
described in the Experimental Procedures. A PCR cycle number of 40 was used in all the
samples. Human GAPDH expression was used as a loading control and a PCR cycle
number of 30 was used for its amplification.
Effect of an OCT Inhibitor, Cimetidine, on Colon Cancer Cell Line Sensitivity to
Cisplatin and Oxaliplatin
To evaluate the potential role of OCT1 in the cytotoxicity of oxaliplatin and
to determine whether OCT1 contributes to the differences in activities of cisplatin
- -L.
and oxaliplatin, we determined the sensitivities (IC5o) of both oxaliplatin and
cisplatin in the colon cancer cells in the presence and absence of an OCT
inhibitor, cimetidine (1.5 mM). The resistance factor (RF) due to the presence of
cimetidine was defined as the ratio of the IC5o value in the presence of cimetidine
to that in the absence of cimetidine. As shown in Table 2.2B, the sensitivity of
oxaliplatin was higher (lower IC50) than that of cisplatin in each of the tested
colon cancer cell lines in the absence of cimetidine (control, the mean ± SE of
IC50  in the six cell lines: 3.88 ± 1.42 pM (oxaliplatin) vs. 10.5 ± 2.02 pM
(cisplatin)). However, in the presence of cimetidine, oxaliplatin sensitivity was
substantially decreased in each of the cell lines (RF values ranged from 5.04 to
11.4 (p < 0.001)), resulting in IC50 values comparable to, or even higher than
those of cisplatin (mean ± SE of IC50 in the six cell lines: 29.1 ± 10.7 pM
(oxaliplatin) vs. 19.4 ± 4.32 pM (cisplatin)). The effect of cimetidine on cisplatin
sensitivity was small (range of RF values: 1.44-2.47, Table 2.2B).
Discussion
The striking activity of cisplatin in otherwise fatal disease, testicular
cancer, has been established by thirty years of clinical experience. However,
acquired and intrinsic resistance limits its application to a relatively narrow range
of tumor types. To broaden the anticancer spectrum of this platinum agent,
thousands of structural analogs have been tested. Cisplatin analogs with two
ammine ligands, such as carboplatin and nedaplatin (approved in Japan), are
cross-resistant with cisplatin.38 Analogues with different ligands display more
diverse activity profiles. 4 Notably, oxaliplatin, with DACH in place of the two
ammine ligands, in combination with 5-fluoruracil/leucovorin produced response
rates twice that of 5-fluoruracil/leucovorin regimens alone in the treatment of
colorectal cancer,39 against which cisplatin is inactive.6 Efforts to understand the
differences in oxaliplatin versus cisplatin antitumor activity have focused mainly
on the cellular processing of cisplatin- and oxaliplatin-DNA adducts.1 3' 14 40
Defects in MMR cause modest to moderate resistance to cisplatin but not to
oxaliplatin.40, 41 Differences in the mechanism(s) controlling cellular uptake and
efflux of these platinum compounds, although rarely studied, can also contribute
to their disparate activities considering the nature of their chemical structures.
In the present study, we observed that the influx transporters, OCT1 and
OCT2, play a critical role in the cellular uptake and consequent cytotoxicity of
oxaliplatin (Table 2.1 and Figure 2.2). In contrast, the two transporters were
relatively unimportant in mediating the uptake and cytotoxicity of cisplatin and
carboplatin (Table 2.1). Overexpression of OCT1 and, more strikingly, OCT2 in
transfected cells not only increased the rate of cellular platinum accumulation but
also elevated the level of platinum-DNA adducts after oxaliplatin exposure
(Figure 2.3 and Figure 2.4). These effects were blocked by known OCT
inhibitors. The data strongly suggest that oxaliplatin is an excellent substrate of
human OCT1 and OCT2, and the cellular uptake of platinum mediated by these
transporters has ready access to the key pharmacological target (DNA). These
results are in contrast to platinum uptake mediated by human Ctrl, which
appears to sequester the drug in some intracellular compartment, rendering it
inaccessible to the pharmacological target 18. It should be noted that a modest
increase in cisplatin uptake (Figure 2.3B) and sensitivity (2.23-fold, p < 0.001,
Table 2.1B) was observed in HEK-hOCT2 cells in comparison to HEK-MOCK
cells, suggesting that cisplatin is a weak substrate of OCT2, consistent with
previous work 33
It is noteworthy that expression of OCT1 or OCT2, even at low levels, may
play a significant role in the cytotoxicity of oxaliplatin. We consistently observed a
more than three-fold increase (3.18-fold) in the IC50 value of oxaliplatin in HEK-
MOCK cells in the presence of the OCT inhibitor, cimetidine (Figure 2.2E), but
not for cisplatin or carboplatin (data not shown). The decrease in oxaliplatin
sensitivity in HEK-MOCK cells by the OCT inhibitor is most likely due to inhibition
of intrinsic OCT1 and/or OCT2 activity in HEK 293 cells. Both transporters were
detected in HEK-MOCK cells in PCR studies using a cycle number of 40 (data
not shown). Furthermore, cimetidine consistently produced a significant decrease
in the cellular uptake of oxaliplatin, but not of cisplatin or carboplatin in HEK-
MOCK cells (Figure 2.3B, 2.3C). Although it might be possible that cimetidine
reacts with the platinum compounds and therefore inactivates them, this
explanation is unlikely to be of the primary importance since we would have
expected to observe similar effects of cimetidine on the cellular uptake and
cytotoxicity of cisplatin and carboplatin. Taken together, the data suggest that low
levels of expression of OCT1 and OCT2 play a significant role in sensitizing cells
to oxaliplatin.
Structure-activity relationship studies revealed that the nature of the amine
ligand bound to platinum is important for interaction with OCT1, with an organic
component being required for effective interaction. On the other hand, the
structure of the leaving ligand seems to be unimportant. We showed that a
monoaqua derivative of oxaliplatin, either the chloro or hydroxo species, -not a
divalent diaqua complex, was likely to be the preferred substrate of OCT1 (Figure
2.5). These results are consistent with previous work showing that OCTs interact
with small molecular weight monovalent organic cations 25. Although the
structure-activity relationships were established for platinum-OCT1 interactions, it
is likely that the conclusions will apply to platinum-OCT2 interactions because the
two transporters have largely overlapping substrate specificities.- These: studies
establish the basis for the design of additional platinum complexes to facilitate
the development of an even more detailed structure-activity relationship, which
could be used to predict their interaction with OCTs. We anticipate the potential
to target platinum complexes for therapy against tumors that express OCT1. and
OCT2.
Our structure-activity relationship studies further suggest that OCTs do not
play a major role in determining the cytotoxicity of platinum compounds with two
ammine ligands, such as cisplatin, carboplatin and nedaplatin. In contrast, OCTs
may be important for mediating cytotoxicity of platinum compounds with organic
amine ligands (Table 2.2B). Cell lines that are resistant to cisplatin are cross-
resistant to the diammine complexes, carboplatin and nedaplatin, but not to the
DACH compounds, oxaliplatin and tetraplatin, which share a similar activity
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profile 4,38. Differences in the activity profiles of these compounds parallel the
differences in their interaction with OCTs, suggesting that interactions with OCT1
and OCT2 may explain, at least in part, differences in the activities and tumor
specificities of platinum complexes.
It is likely that the activity of oxaliplatin in colorectal cancer can be
explained, at least in part, by the selective uptake via OCTs. In this study, we
detected OCT1 expression in all twenty human colon cancer tissue samples and
OCT2 expression in 11 out of 20 tissue samples (Figure 2.6). Similar levels of
OCT1 were also detected in the six tested human colon cancer cell lines
although OCT2 was not detectable (Figure 2.6). However, both OCT1 and OCT2
expression have been detected in another human colon cancer cell line, Caco-2
28,31. As has been observed previously 4, drug sensitivity to oxaliplatin was
greater than that of cisplatin in each of the six colon cancer cell lines (Table
2.2B). The higher activity of oxaliplatin in comparison to that of cisplatin in these
colon cancer cells is probably a consequence of the selective uptake of
oxaliplatin mediated by the intrinsic OCT1 in these cells, since similar activities of
oxaliplatin and cisplatin were observed in these cells when OCT1 was blocked by
cimetidine (Table 2.2B).
Based on the expression of OCT1 and OCT2 in the colon cancer tissue
samples and the OCT-dependent activity of oxaliplatin in the cell lines, it is
reasonable to speculate that these transporters are important determinants of
oxaliplatin activity in colorectal cancer. Also, it is possible that variable
expression of OCTs, especially OCT2, may account for the variability in response
to oxaliplatin treatment. Further studies are required to determine whether
expression levels of OCT1 and OCT2 may be used as markers for the rational
selection of oxaliplatin-based versus irrinotecan-based combination therapies for
treatment of individuals with colorectal cancer. Such selection is now primarily
based on side-effect profiles or clinical experience 42. Oxaliplatin-based therapy
may be a better choice for patients with high levels of OCT1 and OCT2 in their
tumor samples. In addition, genotyping for non-functional and reduced function
polymorphisms of OCT1 and OCT2 may be incorporated in the decision-making
process.43,44
Currently, platinum based therapies are used in the treatment of a variety
of tumors including testicular cancer, ovarian cancer, small cell lung cancer and
head and neck cancers 38. In these therapies, cisplatin is often the drug of choice
because other platinum compounds such as oxaliplatin are not superior.
However, our studies suggest that when OCT1 or OCT2 is expressed in the
tumor, oxaliplatin may be a better choice. Recently, OCT1 and OCT2 expression
has been observed in a number of human cancer cell lines 31, suggesting that
these transporters may be expressed in the corresponding tumors. The results of
this study clearly suggest the need for further investigations to determine whether
expression of OCTs can provide a basis for the rationale selection of platinum
based therapies.
Experimental Procedures
Drugs and Reagents
Cisplatin, carboplatin, oxaliplatin, cimetidine, disopyramide, N-methyl-4-
phenylpyridinium (MPP+) and thiazolyl blue tetrazolium bromide were purchased
from Sigma (St. Louis, MO). Solutions of carboplatin (10 mM) and oxaliplatin (5
mM) were freshly prepared in water. A solution of cisplatin (2 mM) was made in
1 x phosphate buffered saline (PBS). These stock solutions were immediately
aliquoted and stored frozen at -20 0C and discarded one month after preparation.
[methyl- 3H]-MPP' was from Perkin Elmer (Boston, MA) and tetraethylammonium
(TEA) bromide [ethyl-1- 14C] was from American Radiolabeled Chemicals (St.
Louis, MO). Hygromycin B and G418 were from Invitrogen (Carlsbad, CA). The
cell culture medium Dubecco's Modified Eagle Medium (DMEM), RPMI and fetal
bovine serum (FBS) were from the Cell Culture Facility of University of California,
San Francisco (San Francisco, CA).
Cell Lines and Transfection
Madin-Darby canine kidney (MDCK) cells stably transfected with the full
length human OCT1 cDNA (MDCK-hOCT1) and with the empty vector (MDCK-
MOCK) were established previously in our laboratory 43, Human embryonic
kidney (HEK) 293 cells transfected with pcDNA5/FRT vector (Invitrogen)
containing the full length human OCT2 cDNA (HEK-hOCT2) and with the empty
vector (HEK-MOCK) were established using Lipofectamine TM 2000 (Invitrogen)
per manufacturer's instructions. The stable clones were selected with 75 pg / ml
of hygromycin B. HEK 293 cells transfected with pcDNA3 vector containing the
full length human OCT3 cDNA (HEK-hOCT3) and with the empty vector (HEK-
MOCK) were also established using Lipofectamine TM 2000. The stable clones
were selected with 600 pg / ml G418. The pcDNA3 vector containing the full
length human OCT3 cDNA was a kind gift from Dr. Bonisch (Institute of
Pharmacology and Toxicology, University of Bonn, Germany). All the colon
cancer cell lines (LS180, SW620, DLD, HCT116, HT20 and RKO) used in the
present study were from American Type Culture Collection (Manassas, VA).
Cell Culture
The culture medium for stably transfected MDCK and HEK 293 cells is
DMEM supplemented with 10% FBS and 100 units / ml penicillin and 100 pg / ml
streptomycin (Invitrogen). To maintain the transgene expression, :G418
(Invitrogen, 600 [pg / ml) was added to the culture medium for MDCK transfected
cells, human OCT3 transfected HEK 293, cells (HEK-hOCT3) and the
corresponding HEK-MOCK cells; Hygromycin B (Invitrogen, 75 pLg / ml) was
added to the culture medium for human OCT2 transfected HEK 293 cells (HEK-
hOCT2) and the corresponding HEK-MOCK cells. The culture medium for all the
colon cancer cell lines (RKO, DLD, HT29, HCT116, LS180 and-SW620) is RPMI
containing 10% FBS, 100 units / ml penicillin and 100 pg / ml streptomycin. All
the cells were grown at 370C in a humidified atmosphere with 5 % CO2/ 95 % air.
Drug Sensitivity Assay
Cytotoxicity of the platinum compounds was measured by MTT (thiazolyl
blue tetrazolium bromide) assay. Cells were seeded in 100 fl of the culture
medium without any antibiotics in 96-well plates at a predetermined cell density.
For HEK 293 cells, poly-D-lysine coated plates were used. After overnight
incubation, the platinum compounds were then added to the culture medium to
give the indicated final concentrations. For the OCT inhibitor studies, the
inhibitors (disopyramide or cimetidine) were added to the medium at a specified
concentration immediately before the addition of the platinum compounds. After
incubation for a specified time period, the drug-containing medium was replaced
with fresh, drug-free medium and the incubation was continued for a total of 72
hours (start from the addition of platinum compounds). Then the MTT assay was
performed similarly as previously described 45. The IC5so (the drug concentration
which inhibits 50% of cell growth) values were obtained by fitting the percent of
the maximal cell growth at different drug concentrations (F) with the equation,
F=100x(1-C7I(IC5so+C)), using WinNonlin (Pharsight, Mountain View, CA). The
maximal cell growth was the cell growth in the medium without any platinum
compounds; C is the concentration of the platinum compound and y is the slope
factor.
Cellular Uptake of TEA or MPP"
MDCK or HEK 293 Cells were grown in 24-well plates to > 90%
confluence in the culture medium without any antibiotics. The poly-D-lysine
coated plates were used for HEK 293 cells. The cells were washed with 1 x PBS
first and then incubated in the uptake buffer (1 x PBS) containing 10 pM 14C-TEA
or 2 pM 3H-MPP' as specified. For the OCT inhibitor studies, the indicated OCT
inhibitor (disopyramide or cimetidine) was added to the uptake buffer at specified
concentration together with the radioactive substrate. The uptake was performed
at room temperature for 2 min (14 C-TEA uptake) or 5 min (3H-MPP' ) and then
the cells were washed with ice-cold PBS for three times. The cells were then
lysed with the lysis buffer (0.1 N NaOH, 0.1% SDS) for scintillation counting and
BCA protein assay (Pierce, Rockford, IL) to determine the uptake.
Cellular Accumulation of Platinum
The cellular accumulation of platinum was determined as previous
described18 with some modifications. Briefly, the cells were grown in 100 mm x
20 mm dishes in the culture medium without any antibiotics to over 90%
confluence. For HEK 293 cells, poly-D-lysine coated dishes were used. For
platinum accumulation, the cells were incubated in the culture medium containing
the indicated concentrations of the platinum compounds at 37 0C in 5% CO 2 for 2
hr unless specified. After incubation, the dishes were immediately placed on ice
and the cells were washed with 6 ml of ice-cold PBS for three times and collected
with a rubber policeman. The cell pellets were obtained by centrifugation at 400 x
g and at 40C for 15 min. For the OCT inhibitor studies, the incubation medium
also contained the indicated inhibitor (disopyramide or cimetidine) in addition to
the platinum compounds. The resulting cell pellets were then dissolved into 200
pl of 70% nitric acid at 650C for at least 2.5 hours, and then distilled water
containing 10 ppb of iridium (Sigma) and 0.1% Triton X-100 was added to the
samples to dilute nitric acid to 7%. The platinum content was measured by
inductively plasma coupled mass spectrometry (ICP-MS) in the Analytical Facility
at University of California at Santa Cruz (Santa Cruz, CA). Cell lysates from a set
of identical cultures were used for BCA protein assay.
Platinum-DNA Adduct Formation
The platinum content associated with genomic DNA was determined as
previously described20 with some modifications. Briefly, the cells were grown in
100 mm x 20 mm dishes in the culture medium without any antibiotics to over
90% confluence. For HEK 293 cells, poly-D-lysine coated dishes were used.
Then, the cells were incubated in the culture medium containing the specified
concentrations of the platinum compounds at 370C in 5% CO 2 for 2 hours (or 25
min as specified). In some experiments, phosphate buffer (PB: 1.06 mM KH2PO 4,
2.97 mM Na2HPO 4, pH 7.4) containing 155 mM NaCI (PB-CI buffer) or 103 mM
Na2SO 4 (PB-SO 4 buffer) was used instead of the culture medium as specified.
For the OCT inhibitor study, the incubation medium (buffer) also contained
disopyramide or cimetidine). If PB-CI or PB-SO 4 buffer was used, the cells were
washed with the same buffer once before drug incubation. After incubation, the
cells were washed with ice-cold PBS, scraped and pelleted. Genomic DNA was
isolated from the cell pellets using Wizard® Genomic DNA Purification Kit
(Promega, Madison, WI) following the manufacturer's instruction. Briefly, the cells
were lysed with Nuclei Lysis Solution. After RNA digestion and protein
precipitation, the lysates were centrifuged and the resulting supernatant was
aliquoted. The genomic DNA prepared from two different aliquots of the
supernatant was used for platinum and DNA content determination, respectively.
For the determination of platinum, the DNA samples were treated with 70% nitric
acid at 65 0C and diluted in the same way as described above. The platinum
content was analyzed using ICP-MS and the DNA content was measured by
absorption spectroscopy.
RNA Isolation
Cultured cells were grown in 100 mm x 20 mm dishes to 70-80%
confluence. Total RNA was isolated using RNeasy® Mini Kit (Qiagen, Valencia,
CA) following manufacturer's instruction, quantified by spectroscopy and stored
at -80 0C until use. Samples of tumor and normal colon mucosa were collected
from colon cancer resection from Department of Surgery, Queen Mary Hospital,
University of Hong Kong. Tissues were frozen in liquid nitrogen within half an
hour after they were resected. Nonneoplastic mucosa from colon was dissected
free of muscle and histologically confirmed to be tumor free by frozen section.
Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA). This study was
approved by the Ethics Committee of the University of Hong Kong and the
Internal Review Board of University of California, San Francisco.
RT-PCR
The first-strand cDNA was synthesized from 2 pg of total RNA using
SuperScript TM III First-Strand Synthesis System for RT-PCR kit (Invitrogen) in a
20 pl reaction mixture, and the random hexamers were used as the primer. The
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sense and antisense primers for human OCT1 were 5'-CTG TGT AGA CCC CCT
GGC TA-3' and 5'-GTG TAG CCA GCC ATC CAG TT-3', corresponding to the
nucleotide positions 408-427 and 751-770 (accession number: NM_003057),
respectively, and the size of the expected PCR product is 363 bp. The sense and
antisense primers for human OCT2 were 5'-CCT GGT ATG TGC CAA CTC CT-
3' and 5'-CAC CAG GAG CCC AAC TGT AT-3', corresponding to the nucleotide
positions 590-609 and 904-923 (accession number: NM_003058), respectively,
and the size of the expected PCR product is 334 bp. The sense and antisense
primers for human OCT3 were 5'-ATC GTC AGC GAG TTT GAC CT-3' and 5'-
TTG AAT CAC GAT TCC CAC AA-3', corresponding to the nucleotide positions
445-464 and 749-768 (accession number: NM_021977), respectively, and the
size of the expected PCR product is 324 bp. The sense and antisense primers
for human GAPDH were 5'-AAT CCC ATC ACC ATC TTC CA-3' and 5'-TGT
GGT CAT GAG TCC TTC CA-3', corresponding to the nucleotide positions 289-
308 and 587-606 (accession number: NM_002046), respectively, and the size of
the expected PCR product is 318 bp. The sense and antisense primers for dog
GAPDH were 5'-GGT GAT GCT GGT GAG TA-3' and 5'-GTG GAA GCA GGG
ATG ATG TT-3', corresponding to the nucleotide positions 256-275 and 607-626
(accession number: AB038240), respectively, and the size of the expected PCR
product is 371 bp. All sets of primers were designed to anneal with sequences in
different exons of the genes. An annealing temperature of 581C was used for
PCR amplification. A cycle number of 40 was used for the detection of human
OCT1 and OCT2 in the colon cancer cell lines and colon tissue samples. A cycle
of 30 was used to detect human OCT1, OCT2 or OCT3 in the corresponding
OCT-transfected cells and the MOCK cells. For the detection of human or dog
GAPDH, a PCR cycle number of 30 was used in all the conditions.
Synthesis of Platinum Analogs
Potassium tetrachloroplatinate(II) was a gift from Engelhard Corp. and the
starting materials cisplatin and potassium amminetrichloroplatinate(ll) were
synthesized as reported 46,47. 1H NMR spectra were acquired on a Varian 300
MHz spectrometer. FT-IR spectra were measured on an Avatar 380 FT-IR
(Thermo Nicolet, Waltham, MA). ESI-MS spectra were obtained on an Agilent
Technologies 1100 Series LCMS instrument. Previously reported procedures
were used to prepare [Pt(C12)(en)] 46, cis-[Pt(NH3)(cy)C 2] 47, and [Pt(R,R-
DACH)C12] 48. The [Pt(S,S-DACH)C 2] and [Pt(S,S-DACH)oxalato] were
synthesized as described 49. FTIR and 1H NMR spectra of all compounds
matched literature spectra.
Preparation of [Pt(NH3)2 (trans-1,2-(OC0)2C 6H70)]: The compound was prepared
as described for the Pt-DACH derivative 50. Solubility problems, similar to those
reported for the DACH compound, prevented analysis by NMR spectroscopy. IR
(KBr, cm -1) 3266 (sh), 2920 (s), 2850 (s), 1618 (s), 1556 (sh), 1384 (vs), 1279
(w), 1222 (m), 1111 (w), 1030 (w), 772 (w), 719 (w), 588 (b). ESI-MS: [M+H] =
400.2 amu (observed), 400.3 amu (calculated).
Preparation of [Pt(R,R-DACH)(H20)2+: [Pt(R,R-DACH)CI21 was dissolved in
distilled water (200 pM) and incubated with silver nitrate (400 pM) in dark for 10
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hours. [Pt(R,R-DACH)(H20) 2 2+ was obtained by filtering the reaction mixture to
remove the silver chloride precipitate.
Statistical Analysis
The differences between the mean values were analyzed for significance
using Student's t test. P values < 0.05 were considered statistically significant.
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Chapter 3
Synthesis of Pt(ll) and Pt(IV) Compounds
for Uptake by the Organic Cation Transporters:
Extension of Structure-activity Relationship
Introduction
The structure-activity relationship developed in chapter 22 was used to inform
design of new compounds as drugs for colorectal cancer and other cancers that contain
the organic cation transporters. Compounds were characterized with respect to
cytotoxicity in MDCK cells that were stably overexpressing hOCT1.2
In addition to studying compounds in cells with overexpressed transporters, it is
interesting to study the response of cells in the absence of these genes. Silencing of
genes by RNAi works by introducing a plasmid that codes for short (21-28 nucleotides)
double-stranded RNA. Longer precursors are processed into small interfering RNAs
(siRNAs) by a cytoplasmic ribonuclease called Dicer. 3 Using the antisense strand of the
siRNA as a template, the RNA-induced silencing complex (RISC) recognizes and
cleaves any mRNA that is complementary to the template, resulting in rapid degradation
of mRNA for the target protein.
The original structure-activity relationship for platinum-based antitumor drug
candidates dictates that complexes should bear no net charge and have two amine or
ammine groups plus two relatively labile groups that can be aquated under physiological
conditions.4 The structure-activity relationship developed for the treatment of tumor cells
containing organic cation transporters (OCTs)2 indicates that platinum-based OCT
substrates 1) have a sizeable organic component, such as a diaminocyclohexyl ligand,
suggesting an non-covalent interaction between protein and substrate (n-n stacking,
hydrogen bonds, hydrophobic interactions);5 and 2) be in a cationic state prior to
uptake, possibly due to a cation-n interaction between the protein and the platinum
complex." Based on these findings, we synthesized compounds that were a) cationic
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due to structure, specifically ([Pt(dien)CI]CI, [Pt(R, R-DACH) (acac)]CI, cis-
[Pt(NH 3)2(pyridine)CI]CI, and trans-[PtCI2(NH3)(piperazine)]CI); b) neutral compounds
expected to be aquated quickly, namely (trans-[PtCI2(pyridine)2], trans-
[Pt(cyclopentylamine)2C12]); and c) aromatic compounds that could take potentially take
part in iT-T stacking interactions, including ([Pt(R,R-DACH)(acac)]CI, cis-
[Pt(NH 3)2(pyridine)CI]CI, cis-[Pt(NH 3)(benzylamine)C12], and trans-[PtCI2(pyridine)2]).
Additionally, we synthesized one cationic compound with an aromatic component, cis-
[Pt(NH 3)2(2-amino-3-picoline)CI]CI, based on a hit from a high-throughput screen of
platinum(ll) compounds for antitumor activity.7
Finally, we used drugs currently undergoing clinical trials to inform the design of
new compounds as OCT substrates. We synthesized cis-[Pt(NH 3)2(2-picoline)CI]CI
based on picoplatin, cis-[Pt(NH 3)(2-picoline)C12] (also known as AMD473), a drug that
recently entered clinical trials under the control of Poniard Pharmaceuticals. Picoplatin
was designed with additional steric bulk around the platinum center to reduce
inactivation by cellular thiols, such as glutathione. 8,9 The phase III trial of picoplatin,
SPEAR (Study of Picoplatin Efficacy After Relapse) is underway in Europe and India
and is also focused on patients with small cell lung cancer. A phase I trial in colorectal
cancer (combination therapy with 5-fluorouracil) and a phase II trial in prostate cancer
(combination therapy with docetaxel and prednisone) are also underway.
The compounds were characterized for cellular cytotoxicity and accumulation in
cells overexpressing OCT1 and cells that had endogenous levels of OCT1 knocked
down by RNAi.
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Chart 3.1 Cationic platinum compounds.
Experimental
Materials
Potassium tetrachloroplatinum(ll) was a gift from Engelhard Corp. Both cisplatin
and oxaliplatin were synthesized as reported previously.10' 11 The known compounds
trans-[PtCI 2(pyridine)2 , 12 trans-[Pt(cyclopentylamine) 2CI21, 1 2 trans-[Pt(NH 3)(pz)Cl2]Cl
(1),13 [Pt(R,R-DACH)(acac)]CI (2),14 [Pt(dien)ClI]CI (4),15.16 cis-[Pt(NH3)2(pyridine)Cl]Cl
(5),17 and cis-[Pt(NH 3)2(2-picoline)CI]CI (7)18 were synthesized as described. All other
chemicals and solvents were from commercial sources. 1H NMR and 195pt NMR
spectra were obtained on Varian 300 and 500 MHz spectrometers, respectively. NMR
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spectra are supplied as Figures 3.11-3.23. Electrospray ionization-MS (ESI-MS)
spectra were obtained on an Agilent Technologies 1100 Series liquid
chromatography/MS instrument. Fourier transform-IR (FT-IR) spectra were measured
on an Avatar 380 FT-IR. Cyclic voltammetry experiments were performed on a 263
EG&G Princeton Applied Research electrochemical analyzer using a three-electrode
setup with a glassy carbon working electrode, a platinum wire auxiliary electrode and an
Ag/AgCI reference electrode. Electrochemical data were uncorrected for junction
potentials. DNA concentrations were measured by UV-Vis absorption spectroscopy at
260 nm on a Cary 50 Bio UV-Visible spectrometer equipped with a microprobe from C
Technologies Inc.
Synthesis of cis-[Pt(NH3) (benzylamine) C/2] (3)
The trans isomer of this complex has been synthesized previously.19 To a
solution of [Et 4N][PtNH 3CI 3]20 (1.11 mmol) in 4 mL H20 was added a solution of
benzylamine in 0.5 mL H20. The orange mixture was stirred for 9 h in the dark at room
temperature, although an orange precipitate was observed after only 30 min. The
orange precipitate was collected by filtration and washed with water (4x), ethanol (3x)
and ethyl ether (2x) to yield an orange solid (73 mg, 17%). 1H-NMR (d-DMF, 300 MHz)
6 4.034 (m, 2H), 4.292 (s, 3H), 5.315 (s, 2H), 7.376 (m, 3H), 7.473 (dd, 2H, J=1.5 Hz,
6.6 Hz); 195Pt NMR (CD 30D, 500 MHz) 6 -2163.4. ESI-MS m/z calculated (M+Na):
412.9901, found: 412.9905.
Synthesis of cis-[Pt(NH3)2(2-amino-3-picoline)CI]CI (6)
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One equivalent of cDDP (200 mg, 0.668 mmol) was dissolved in 2 mL of DMF, to
which AgNO 3 (100 mg, 0.596 mmol) was added dropwise. After 4 h, at which time an
aliquot of the supernatant added to NaCI produced no AgCI precipitate, the reaction was
centrifuged (10 min, 10,000 x g). The supernatant was collected, 2-amino-3-picoline
(0.532 mmol, 0.79 equiv) was added, and the reaction was stirred for 12 h. The
lyophilized powder was recrystallized twice from 0.1 N HCI and once from methanol to
yield 41.1 mg (18.9%). ESI-MS m/z calculated (M+H): 372.06, found: 372.0.
Synthesis of cis, cis, trans-[Pt(NH3)2(pyridine)CI(OH)2]CI (8)
One equivalent of cis-[Pt(NH 3)2(pyridine)CI]CI (100 mg, 0.264 mmol) was
dissolved in 3.4 mL water to make a faintly yellow solution. After the solution was
heated to 500C, 1.4 mL of H20 2 (50% w/v) was added and the solution was stirred for 2
h. The colorless solution was then lyophilized to dryness. The white powder was
washed with acetonitrile (5 times) to produce the product (21.4 mg, 0.05 mmol, 21.50%)
1H-NMR (d-methanol, 300 MHz) 6 7.691 (t, 2H, J=7.5 Hz), 8.157 (t, 1H, J=7.5 Hz),
8.946 (m, 2H); 195Pt NMR (H20, 500 MHz) 6 678.6. ESI-MS m/z calculated (M+):
377.03, found: 377.0. Elemental analysis for platinum content by AAS: calculated
51.66%, found 51.65 + 2.17%.
Electrochemical Studies of cis, cis, trans-[Pt(NH3)2 (pyridine) C(OH)2]CI
Cyclic voltammetry measurements were performed at 25 oC at pH 6.0 or pH 7.4
on 2 mM solutions of complex 8 in 0.1 M KCI and 10 mM sodium phosphate buffer.
Nitrogen was bubbled through the solutions and measurements were performed under
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a nitrogen atmosphere. Measurements were carried out at six different scan rates from
50 to 300 mV s-1.
Elemental Analysis of Platinum
Platinum was quantified by atomic absorption (AA) spectroscopy (Aanalyst 300,
HGA-800 graphite furnace, AAWinLab software version 3.0, Perkin Elmer, Wellesley,
MA). A hollow cathode platinum lamp with 265.9 nm emission was used with a slit width
of 0.70 nm. Pyrolysis was performed at 1200 oC for 20 s and atomization at 2650 oC for
5 s. Samples in water were diluted to 100 pg/L and two dilutions were each measured in
triplicate and all data were averaged. The instrument was calibrated over a range of 50-
150 Ig/L and an r value of > 0.998 was obtained for the linear fit in all cases.
Plasmids for RNAi Silencing of OCTI
The pSicoR-GFP plasmid (Figure 3.1) was chosen for generation of shRNA
against hOCT1 in human colorectal cells and was generously provided by the Tyler
Jacks lab at MIT. Three different shRNA-encoding DNA sequences were designed
according to previously derived principles,3'2 1 with siRNA sequences beginning at 803,
806, and 1142 nucleotides from the origin of the sequence NM_003057, as found in the
PubMed Nucleotide database. Cloning into pSicoR was performed as previously
described.1 Three positive clones per sequence were identified by digestion with Xhol
and Xbal, which, for positive clones, yields a fragment -50 bp larger than the empty
vector. All plasmids were sequenced by the Genewiz GC-rich template sequencing
service.
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(ViraPower, Invitrogen). Six
hours after transfection, the
medium was replaced with
Figure 3.1. Plasmid map of A49e3616)
pSicoR-GFP.' fresh, antibiotic-free
medium. After 48 h, GFP expression was examined by fluorescence microscopy and
the virus-containing medium was removed for the purpose of infecting the target cell
line. The medium was passed through a 0.45 tm syringe filter and used to replace the
medium of HT-29 cells. Twenty-four hours after infection, the virus-containing medium
on the HT-29 cells was replaced with fresh medium and discarded after treatment with
bleach. Cells were grown to confluence in T-75 flasks and GFP-expressing cells were
collected by FACS.
RT-PCR
RNA was isolated from 1-2 x 106 cells in the presence of P-mercaptoethanol and
was purified on a Qiagen silica column following digestion with DNase I. RNA was
primed using an oligo d(T)18 primer and cDNA was generated with ImProm_ll reverse
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transcriptase (Promega) for 60 min at 42°C. PCR was performed using specific primers
for GADPH and hOCT1 as described.2
DNA-Platinum Adducts in Live Cells
Cells were plated in two 175 cm 2 flasks per cell line. Either 400 pM 5 or 3 pM
oxaliplatin (approximate IC80 for each) was added one day later, at 90% confluence.
The platinum-containing medium was removed after 2 h and cells were collected using
trypsin/EDTA, washed twice with ice-cold PBS and resuspended in a digestion buffer
(100 mM NaCI, 10 mM Tris-HCI pH 8.0, 25 mM EDTA pH 8.0, 0.5% SDS, 0.1 mg/mL
proteinase K) for lysis over 15 h at 500C. Protein was extracted in
phenol/chloroformlisoamyl alcohol and the aqueous layer was ethanol precipitated
twice. Approximately 40 pg DNA was obtained per 175 cm 2 flask. DNA concentration
was determined by absorption at 260 nm and the A260/A280 ratio was 1.9 or greater for
all samples. Platinum concentration was determined by atomic absorption spectroscopy
and rb values were calculated as bound Pt atoms per nucleotide.
Results
Synthesis of Cationic Complexes for OCT-Containing Tumors
The known compounds, trans-[PtC12(pyridine) 21, 12 trans-[Pt(cyclopentylamine) 2CI2 lz 2
trans-[Pt(NH 3)(piperazine)CI 2]CI (1),13 [Pt(R,R-DACH)(acac)]CI (2),14 [Pt(dien)CI]CI
(4), 15,16 cis-[Pt(NH3)2(pyridine)CI]CI (5),17 and cis-[Pt(NH3)2(2-picoline)CI]CI (7)18 were
synthesized as described in the literature. The compounds cis-
[Pt(N H3)(benzylamine)CI21 (3), cis-[Pt(NH 3)2(2-amino-3-picoline)CI]CI (6), and
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cis,cis,trans-[Pt(NH3)2(pyridine)CI(OH)2]CI (8) had not been synthesized previously. The
use of one equivalent of AgNO 3 to activate cisplatin at one position only followed by
introduction of the selected amine ligand is a preferred method of producing platinum
triamines. 17 ,22 An alternate method, heating cisplatin and the selected amine ligand in
water at 50-60 oC for several days, leads to a large proportion of disubstituted products
(cis-[Pt(NH 3)2(Am) 2 2+ 17 Performing the reaction without heat produces a more
favorable product distribution, but is overall low-yielding. The large amount of
disubstituted products may be due to the low solubility of cisplatin in water, which
results in much more available amine than platinum in the initial stages of the reaction.
Moreover, the reaction with AgNO 3 replaces a chloride ligand with either O1-DMF or
NO03, either of which is relatively more labile.17
Redox Properties of cis, cis, trans-[Pt(NH3)z(pyridine)C(OH)2]C (8)
The reduction potential of 8 is critical to its function in the body, because only the
platinum(ll) form of the compound will readily bind DNA. The electrochemical behavior
of 8 indicates irreversible loss of axial ligands upon reduction. At a pH value of 7.4
(Figures 3.4 and 3.5), a value chosen because it reflects the pH in the bloodstream, the
reduction potential of 8, extrapolated to 0.0 mV s1 is -0.228 V vs. NHE. At a pH of 6.0
(Figures 3.2 and 3.3), a value that reflects the pH in endosomes and lysosomes, the
reduction potential of 8 shifts to -0.195 V vs. NHE. The complex is more readily reduced
due to protonation of the axial ligands as they dissociate.
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Figure 3.2. Cyclic voltammetry measurements of complex 8 at pH 6.0. Measurements were made at
25 *C on compound 8 dissolved to a final concentration of 2.0 mM in 0.1 M aqueous KCI buffered
with 10 mM phosphate. The scan rate was varied as shown.
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Figure 3.3. Scan rate vs. potential at pH 6.0. Measurements were made at 25 "C on compound 8
dissolved to a final concentration of 2.0 mM in 0.1 M aqueous KCI buffered with 10 mM phosphate.
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Figure 3.4. Cyclic voltammetry of compound 8 at pH 7.4. Measurements were made at 25 oC on
compound 8 dissolved to a final concentration of 2.0 mM in 0.1 M aqueous KCI buffered with 10
mM phosphate. The scan rate was varied as shown.
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Figure 3.5. Scan rate vs. potential at pH 7.4. Measurements were made at 25 'C on compound 8
dissolved to a final concentration of 2.0 mM in 0.1 M aqueous KCI buffered with 10 mM phosphate.
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Cytotoxicity in OCT1(+) vs. hOC T1(-) Cell Lines
Compounds were evaluated for cytotoxicity in hOCT1(+) and hOCT1(-) cell lines
by Shuzhong Zhang in the lab of Kathy Giacomini at UCSF. Cytotoxicity was measured
in MDCK cells by the MTT assay. Cells were exposed to the compounds in DMEM for 7
h, after which the drug-containing medium was replaced with fresh DMEM. Following a
72-hour incubation, cytotoxicity was evaluated by the MTT method as previously
described.2 3 The data, reported in Table 3.1 and Figure 3.6, show improved cytotoxicity
in the hOCT1 (+) cell line for five of the seven "second generation" compounds tested.
The cis-[Pt(NH 3)(benzylamine)CI2] compound is as toxic as oxaliplatin in this line and
shows a greater difference between OCT1(+) and OCT(-) cells (24.5-fold vs. 22-fold
difference). The [Pt(R,R-DACH)(acac)]CI compound also exhibits a large difference in
OCT + vs - cytotoxicities (21.2-fold), although it is two to three times less cytotoxic than
oxaliplatin. The cis-[Pt(NH 3)2(pyridine)CI]CI compound displayed the greatest
improvement in cytotoxicity of 87-fold (Table 3.1, Figure 3.6), although it is also about
two-fold less cytotoxic than oxaliplatin in the OCT1(+) cell line. One other tested
compound with a single labile ligand is 4, a compound regarded as inactive in much of
the platinum literature that showed a 10-fold improvement in cytotoxicity in MDCK-
OCT1 cells.
Platinum(ll) compounds of the form trans-[Pt(Aml)(Am2)CI2], where Ami and
Am2 are am(m)ine ligands, aquate four times faster than the corresponding cis
compounds. 24 The facile aquation, which leads to faster formation of a cationic form as
compared with oxaliplatin, was not sufficient for activation of the traditionally inactive
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trans geometry. Neither trans-[PtC12(pyridine) 21 nor trans-[Pt(cyclopentylamine)2C1 21
showed activity in the MDCK-OCT1 cells.
Table 3.1. ICso values for MDCK with overexpressed hOCT1.
fold decrease
Compound ICso hOCTI(+) (aM) for OCT1 + vs. -
trans-[PtCI 2(pyridine)21 >400 NA
trans-[Pt(cyclopentylamine) 2C1 2] >400 NA
trans-[PtCI2(NH 3)(piperazine)]CI (1) 94 5.1
cis-[Pt(NH3)(benzylamine)C 21 (3) 1.15 24.5
[Pt(dien)CI]CI (4) 62 + 16.8 10
[Pt(R,R-DACH)(acac)]CI (2) 8.68 + 1.39 21.2
cis-[Pt(NH3)2(pyridine)Cl]CI (5) 8.09 + 1.62 87
oxaliplatin 3.9 + 1.3 22
cisplatin 3.6 + 0.3 1.7
0 OCI(+)vs OCT*(.)
A ODT2(+ vs OCT2(0
H 46
Cki Ai
IIA L ,'~n'c:
I+
Figure 3.6. Plot of improvement in cytotoxicity for compounds studied (ICso in OCT(-) divided by
ICs0 in OCT(+) cells).
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Knockdown of hOCTI in Human Colorectal Cancer Cells
Generation of shRNA against OCT1 in human colorectal cells was achieved
using a versatile plasmid platform designed by Andrea Ventura in the Jacks lab at MIT.
The plasmid pSicoR-GFP (Figure 3.1) contains the U6 promoter for RNA polymerase III,
which has been widely used to generate shRNAs. The Lox-STOP-Lox element in this
promoter allows conditional turn-off of shRNA expression upon addition of Cre
recombinase.' GFP is also expressed by the plasmid, allowing verification of
transfection and infection by fluorescence microscopy.
Three DNA sequences coding for shRNA against hOCT1 were successfully
cloned into pSicoR-GFP and those plasmids, along with the requisite viral packaging
vectors, were transfected into 293T/17 cells. Virus generation was robust and a high
viral titer was obtained, as observed by fluorescence microscopy (Figure 3.7).
Human colorectal HT-29 cells were successfully infected by incubation with the
virus-containing medium produced by the 293T/17 cells, as detected by fluorescence
microscopy (Figure 3.7). The GFP-expressing cells, which comprised 76.2%, 92.4%,
and 0.07% of the cells infected with the 1142, 806, and 803 clones, respectively, were
collected by FACS (fluorescence-assisted cell sorting).
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293T/17 in virus generation.
Figure 3.7. Fluorescence microscopy (10x magnification) of 293T/17 cells in the virus-generation
stage (left column) and in infected HT-29 cells (right column), 4 weeks after successful infection.
The number of cells showing fluorescence is nearly 100%, as verified by fluorescence-assisted
cell sorting.
Validation of OCT1 Knockdown
RT-PCR was performed using previously described primers.2 Analysis of gene
silencing by RT-PCR is an accepted method of validation (See Table 3.2). Expression
of OCT1 mRNA was reduced by 28% in the HT-29/pSicoR-1142_3 line, 53% in HT-
29/pSicoR-803_6, and 86% in HT-29/pSicoR-806_4 (Figures 3.8 and 3.9).
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HT-29 cells after infection.
Method Detection Level Advantage Disadvantage Throughput
Northern blot Endogenous mRNA Easy RNA isolation Low
qRT-PCR (TaqMan® or Endogenous mRNA Sensitive, quantitative RNA isolation, primer High
SYBR® Green design
QuantiGene@ Endogenous mRNA Sensitive, quantitative, Cost High
www.genospectra.com works on crude lysate
Western blot, IF, ELISA, Endogenous protein Easy Antibody availability Low
FACS, etc.
Western blot, IF, etc., on Exogenous fusion Same antibody for In-frame cloning, High
epitope tag protein detection restricted target region
Fluorescent/enzymatic Exogenous protein Entire cDNA can be High
reporter assay (translated from targeted, only reporter
chimeric mRNA) is translated
mRNA, messenger RNA; qRT-PCR, quantitative reverse transcription PCR; IF, immunofluorescence; ELISA, enzyme-
linked immunosorbent assay; FACS, fluorescence-activated cell sorting.
Table 3.2. Table of commonly used functional validation methods for mammalian RNAi.3 Table
reproduced from Jacks, T.; et. aL, Biotechniques, 2005.
100% 1
90%
80%1
70%-
60%
50%-
40%-
30%-
20%-
10%
86%
53%
28%
0% I
HT-29, 1142 clone HT-29, 803-6 clone HT-29, 806-4 clone
Figure 3.8. Plot of percent knockdown of hOCT1 by shRNA relative to native HT-29 mRNA for
OCT1 (0% knockdown).
107
I _ _ _ _ _ _
I I
1 2 3 4 5 6 7 8 1 2 3 4
Figure 3.9. Agarose gel showing bands resulting from detection of mRNA of hOCT1 and GADPH in
human colorectal cell lines. A: Semi-quantitative RT-PCR. Lane 1: GADPH primers only, lane 2:
hOCT1 primers only, lane 3: HCT-116, lane 4: 293T/17, lane 5: HT-29 wild-type, lane 6: HT-29 with
pSicoR-803_6, lane 7: HT-29 with pSicoR-806_4, lane 8: no DNA control reaction. B: Comparison
of knockdown from three plasmids. Lane 1: HT-29 wild-type, lane 2: HT-29 with pSicoR-1142_3,
lane 3: HT-29 with pSicoR-806_4, lane 4: HT-29 with pSicoR-803_6.
Cytotoxicity of Platinum Compounds in hOCT-Knockdown Cell Lines
The response of hOCT1-knockdown cells to varying doses of either oxaliplatin or
5 was evaluated in two separate experiments, each performed in triplicate for each
compound. The IC50 values for 5 and 6 were evaluated in the control cell line as well
and both values were on the same order of magnitude as 4 and much less toxic than
oxaliplatin. The IC50 values for both oxaliplatin and 5 were directly related to the level of
OCT knockdown, as shown in Table 3.3, which is the inverse of what would be
expected if OCT1 were implicated in cellular accumulation.
The lowest IC50 values of 133 pM and 0.81 pM for 5 and oxaliplatin, respectively,
were obtained for the HT-29/pSicoR-806_4 cell line, the cells with the lowest level of
OCT1 mRNA. The trend was pronounced for 5, which showed IC50 values of 260, 287,
and 719 pM in cells with the second lowest, second highest, and highest (wild-type)
level of OCT1 mRNA. The corresponding results for oxaliplatin were 1.62, 1.75, and
3.22 pM.
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Table 3.3. ICso values for knockdown cell lines.
5 oxaliplatin 6 7
HT-29 719 pM 3.22 piM 770 pM 460 IpM
HT-29/pSicoR-1 142_3 260 VpM 1.62 IpM
HT-29/pSicoR-803_6 287 jM 1.75 jiM
HT-29/pSicoR-806_4 133 jM 0.81 jiM
Uptake in hOC T1(+) vs. hOC T1(-) Cell Lines
DNA platination levels were measured in HT-29 and HT-29/pSicoR-806_4 cells,
which allowed comparison of lines with the highest and lowest levels of OCT1. The rb
values for 5 were 1.9 x 10-4 + 7.2 x 10-6 and 2.4 x 10-4 + 1.6 x 10-5 in HT-29 and HT-
29/pSicoR-806_4, respectively.(Table 3.4, Figure 3.10) The rb values for oxaliplatin
were 9.4 x 10-6 + 1.7 x 10-6 and 6.1 x 10-6 + 1.2 x 10-6.
Table 3.4. DNA Platination Levels in Normal and OCT1-knockdown Cell Lines (rb)
HT-29 control (CD8)
HT-29 with pSicoR-806_4
1.9 x 10-4 + 7.2 X 10-6
2.4 x 10-4 + 1.6 x 10-5
9.4 x 10-6 + 1.7 X 10-6
6.1 x 10-6 + 1.2 x 10-6
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Figure 3.10. Uptake in HT-29 vs. HT-29 OCT1-knockdown cells expressed: as platinum ,atoms
bound per nucleotide (rb) Compounds tested were oxaliplatin (oxal) and compound 5 (py).
Discussion
Synthesis of Compounds as OCT Substrates
Using the previously developed structure-activity relationship as a starting
point,2 a variety of new compounds were designed as potential OCT substrates. The
synthesis and investigation of cationic compounds that do not require aquation prior to
OCT uptake was of particular interest. A more inert cationic Pt(IV) complex was also
synthesized for the purpose of tuning activation of the complex. The synthesis of cis-
[Pt(NH 3)2(2-amino-3-picoline)CI]CI was motivated by results of a high-throughput screen
of platinum(ll) compounds in which cis-[Pt(NH 3)(2-amino-3-picoline)CI 2] was one of four
hits.7 The related compound cis-[Pt(NH3)2(2-picoline)CI]CI was synthesized to probe the
behavior of a cationic, monofunctional form of "picoplatin," or cis-[Pt(NH3)(2-
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picoline)C12], a compound designed to overcome cisplatin resistance that is currently in
clinical development.8
Redox Properties of a Cationic Pt(IV) Compound
The redox properties of 8 indicate the complex is less readily reduced than
satraplatin (c,c,t-[Pt(NH3)2(cyclohexylamine)CI(OH)2], also known as JM216), the first
orally active platinum compound to undergo clinical investigation. The ease of reduction
of satraplatin and similar Pt(IV) complexes is related to the electron-withdrawing nature
of the axial ligands and the steric bulk of all ligands.25 Satraplatin has a relatively bulky
cyclohexylamine ligand and relatively electron-withdrawing acetate axial ligands, both of
which contribute to its high redox potential of -0.053 V vs. NHE.25 This high redox
potential renders it readily reducible in the bloodstream. Hemoglobin in red blood cells
are implicated as a key catalyst in the NADH-dependent reduction and contribute to the
rapid (<30 min) reduction of satraplatin in blood.2 6
The redox potential of 8 is lower than that of satraplatin, but higher than those of
c,c,t-[Pt(ipa)C12(OH)21 (-530 mV vs. NHE) 25 and [Pt(en)C 2(OH) 2] (-684 mV vs. NHE) 27
because of its cationic nature. Because only one Pt(IV) complex has ever been tested in
humans, the ideal reduction potential for an orally bioavailable platinum drug remains to
be determined. The redox behavior of 8 suggests that it will remain intact for a longer
period than satraplatin, which has a shorter-than-desirable half-life in blood, but will be
reduced in cells over time to bind DNA, its cytotoxic target.
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Cytotoxicity of Platinum(ll) Compounds in MDCK-HOCT1 Cells
A comparison of the difference in IC50 values in MDCK-MOCK cells and MDCK-
hOCT1 cells is plotted in Figure. 3.6. This figure includes data from chapter 2.2 Absolute
values for IC50 are shown in Table 3.1. Comparing absolute values for IC5o for the seven
drug candidates, only compound 3, has a potency equal to or greater than oxaliplatin or
cisplatin. Compound 3 has about half the IC50 of oxaliplatin and cisplatin in MDCK-
OCT1 cells and has about the same IC50 as oxaliplatin (but not cisplatin) in MDCK cells
without the transporter. The stability of this compound in biological milieu may be
related to its potency, although the trans isomer of this complex was stable enough to
undergo reflux in water and H20 2 for 2 h.19
Of the seven second generation compounds, five show improved cytotoxicity in
OCT1 (+) as compared with OCT1 (-) cell lines. The best improvement was seen for cis-
[Pt(NH 3)2(pyridine)CI]CI, 5, a monofunctional compound with only one leaving group and
three neutral am(m)ine ligands, The absolute IC50 value of 5 is about 2-fold higher than
oxaliplatin, even in the MDCK-hOCT1 line. Because of this high IC50 , a relatively high
load of 5 might need to be delivered to patients for it to be effective even though 5 is
likely to be much more potent in tumors expressing OCT1 than in cells without OCT1.
This compound has previously shown activity without overt toxic side effects in a i.p./i.p.
mouse model," suggesting potential viability as a drug.
Another compound with a single leaving group is 4, a compound often used in
the platinum literature to model the "inactive" monofunctional adduct. The 10-fold
improvement in cytotoxicity of this compound in MDCK-OCT1 cells suggests that its
inactivity arises in part from low cellular accumulation and not from the cell killing ability
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of the monofunctional platinum-DNA adduct. Compound 5 will be investigated in more
detail as "pyriplatin" in chapters 4 and 6.
Knock-down of OCTI in a Colorectal Cancer Cell Line
Studies in cells with overexpression of organic cation transporters have provided
results relevant for the transporter community regarding whether platinum compounds
could be substrates for OCTs. More relevant to the cancer community is the issue of
whether these transporters will be an important factor in cancer therapy. The hOCT1 is
expressed in human colorectal tumors, 2 but we did not know whether the organic cation
transporters would be relevant to platinum drug potency in cells with normal levels of
the transporter. Initial studies of oxaliplatin cytotoxicity using an inhibitor of OCT1
(disopyramide) in HT-29 cells, a colorectal cell line only expressing OCT1 (and no
OCT2 2), showed no difference in oxaliplatin potency between cells treated with the
inhibitor and control cells. We resolved to generate cells that lacked OCT1 to eliminate
all transport by OCTs. Among the three sequences used to knock down OCT1, a
sequence that started at position 806 in the gene produced the best knockdown of
OCT1 in HT-29 cells.
Cytotoxicity of Platinum(lI) Compounds in HT-29 and hOCTi-Depleted Cell Lines
The ICso values for both oxaliplatin and 5 increased as the level of OCT
knockdown increased. The compounds were more potent in cell lines with low levels of
OCT1, which is the inverse of what should be expected if OCT1 were implicated in
uptake of these compounds.
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DNA Binding in Cells with Depleted hOCTi
DNA binding experiments comparing 5 in HT-29 and HT-29/pSicoR-806_4
showed a 125% increase in DNA-bound platinum for the HT-29/pSicoR-806_4 line
(Figure 3.10, Table 3.4), which corresponds to the decrease in IC50 seen in the
knockdown line. In contrast, oxaliplatin experiments showed only 65% DNA-bound
platinum in the HT-29/pSicoR-806_4 as compared with HT-29 cells. Because oxaliplatin
forms many fewer adducts on DNA than other platinum compounds, 28 the background
on these measurements was very high and the difference between the control and
knockdown samples were within the error of measurement.. This was not the case for
the pyriplatin measurements, which reinforce the trend seen in the IC50 values.
Conclusion
The conflicting results regarding the organic cation transporter studies indicate
that the mechanism of uptake for 5 and oxaliplatin may be too complex to attribute to a
single transporter. The cell may increase transcription of genes coding for other
transporters to compensate for the lack of hOCT1, a plausible theory because of the
multitude of cation transporters in the cell. 29 The compound 5 is still of strong scientific
interest because it is a cytotoxic, cationic compound that binds in a monofunctional
manner with DNA. The interest of drug companies in compounds that differ significantly
from cisplatin, carboplatin, and oxaliplatin in their mechanisms of action is strong. The
well-developed talent of our lab in structural characterizations of platinum-DNA
interactions suggests we should pursue compounds, including compound 5, that
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interact in novel ways with DNA. The focus on single proteins within the cell, such as
hOCT1, hOCT2, or HMGB1 can yield highly relevant information for the respective
protein communities, but may not always produce useful insight into the design of
anticancer drugs. In the case of 5, a representative of a class of compounds that has
been investigated by our lab previously and tested for use in leukemia, 30 ,31 we have
identified a valuable exception that will be evaluated in detail in Chapters 4 and 6.
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Figure 3.11. H NMR of trans-[Pt(NH 3)(piperazine)CI2]CI in D20.
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Figure 3.12. 195Pt NMR of trans-[Pt(NH 3)(piperazine)CI 2]CI in D20.
062606ac in CD300, C1H 21N22Pt
-15IW
70 8.0 5.0 4.0 3.0 2.0 1.0
Figure 3.13. 'H NMR of [Pt(R,R-DACH)(acac)]CI in CD30D.
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Figure 3.14. 195Pt NMR of [Pt(R,R-DACH)(acac)]CI in CD30D.
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Figure 3.15. H NMR of [Pt(R,R-DACH)(F6-acac)]CI in d-DMF.
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Figure 3.16. 195t NMR of [Pt(R,R-DACH)(F6-acac)]CI in DMF.
Figure 3.17. 1H NMR of cis-[Pt(NH 3)(benzylamine)CI2] in d-DMF.
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Figure 3.18.195pt NMR of cis-[(NH3)(benzylamezin)CI2 in CH3H.30002000
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Figure 3.19. 1H NMR of [Pt(dien)CI]CI in D20.
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Figure 3.20. 1H NMR of cis-[Pt(NH3)2(pyridine)CI]CI in D20.
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Figure 3.21. 195pt NMR of cis-[Pt(NH 3)2(pyridine)CI]CI in CD 3OD.
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Figure 3.22. 1H NMR of cis,cis,trans-[Pt(NH3)2(pyridine)CI(OH)2]CI in CD30D.
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Figure 3.23. 195Pt NMR of cis,cis,trans-[Pt(NH3) 2(pyridine)CI(OH) 2]CI in H20.
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Chapter 4
Pyriplatin, cis-[Pt(NH3)2(pyridine)CI]CI, a Monofunctional, Cationic
Platinum(ll) Antitumor Agent
This chapter is composed, in part, of material from a published work (Proc Nat/ Acad Sci
USA 2008, 105, 8902-8907).'
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Introduction
The three FDA-approved platinum-based anticancer drugs, cisplatin, carboplatin,
and oxaliplatin, form similar adducts on DNA, although only oxaliplatin is active in
colorectal cancer. Organic cation transporters OCT1 and OCT2 have been implicated in
the uptake of oxaliplatin by colorectal tumors.2 We discovered cis-diammine-
(pyridine)chloroplatinum(llII), pyriplatin, as a highly effective organic cation transporter
substrate that shows 80-fold increased cytotoxicity in OCT(+) mammalian cell lines.
The recent surge in clinical trials involving platinum anticancer drugs reflects the
underlying potency and success rate of cisplatin. Most recent is the success of
oxaliplatin in treating colorectal cancer.3 Several platinum compounds that violate the
classical structure-activity relationships for cisplatin are now in the clinic, including
platinum(IV), 4 polyplatinum,5 and platinum complexes with a trans stereochemistry.6-13
Inspired by recent work 2 that identified the organic cation transfer receptors OCT1 and
OCT2 as mediators of oxaliplatin entry into cells, we discovered cis-diammine-
(pyridine)chloroplatinum(ll), pyriplatin, to be a viable candidate for anticancer drug
development. The anticancer activity of pyriplatin was established in rodents over 20
years ago14,15 but, perhaps because unlike cisplatin it forms monofunctional rather than
bifunctional cross-links with target DNA, the compound was never tested in humans. In
the present report we describe the remarkable properties of pyriplatin including (i) its
ability to block transcription and elude nucleotide excision repair, two mechanistic
features that endow cisplatin with its anticancer activity; (ii) accumulation mediated by
the OCT1/OCT2 receptors significantly better than that of oxaliplatin; and (iii) the X-ray
crystal structure of a DNA dodecamer duplex containing a monofunctional adduct of the
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complex bound to a central guanosine residue. Features of the structure bear a
remarkable resemblance to those of the cisplatin intrastrand d(GpG) cross-link in DNA,
which may account for the properties of pyriplatin.
Goals of the Chapter
The aim of the work described in chapter 4 is to characterize the interaction of a
cationic, monofunctional platinum compound, pyriplatin, with DNA in cells and in vitro.
Based on work in chapters 2 and 3, the hypothesis that the antitumor activity and
accumulation of pyriplatin in cancer cells is due to organic cation transporters was also
investigated.
Results
Cytotoxicity in Cells Expressing hOC T or hOCT2
Mammalian cells stably expressing human OCT1 or OCT2 or a control plasmid
were used to study the cellular accumulation and cytotoxicity of pyriplatin and
oxaliplatin. Pyriplatin is 87-fold more cytotoxic in cells expressing hOCT1 than in cells
that lack the transporter, whereas oxaliplatin was only 12-fold more effective. The
cytotoxicity of pyriplatin in cells expressing hOCT2 is 137-fold improved over the
corresponding control cells, compared with a 53-fold increase with oxaliplatin (Figure
4.1). The outstanding improvement in cytotoxicity and large therapeutic window seen in
the response of cells containing either OCT1 or OCT2 to pyriplatin immediately set this
compound apart from the others tested (Chapter 3). The potency of pyriplatin is much
lower than that of oxaliplatin in all four cell lines in Table 4.1.
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Figure 4.1. Antiproliferative effects of pyriplatin and oxaliplatin evaluated in MDCK cells
expressing either hOCT1 or a control plasmid.
Table 4.1. Comparison of IC50 values for pyriplatin and oxaliplatin in cells with and without hOCT1
and hOCT2. IC50 values are expressed as mean±SD from three experiments and quadruplicate
measurements were obtained in each experiment.
IC50 values (pM)
Pyriplatin
Oxaliplatin
MDCK-MOCK
704 + 280
40.5 + 1.6
HEK-MOCK
MDCK-hOCT1
8.1 + 1.2
3.3 + 1.0
HEK-hOCT2
Fold Change
87
12
Pyriplatin 206 + 56 1.50 + 0.22 137
Oxaliplatin 4.0 + 1.3 0.075 + 0.009 53
Accumulation of Pyriplatin in Cells Expressing hOCTi or hOCT2
Examination of treated cells for platinum content revealed that accumulation of
pyriplatin is 68-fold higher in hOCT2-containing cells than in cells not expressing the
transporter. Cells expressing hOCT1 accumulated 23-fold more platinum than the
corresponding MOCK-transfected cells. Treatment of cells with oxaliplatin resulted in a
4.7-fold increase in hOCT1 cells than in control cells (Table 4.2) and a 23-fold increased
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Table 4.2. Platinum accumulation in hOCT1 cells-cells were incubated with 10 pM platinum for 2
h and assayed for platinum content by ICP-MS. Units are in pmol/mg protein. Data are expressed
as the mean of six measurements + one standard deviation.
MDCK-MOCK MDCK-hOCT1 Fold Change
Oxaliplatin 13.9+0.94 65.6+4.1 4.7
Pyriplatin 33.1+0.5 779+67.2 23
Table 4.3. Platinum accumulation in hOCT2 cells-cells were incubated w
and assayed for platinum content by ICP-MS. Units are in pmol/mg protei
the mean of six measurements + one standard deviation.
HEK-MOCK HEK-hOCT2 Fold Change
,ith 2 pM platinum for 2 h
n. Data are expressed as
Oxaliplatin 5.65+0.72 130+11 23
Pyriplatin 18.7+1.6 1278+69.4 68
platinum accumulation in hOCT2 cells than in control (Table 4.3). Measurements of
platinum levels on DNA after pyriplatin treatment were not obtained, but DNA platination
by oxaliplatin closely tracks its accumulation in cells expressing hOCT1 and hOCT2.
Increases in cellular accumulation as well as DNA platination are reversible by OCT1
and OCT2 inhibitors.2 The level of pyriplatin bound to DNA of cancer cells that are not
overexpressing OCTs has been determined for other purposes (Chapter 3, Chapter 6).
In those cases, DNA platination levels achieved by pyriplatin are generally greater than
those found for oxaliplatin when cells are treated with the compounds at the IC50
concentrations.
Platination of Plasmid DNA
Plasmid (pBR322) DNA was incubated with pyriplatin or cisplatin for 24 h in
Hepes buffer and platination levels were measured by atomic absorption spectroscopy.
The results were plotted (Figure 4.2) as platinum atoms bound per nucleotide (rb) vs.
the formal ratio of platinum added per nucleotide (rf). The plot indicates that the level of
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plasmid-bound platinum is, within experimental error, the same for cisplatin and
pyriplatin.
0 0
* pyriplatin
o cisplatin
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Figure 4.2. Results of rf vs. rb determination. A) Combined plot with cisplatin and pyriplatin
overlaid. B) Rf vs. rb for cisplatin only. C) Rf vs. rb for pyriplatin only. Error bars show one
standard deviation of data points measured in triplicate.
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Agarose gel electrophoresis to analyze the unwinding of pBR322 DNA globally
platinated with pyriplatin (Figure 4.3) was performed concurrently with atomic absorption
spectroscopy on the samples plotted in Figure 4.2. This method of analysis of the
1 1 2 3 568 9
1 2 3 4 5 6 7891112 4i 1
Figure 4.3. Analysis of DNA unwinding by agarose gel. Lanes as follows, wherein values are
reported as rf, then rb (rf/rb): A) cisplatin: 1) 0.072/0; 2) 0.13/0.085; 3) 0.39/.006; 4) 0.65/0.005;
5) 1.04/0.019; 6) 1.57/0.038; pyriplatin: 7) 0.07210; 8) 0.13/0.002; 9) 0.3910.007; 10) 0.6510.014; 11)
1.04/0.020; 12) 1.5710.019. B) pyriplatin: 1) 0.039/0; 2) 0.052/0; 3) 0.065/0; 4) 0.07810.001; 5)
0.13/0.002; 6) 0.26/0.003; 7) 0.39/0.007; 8) 0.52/0.011; 9) 0.65/0.014; 10) 0.78/0.012; 11)
0.91/0.017; 12) 1.04/0.020; 13) 1.17/0.023; 14) 1.3/0.024; 15) 1.43/0.026; 16) 1.57/0.019; 17)
1.83/0.026; 18) 2.08/0.030; 19) 2.34/0.033; 20) 2.6/0.034
unwinding of plasmid DNA is based on the principle that negatively supercoiled circular
DNA becomes positively wound when the duplex is locally unwound, a phenomenon
encountered upon the formation of intrastrand crosslinks by cisplatin. Each intrastrand
Pt-DNA adduct formed by cisplatin unwinds the DNA duplex by 130, whereas the
monofunctional adducts formed by compounds such as [Pt(dien)CI] and [Pt(NH 3)3CI]
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unwind the DNA duplex by only 60.16.17 Treatment of plasmid DNA with pyriplatin did not
induce measurable unwinding of the superhelix at rb (platinum bound per nucleotide)
values of up to 0.034. This observation is consistent with the formation of
monofunctional platinum-DNA adducts in solution.
Repair of DNA Damage Induced by Pyriplatin
We further examined the cellular response to pyriplatin by launching an
investigation into cellular repair of the DNA damage caused upon the formation of DNA
adducts. Nucleotide excision repair (hereafter "excision repair") is the repair pathway by
which the major product of cisplatin-induced DNA damage, the intrastrand d(GpG)
lesion,1 8' 1 9 iS repaired. 2 0 The vitality of the excision repair pathway in human cells is a
key indicator of the sensitivity of the tissue, and the entire patient, to platinum-based
chemotherapy. Human cells from disorders in which nucleotide excision repair
deficiency is a phenotype, such as xeroderma pigmentosum, 21 and Cockayne
syndrome, 2 are exquisitely sensitive to cisplatin damage. A test for the presence of a
key protein in the excision repair pathway, ERCC1, is in FDA Phase III trials for use as
a predictive factor in tailoring chemotherapy to patients with non-small cell lung
cancer.2 3 Conversely, increased efficiency of the excision repair pathway leads to rapid
removal of cisplatin adducts and the upregulation of ERCC1 is associated with cisplatin
resistance in human tumor cells. 24,25
In comparing the repair of three different site-specifically platinated 156mer
probes, prepared as described26,27 (Figure 4.4 and 4.5) we obtained 3.5% repair of the
cisplatin-modified DNA, 1% repair of the pyriplatin adduct, and 0.3% repair of the
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[Pt(dien)CI]CI adduct after 60 min reactions (Figure 4.6 and 4.7). This rate and amount
of repair is comparable to the 1% repair previously observed for d(GpG) probes
platinated with cisplatin,20 26'28 and is less than the 10% repair observed for cisplatin-
modified d(GpTpG) probes.28
A B C
5 35
D E
Fragment B: 5' 32 P-labeled, platinated DNA 14mer
Anneal, ligate
* 3
SAdd cell-free extracts from HeLa cells
Allow excision repair to proceed
-4.
excised
Figure 4.4. Preparation of site-specifically platinated probe and diagram of in
vitro nucleotide excision repair assay.
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63mer:
5'-ATCAATATCCACCTGCAGATTCTACCAAAAGTGTATTTGGAAACTGCTCCA
TCAAAAGGCATG-3'
14mer-G strand
5'-TTCACCGCAATTCC-3'
14mer-GG strand
5'-TTCACCGGAATTCC-3'
79mer
5'-CCTCAACATCGGAAACTACCTCGTCAAAGGTTTATGTGAAAACCATCTTA
GACGTCCACCTATAACTACCTGGGAACC-3'
86mer-C strand
5'-ATGTTGAGGGGAATTGCGGTGAACATGCCTTTTGATGGAGCAGTTTCCAAA
TACACTTTTGGTAGAATCTGCAGGTGGATATTGAT 3'
86mer-CC strand
5'-ATGTTGAGGGGAATTCCGGTGAACATGCCTTTTGATGGAGCAGTTTCCAAA
TACACTTTTGGTAGAATCTGCAGGTGGATATTGAT-3'
70mer
5'-GGTTCCCAGGTAGTTATAGGTGGACGTCTAAGATGGTTTTCACATAAACCT
TTGACGAGGTAGTTTTCCG-3'
Figure 4.5. DNA oligomer components of 156mer repair probe.
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py py
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Time (min)
Figure 4.6. Kinetics of repair for pyriplatin-modified-DNA (py) reported as %
repair relative to the 156mer band (CHO extracts).
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Figure 4.7. Representative gels showing nucleotide excision repair products. Lane assignments:
A. Comparison of three probes. (1)100 bp ladder, (2) cisplatin 0 min, (3) cisplatin 30 min, (4)
cisplatin 60 min, 5-7) pyriplatin 0/30/60 min, 8-10) [Pt(dien)CI]CI 0/30/60 min. B. Kinetics of repair
for pyriplatin. (1) cisplatin 0 min, (2) cisplatin 60 min, 3-(8) pyriplatin 0/15/30160/90/120 min.
A decrease in repair due to shielding by the nuclear structure-specific DNA
binding protein HMGB1 29 was also observed, suggesting that some perturbation of the
DNA structure does occur upon binding of the monofunctional pyriplatin. Repair of the
1,2-d(GpG) cisplatin adduct was inhibited by 77% upon addition of full length, fully
reduced HMGB1 to 3.2 pIM, whereas repair of the pyriplatin and [Pt(dien)CI]CI adducts
was reduced by 65% and 32%, respectively (Figures 4.8, 4.9).
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Figure 4.9. Comparison of 3 probes +/- HMGB1 1,. 1) :cisplatin 0 min, 2) cisplatin 30 min, 3)
cisplatin + .06 mM DTT 30 min, 4) cisplatin, DTT, 4 pM HMGBlru1, 5) pyriplatin -0 min, 6)
pyriplatin, DTT 30 min, 7) pyriplatin, DTT, HMGB1 30 min, 8) [Pt(dien)CI]Cl, 0 min, 9)
[Pt(dien)CI]CI, DTT, 30 min, 10) [Pt(dien)CI]CI, DTT, HMGB1, 30 min
90%.
80% i
70%
60%-
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cisplatin
Figure 4.8. Decrease in repair due to repair shielding by HMGB1. Percentages are expressed as
% reduction of repair due to HMGB1, where the control reaction (no HMGB1 was set to 0%
inhibition).
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pyriplatin [Pt(dien)CI]
The pyriplatin adduct is clearly recognized by the excision repair machinery,
possibly because of a noncovalent interaction between the pyridine ring and DNA,
suggesting that the transcription inhibition/nucleotide excision repair pathway involved in
cellular processing of cisplatin-DNA adducts is also relevant to pyriplatin-DNA adducts.
Conversely, the reduced repair of pyriplatin relative to that of cisplatin suggests that
DNA damage caused by pyriplatin is able to elude the cellular repair machinery,
rendering those adducts more persistent and potentially more cytotoxic to tumor cells.
Inhibition of Transcription Induced by Pyriplatin in HeLa Cells
Among the proteins and protein complexes that encounter cisplatin-DNA
adducts is the transcription apparatus. Unlike DNA polymerases, which briefly pause at,
and then bypass, cisplatin cross-links, presumably without major downstream effects, 30
RNA polymerases are greatly affected by the presence of these adducts. The
progression of human RNA polymerase II (Pol II) along the DNA strand is almost
completely blocked by cisplatin-DNA adducts, 31 and the arrest and subsequent
ubiquitylation of Pol II initiate transcription-coupled repair, a subpathway of nucleotide
excision repair, and programmed cell death, or apoptosis. 32 Plasmids containing the
lacZ gene downstream of an SV40 promoter were modified with cisplatin, pyriplatin, or
[Pt(dien)Cl] at rblevels from 0 to 0.13 (Figure 4.10) and transfected into HeLa cells. The
products of P-galactosidase activity were assayed colorimetrically after 24 h by addition
of ortho-nitrophenyl-p-galactoside (ONPG). Bypass of platinum adducts by the Pol II
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Figure 4.10. Results of rb vs. rf determination for platination with pyriplatin and cisplatin on pSV-b-
galactosidase plasmid DNA. Error bars show one standard deviation.
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0.000
-.- pyriplatin
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Figure 4.11. Bypass of various platinum adducts by the transcribing complex as assayed in live
cells using a platinated pSV-p-galactosidase reporter plasmid. The percent transcription bypass
relative to cells treated with unplatinated plasmid is plotted vs. platination level (rb value). A
bypass percentage of 100% indicates that there was no decrease in transcription of the reporter
protein due to platination. Error bars represent the standard deviation of three samples from the
same cell preparation and the experiment was repeated twice.
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complex led to increased transcription of the lacZ gene and absorbance at 420 nm
arising from ONPG cleavage by 13-galactosidase. There was a clear difference between
Pol II bypass of cisplatin vs. [Pt(dien)Cl] adducts, relative to that for the unplatinated
control plasmids (Figures 4.11, 4.12), with [Pt(dien)CI] requiring 5 times the platination
level as cisplatin to block progression of RNA Pol II completely. In contrast, transcription
inhibition by the monofunctional pyriplatin adducts very nearly matched that of cisplatin
and was much more effective than inhibition by [Pt(dien)CI] . Transcription of the
cisplatin-modified plasmid was effectively inhibited at an rbvalue of 2.5 x 10-3
90%, 5.0%
0% Transcription Bypass
1% Repair after 60 min
pyriplatin
i
m [ n
*
[Pt(dien)CI]CI
Figure 4.12. Comparison of successful transcription bypass and repair of various Pt-DNA adducts.
Adducts of pyriplatin, much like those of cisplatin, allow minimal bypass by RNA pol II, but are
inefficiently repaired. The level of repair of pyriplatin adducts is comparable to that of
[Pt(dien)CI]CI adducts. Repair values report percent excision products detected after 60 min and
transcription bypass values are given at rb = 0.0039 for the p-gal live-cell assay. Repair error bars
are the standard deviation of five, five, and two separate experiments for cisplatin, pyriplatin, and
[Pt(dien)CI]CI, respectively. Absence of an error bar indicates very small deviation between
experiments. Transcription error bars are the standard deviation of samples prepared in triplicate.
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Inhibition by [Pt(dien)CIlJ-modified plasmids was the same as that of the
unplatinated control at rb = 7.8 x 10-3 whereas transcription from the pyriplatin-modified
plasmid was reduced to 16% that of the control at an rbvalue of 3.9 x 10-3 (Figure 4.12).
Discussion and Conclusions
Identification of cis-[Pt(NH 3)2(pyridine)CI]CI as a highly cytotoxic agent in tumor
cells transfected with organic cation transporters led us to question the mechanism of its
cytotoxicity. Pyriplatin is an excellent substrate for OCT1 and OCT2, as revealed by its
increased accumulation in cells that overexpress these transporters. The fact that cells
expressing OCT1 or OCT2 are up to two orders of magnitude more sensitive to
pyriplatin than control cells suggests that pyriplatin could be used to target OCT-
expressing cancers, such as colorectal, liver, or kidney cancers. Pyriplatin has a greater
tumor-targeting potential than oxaliplatin, the colorectal cancer agent that owes its
unique antitumor properties to specific uptake by OCT1 and OCT2. Compared with
oxaliplatin, cDPCP is much less toxic to cells that do not express OCT1 or 2. This
property suggests that, like oxaliplatin, cDPCP will be able to target colorectal or liver
cancer but with a reduction in the severity of side effects for tissues that do not express
OCT1 or OCT2. The presence of these transporters in certain organs, most notably
kidney and liver, may require the use of cotreatments to mitigate toxic side effects.
Nephrotoxicity, the dose-limiting side effect for cisplatin therapy, is less problematic in
oxaliplatin treatment. 33 Liver toxicity is a non-dose-limiting side effect of cisplatin and
oxaliplatin. 34
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Although pyriplatin forms a monofunctional adduct on DNA, as shown by DNA
unwinding studies, adducts of pyriplatin are repaired by the nucleotide excision repair
pathway at a reduced rate than those of cisplatin and pyriplatin binds plasmid DNA as
readily as cisplatin. Because pyriplatin can escape repair, the DNA damage induced by
pyriplatin should endure longer than DNA damaged by cisplatin, thereby increasing the
cytotoxic potential of pyriplatin. The repair of pyriplatin adducts is inhibited by the DNA
damage recognition protein HMGB1, suggesting an interaction between components of
the repair machinery and the platinum complex beyond that observed for other
monofunctional compounds, such as [Pt(dien)CI]CI.
The cytotoxic effect of pyriplatin may be linked with its ability to inhibit Pol II,
which it does significantly better than a model monofunctional compound, [Pt(dien)CI]CI.
Like cisplatin, transcription is strongly inhibited by pyriplatin both in cell extracts and in
live cells.
Pyriplatin largely escapes the nucleotide excision repair pathway and yet inhibits
transcription very effectively. The combination of these effects suggest that its adducts
will persist longer than those of cisplatin yet produce substantial downstream
consequences that might raise the therapeutic potential of pyriplatin relative to cisplatin.
The design of anticancer agents specifically as transcription inhibitors has been
proposed, based on the premise that an extended delay in the restoration of
transcription would induce apoptosis by p53- dependent and -independent pathways.3 5
If true, persistence of transcription blocks would promote cell death and enhance the
potency of pyriplatin. Combined with the high selectivity of pyriplatin for cells expressing
hOCT1 and hOCT2, which are broadly expressed in human colorectal cancer,2 these
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findings support the candidacy of this unique monofunctional cationic complex as an
anticancer drug with a mechanism of action that is likely to differ from that of cisplatin.
Preclinical trials of pyriplatin are ongoing.
Materials and Methods
Materials
Potassium tetrachloroplatinum(ll) was a gift from Engelhard Corp. (now BASF,
Iselin, NJ) and cisplatin36 and cis-[Pt(NH 3)2(py)CI]CI were synthesized as described. 14
Phosphoramidites and other reagents for DNA synthesis were purchased from Glen
Research. Enzymes were purchased from New England Biolabs. Plasmids pBR322 and
pSV-p-galactosidase were purchased from New England Biolabs and Promega,
respectively, and were amplified in 100 mL LB cultures of E. col XL1-Blue cells
containing ampicillin as a selecting agent and purified on Maxi-prep columns (Qiagen).
Plasmids were analyzed for purity by agarose gel electrophoresis and used for
platination reactions. [y-32 P]ATP was obtained from Perkin Elmer. All other chemicals
and solvents were purchased from commercial suppliers.
Instrumentation
1H NMR and 195pt NMR spectra were obtained on Varian 300 and 500 MHz
spectrometers, respectively. Electrospray ionization-MS (ESI-MS) spectra were
obtained on an Agilent Technologies 1100 Series liquid chromatography/MS instrument.
Fourier transform-IR (FT-IR) spectra were measured on an Avatar 380 FT-IR.
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Cell Lines and Transfection
Madin-Darby canine kidney (MDCK) cells stably transfected with the full-length
human OCT1 cDNA (MDCK-hOCT1) and with the empty vector (MDCK-MOCK) were
previously established.3 7 Human embryonic kidney (HEK) 293 cells stably transfected
with the full-length OCT2 cDNA (HEK-hOCT2) and with the empty vector (HEK-MOCK)
were also previously described.2
Cell Culture
The stably transfected MDCK and HEK 293 cells were cultured in DMEM
supplemented with 10% FBS, 100 units/mL penicillin, 100 pg/mL streptomycin
(Invitrogen), and the respective selection antibiotics and grown at 37°C in a humidified
atmosphere with 5% CO 2.
Drug Sensitivity
Cytotoxicities of the compounds were determined by plating cells in 96-well
plates at a predetermined cell density. Cells were then incubated overnight and
platinum complexes with or without an OCT inhibitor (cimetidine or disopyramide) were
added to the culture medium. After drug exposure for 7 h, the medium was replaced
with fresh, drug-free medium and the incubation was continued for a total of 72 h
(starting from addition of platinum compounds). MTT assays were performed as
previously described38 and IC50 values were obtained by fitting F, the percentage of the
maximal cell growth at different drug concentrations, to the equation
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F = 100 x [1-C0 / IC50 + C)] using WinNonlin (Pharsight, Mountain View, CA). The
maximal cell growth was set to the cell growth in the absence of platinum compounds; C
is the concentration of the platinum compound and y is the slope factor.
Cellular Accumulation of Platinum
Studies of cellular accumulation of platinum were based on a previously
described protocol. 39 Cells were incubated in medium with either pyriplatin or oxaliplatin
at 37 0C in 5% CO 2 for 2 h. After incubation, cells were washed with ice-cold PBS,
harvested, and pelleted by centrifugation (400 x g, 40C, 15 min). Cell pellets were
digested by heating at 65 0C in 70% nitric acid for-at least 2.5 h. Samples were prepared
in distilled water containing 10 ppb of elemental iridium as an internal standard (diluted
from Ir standard: 1000 pg/mL in 10% HCI) and 0.1% Triton X-100 to an overall nitric
acid concentration of 7%. Platinum content was measured by inductively coupled
plasma mass spectrometry in the Analytical Facility at the University of California at
Santa Cruz. Cell lysates from a set of identical cultures were used for determination of
protein content by the bicinchoninic acid assay.
Plasmid Preparation and Platination for DNA Unwinding Assays
The plasmid pBR322 was allowed to react with cisplatin or cis-[Pt(NH 3)2(py)CICI
in 24 mM HEPES, pH 7.4, and 10 mM NaCI over 24 h at 37 oC in the dark. The DNA
concentration was 19.6 pM (in base pairs) and the platinum concentration ranged from
1.5 to 90 iM in 120.4 pL total reaction volume. Rf values varied from 0.039 to 2.6.
Platinum still unbound after 24 h was removed by spin microdialysis (Nanosep
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cartridges, Pall Biosciences, 30,000 MWCO). After loading the DNA solution, spin
cartridges were washed until no further platinum was detected in the wash solution (5 x
100 iL ddH 20). DNA-bound platinum was quantified by atomic absorption (AA)
spectroscopy (Aanalyst 300, HGA-800 graphite furnace, AAWinLab software version
3.0, Perkin Elmer, Wellesley, MA). A hollow cathode platinum lamp with 265.9 nm
emission was used with a slit width of 0.70 nm. Pyrolysis was performed at 12000 C for
20 s and atomization at 2650 0C for 5 s. AA samples were measured in duplicate using a
calibration range of 20-80 gIg/L and an r value of > 0.998 for all calibration curves. DNA
concentrations were measured by UV-Vis absorption spectroscopy at 260 nm (Cary 50
Bio UV-Visible Spectrometer equipped with a microprobe from C Technologies Inc.).
Determination of Pt-Induced DNA Unwinding
Agarose gel electrophoresis was used to determine the extent of DNA unwinding
induced by the Pt-DNA adducts. Samples were concentrated by ethanol precipitation
and loaded onto an ethidium-free 1 % agarose gel (loading solution: 4 pIL ddH 20 plus 6
tL 50% glycerol and 0.002% of each bromophenol blue and xylene cyanol). Gels were
electrophoresed for 4 h at 75 V in lx TAE buffer at room temperature. Gels were then
soaked in 1 pg/mL ethidium bromide in ddH 20 for 15 min, destained in ddH 20 for 5 min,
and imaged in a Fluor-S gel scanner using QuantityOne software (BioRad).
Repair Probe Preparation for Nucleotide Excision Repair
Repair probes were made by synthesizing, annealing, and ligating five short
oligomers to form dsDNA strands of 156 base pairs in length (Figures 4.4, 4.5) and
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were purified and radiolabeled with 3 2 P as described. 26' 27 For platinated strands, the
platination step was performed on the 14mer oligomers prior to assembly of the probe
with either cisplatin (14mer, GG strand), cis-[Pt(NH 3)2(pyridine)CI] (14mer, G strand),
or [Pt(dien)ClI] (14mer, G strand).
Excision Assay
Assays were performed as described20 ' 26' 27 with 10 fmol of the platinated repair
probe and 75 pg cell-free HeLa extract. Reactions were allowed to proceed for 60 min
at 300C and were stopped by the addition of SDS and proteinase K to final
concentrations of 0.34% and 20 pg/mL, respectively. After phenol extraction, 25:24:1
phenol:chloroform:isoamyl alcohol extraction, and careful ethanol precipitation with 10
tg linear polyacrylamide as co-precipitant, reaction products were analyzed by 10%
urea-PAGE. For reactions in the presence of HMGB1, the full length, fully reduced
recombinant form of the protein was added to the DNA and reaction buffer prior to the
addition of the cell extract. After incubation at room temperature for 10 min, cell extract
was added to begin the repair reaction, putting the overall [HMGBl full] at 3.2 jIM.
Evaluation of Excision Kinetics
Excision reactions were performed as described above, with reaction incubation
times of 0, 15, 30, 60, 90, or 120 minutes. After the specified reaction time had elapsed,
reactions were quenched with SDS and proteinase K as previously described. Data
from three separate experiments were averaged.
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Transcription Assay. HeLa cells (ATCC) were cultured in DMEM with 10% fetal bovine
serum at 5% CO 2 in a humidified chamber and restarted upon reaching passage
number 20. Cells were transfected with platinated or unplatinated control plasmids
according to the manufacturer's protocol (Lipofectamine 2000, Invitrogen Corp.). After
24 h incubation, cells were washed twice with PBS, incubated for 15 min in lysis buffer
(25mM bicine, pH 7.8, 0.05% Tween 20, 0.05% Tween 80) and scraped from the plate.
After 15 s vigorous vortexing and centrifugation (18,000 x g), the supernatant was
treated with 2.2 mM ortho-nitrophenyl-p-galactoside (ONPG) and 50 mM P-
mercaptoethanol in 100 mM sodium phosphate, pH 7.3, and 1 mM MgCI 2. Following
incubation at 37 oC for 4 h and addition of sodium carbonate to 0.75 M, the absorbance
of the solution was measured at 420 nm and values from the cells transfected with
platinated plasmid were normalized to those from cells transfected with nonplatinated
plasmid.
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Chapter 5
Characterization of the Role of HMGB1 in the Cellular Response to Cisplatin
151
Introduction
HMGB 1 and the Repair Shielding Hypothesis
The finding that the DNA-binding high mobility group protein HMGB1 recognizes
and binds the major cisplatin-DNA adduct1' 2 led to the hypothesis that these proteins
shield the damaged DNA from excision repair, thereby significantly contributing to the
cytotoxic effect of cisplatin. Subsequent studies investigating the repair-shielding effect
have focused on methods of increasing the amount of HMGB1 in cancer cells to
potentiate the activity of cisplatin. The observation that estrogen and progesterone
upregulate HMGB1 in MCF-7 and Evsa-T cell lines, respectively,3 opened up a new line
of inquiry for the study of cisplatin. The discovery that treatment of MCF-7 cells with
estrogen or progesterone causes a two-fold increase in the sensitivity of the cells to
cisplatin4 was followed up by the synthesis of estrogen-tethered platinum(IV) complexes
for potential use in breast-cancer patients.5 These compounds were also shown to
upregulate HMGB1 in cancer cells and one of the compounds sensitized cells to
cisplatin.
Upregulation of HMGB by Hormones
The biological connection between the estrogen receptor and HMGB1 is related
to the estrogen receptor-DNA interaction. The estrogen receptor binds tightly to
specific DNA sequences, called estrogen response elements, and this binding is
enhanced by the presence of other accessory nuclear factors, including HMGB1.6 The
interaction between the progesterone receptor and the progesterone response element
occurs in a similar manner. The androgen receptor also binds to a specific DNA
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sequence, but the role of HMGB1 in this interaction has not been completely elucidated.
Although androgens have not yet been shown to upregulate HMGB1, the transient
expression of HMGB1 or HMGB2 in HeLa cells has been shown to increase the
apparent DNA binding affinity of the androgen receptor.6 The central DNA binding
domains of all three of these steroid hormone receptors are similar and are composed
of two highly conserved zinc fingers.7
We evaluated the effect of androgens on the upregulation of HMGB1 and on the
cytotoxicity of cisplatin, focusing on the LNCaP human prostate cancer cell line. This
cell line, unlike many prostate cancer cell lines, continues to expresses the androgen
receptor under the conditions required for tissue culture. The choice of the androgen
dehydroepiandrosterone (DHEA) for these cell experiments was partially motivated by
the fact that it was the only androgen receptor substrate directly upstream of
dihydrotestosterone (DHT) in the biosynthetic pathway (Scheme 5.1) that was
obtainable without a DEA license. The exception from the DEA list is due to political
circumstances,8 not scientific reasons. Although it is converted into testosterone and
DHT in the body, DHEA itself is an inferior substrate for the androgen receptor.
Testosterone has a binding affinity over 1800 times that of DHEA and DHT has a
binding affinity over 10,000 fold higher than DHEA. 9 Besides avoiding DEA-controlled
substances, another motivation for the use of DHEA was its common use as a dietary
supplement for the treatment of age-related ailments8'10 and the implication of DHEA in
the prevention of prostate cancer.11 Additionally, cancer cells treated with DHEA do not
exhibit the increased proliferation that is a characteristic of treatment with DHT or
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testosterone. 12 Upon obtaining the DEA license, the more potent DHT (Scheme 5.1)
was also used in cell studies.
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Scheme 5.1. Steroid biosynthetic pathway starting from cholesterol
Retinoic Acid and HMGB 1
Along with progesterone, estrogen, and androgen receptors, the retinoic acid
receptor (RAR) is a member of the steroid receptor superfamily. Unlike androgens and
estrogen, the proliferative effects of which have been implicated in exacerbating the
problems of cancer, all-trans-retinoic acid (ATRA, Chart 5.1) has been shown to have
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Chart 5.1. all-trans-retinoic acid.
an antiproliferative effect on cancer cells.13 For this reason, ATRA is used to treat
cancer patients, particularly those suffering from prostate cancer and leukemia. Three
subtypes of RAR exist, RARa, RARP, and RARy, all of which are receptors for ATRA.
The expression of RARP, a subtype that has been implicated in the antiproliferative
effect of ATRA, is often downregulated in human cancers 14 The human breast cancer
cell line MCF-7 expresses all three types of RAR.14
The connection between retinoic acid and the study of cisplatin drugs is based on
the observation that, like estrogen and progesterone, retinoic acid can also cause the
upregulation of HMGB1. Specifically, embryonal carcinoma cells of the P19 murine cell
line show increased amounts of HMGB1 beginning six days after treatment with 500 nM
retinoic acid.15
Studies in patients and in human cancer cell lines have indicated that the
combination of cisplatin and ATRA has anti-cancer effects. Phase II clinical trials of the
combination of ATRA, cisplatin, and interferon-a in women with recurrent or metastatic
cervical squamous cell carcinoma were carried out in Europe in 2002. The trial was
halted due to unacceptable toxicity after three months, although the preliminary results
showed a good response to the drug combination.16 There are other indications that the
co-treatment of ATRA and cisplatin could sensitize cells to cisplatin treatment. A phase
II trial of the combination plus etoposide in small cell lung carcinoma yielded a 45%
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response rate before it too was stopped due to toxic side-effects. 17 Co-treatment of
cisplatin and ATRA in the ovarian carcinoma cell lines OVCCR1 and NIH-OVCAR-3
potentiated cisplatin cytotoxicity, 1 8,' 9 as did cotreatment in both human ovarian
adenocarcinoma and in head and neck squamous carcinoma cell lines.20
The possibility that ATRA could be linked to both the upregulation of HMGB1 and
increased cisplatin efficacy led us to investigate the nature of HMGB1 upregulation by
retinoic acid.
Effect of Reducing and Oxidizing Cellular Potentials on the HMGB I-DNA Interaction
Transcription factors in the nucleus are often activated or disabled according to
external signals, such as oxidative stress. Redox-sensitive transcription factors include
NF-KB (nuclear factor KB, involved in a pathway activated by HMGB1,21 p53, AP-1
(activator protein-i, specifically c-Jun and c-Fos), SoxR, OxyR,2 2 c-Myb, NF-Y/CBF, SP-
1, NFI/CTF, EGR-1, glucocorticoid receptor, Heat Shock Factor, TTF-1, USF, Pax-8,
Hox B5, PEBP2, GABPa, HLF, and HIF-la).23 (reviewed2 425) Redox-related cell
signaling involves changes in the oxidation state of cysteines that lead to protein
structural changes and modulation of protein activity. The formation of a disulfide bond
under oxidative conditions, for example, can dramatically alter protein structure,
providing a mechanism for oxidative stress to switch transcription factor activity. In the
prototypic switch example, the reduced transcription factor is inactive, whereas the
disulfide form of the protein is transcriptionally active.22 Beyond this on-off switch
mechanism, other cysteine modifications that can occur based on the reduction
potential of a particular cellular organelle, such as S-NO, S-OH, and S-SG
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(SG=glutathione), can more moderately regulate transcription, as has been shown for
the transcription factor OxyR, which is the bacterial transcriptional activator of E. coli.22
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Figure 5.1. Sequence of full length HMGB1, diagram of A and B domains, and structure2 of the A
domain on cisplatin-modified 16mer DNA.
The interaction of metallothionein, a metalloprotein consisting of -33% cysteines, with
zinc depends on an interaction of metallothionein with oxidized glutathione (GSSG) to
release zinc. The combination of oxidized and reduced glutathione (GSH) then enables
the transfer of zinc from metallothionein to an apoenzyme.26 The difficulty in examining
the effect of these various modifications lies in the production of the pure form of
oxidized proteins and the retention of these instable species once they are formed.
Experiments generally require anaerobic conditions and analysis of tryptic digests of the
oxidized or reduced proteins samples by ESI-MS. 22
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Cancer cells are hypoxic, a condition that induces oxidative stress. Oxidative
stress causes a large increase in cellular reduction potential, rendering the cellular
mediator of oxidative stress, glutathione, less able to reduce proteins. Severe oxidative
stress causes cell death. Specifically, moderate stress can trigger apoptosis-and more
intense oxidative stress can cause necrosis. ROS are produced, which cause cellular
damage.
The highly abundant nuclear protein HMGB1 regulates transcription and
remodels chromatin by binding and bending DNA in a structure-specific, non-sequence-
specific manner. 27 The protein is also released into the cytosol during necrosis and is
present at sites of inflammatory diseases. The protein comprises two alpha-helical HMG
box domains (A and B domains) of about 80-amino acids each and an acidic C-terminal
domain. The HMGB1 gene sequence (Figure 5.1) maps to chromosome 1328 and
sequences from mouse, rat, hamster, bovine, pig, and human are almost identical.29
Of the three cysteine residues found in HMGB1,, CyslO6, on the B box,
determines the nuclear or cytoplasmic localization of the protein. The C106S mutant
protein is localized in both the cytosol and nucleus of healthy CHO cells, in contrast to
the wild-type protein, which is observed only in the nucleus. 23 The two A-box cysteines,
Cys23 and Cys45, form a disulfide bond under conditions of oxidative stress, inducing
structural changes in the protein and possibly switching its DNA binding ability. Cys23
and Cys45 are separated by 4.25 A in the HMGB1 A domain-DNA crystal structure,
which was performed under reducing conditions (2.5 mM DTT).2,30 NMR structural
information about the interaction of the A domain with DNA was similarly performed
under reducing conditions (50 iM DTT) and with a C22S mutated protein.31' 32
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The presence of a Cys23-Cys45 disulfide bond in HMGB1 under oxidizing
conditions is not currently disputed.23'33'34 One outstanding question is whether
reversible oxidation of the HMGB1 cysteines occurs in vivo. The cytoplasm and nucleus
are both reducing environments, as compared with the extracellular milieu. Exact redox
potentials in the cytoplasm and organelles of various species depend upon factors such
as the concentration of glutathione reductase and NADPH,35 the presence of
renaturation catalysts, such as the eukaryotic protein disulfide isomerase,36 preferential
transport of GSSH over GSH through cell and organelle membranes, and the
production of oxidizing equivalents as byproducts of other cellular mechanisms.
Generally, favorable conditions for refolding of disulfide-bond-dependent proteins
involve a reduced glutathione to glutathione disulfide (GSH:GSSH) ratio of less than 10.
The GSH:GSSH ratio is about 60 (-233 mV vs. SHE) in the eukaryotic cytoplasm and
about 2 (-180 mV) in the endoplasmic reticulum, as determined for the Mus musculus
hybridoma cell line CRL-1606. 35
If we assume that the HMGB1 disulfide bond could form in vivo, which is not
unreasonable based on western-blot analysis of native HMGB1 from CHO extracts, 23
we additionally wish to understand whether oxidation of this bond switches the binding
affinity of HMGB1 for cisplatin-modified and/or naked DNA. A disulfide bond-based
switch has been observed in the Ku protein, wherein only the oxidized form of the
protein binds cDDP-modified DNA.37 Existing data on HMGB1 are contradictory and
data on HMGB1 and HMGB2 (in which the cysteine sites are conserved) interacting
with platinated DNA is based on poorly characterized, globally platinated material.
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Mutations and covalent modifications of Cys23 and Cys45 have no effect on nuclear
localization of HMGB1, 23 but do modulate HMGB1 -DNA binding and alter the overall
structure of the protein. Global modification of full-length HMGB1 with Ellman's reagent
(DTNB; 5,5'-dithiobis(2-nitrobenzoic acid), hydrogen peroxide, or N-ethylmaleimide
(NEM) reduces HMGB1 binding to globally platinated DNA by 81%, 90%, and 85%,
respectively, whereas incubation with 2-mercaptoethanol has no effect on the protein
interaction with platinated DNA binding.3 8 DTNB and NEM modify cysteinate thiols and
prevent formation of the Cys23-Cys45 disulfide bond. 2-Mercaptoethanol would also
ensure the reduced form of the protein. Conversely, hydrogen peroxide is an oxidizing
agent that would induce formation of the disulfide bond. The authors conclude that the
reduced form of the protein has the higher affinity for Pt-DNA, although, based on the
data, this conclusion does not seem obvious. 38 Contrary to these results on full-length
HMGB1, NEM does not inhibit the interaction of the AB-only fragment of HMGB1 with
unplatinated DNA, 39 indicating that NEM-induced modifications along the C-terminal tail,
not around Cys23 or Cys45, are responsible for the observed modulation in DNA
binding ability. Supporting evidence for the localization of chemically induced oxidative
effects to the C-terminal tail includes the fact that C-domain-induced structural changes,
such as induction of DNA looping and compaction, are not observed in the presence of
NEM. 40
The effect of site-specific mutations of the HMGB2 protein, in which the cysteine
sites are conserved, on protein affinity to globally platinated DNA add further conflicting
data. Mutations C45S and C106S, but not C23S, resulted in significant reductions in
protein-platinated DNA binding (25% and 50%, respectively).41 If a Cys23-Cys45
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disulfide bond were somehow involved in the modulation of DNA binding, one might
expect similar effects for the C23S mutation as for the C45S mutation. Contrary to this
HMGB2 study, an HMGB1 C23A mutant showed reduced binding affinity for
unplatinated duplexes and 4WJ DNA. Neither C45A nor C106A mutants were
examined.42
HMGB1 in the reduced form binds H1 with significantly greater affinity than in the
oxidized form, although this interaction may involve a 4:1 HMGB1:H1 complex, a
complex that has never been found at the sites of HMGB1/cisplatinated DNA
interactions.4 3
In conclusion, a disulfide bond is most definitely formed in HMGB1 under certain
in vitro conditions and, although the specific redox potential has not been determined, it
is likely that the disulfide bond forms in vivo under conditions of oxidative stress.
Reports on the nature of oxidized and reduced HMGB1 binding to globally platinated
DNA are conflicting and no studies on site-specifically platinated DNA have been
performed. Definitive experimental work on the relative affinity of oxidized and reduced
HMGB1 for site-specifically platinated DNA would greatly improve the current scientific
understanding of this protein.
HMGB4
A new member of the mammalian HMGB family, HMGB4 (NCBI Reference
Sequence: NP_660206.2), has recently been characterized.44 The murine form of
HMGB4 is isolable from adult mouse testis and a virtually identical protein is found in
humans. The protein is of particular interest because of the connection with the testis,
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an organ in which the treatment of tumors with cisplatin is extraordinarily effective (over
99% cure rate). Comparison of the human HMGB4 and human HMGB1 sequences
(Chart 5.2) reveals that the phenylalanine at position 38 that is critical for the binding of
HMGB1 to cisplatin-modified DNA 2 is conserved in the HMGB4 sequence. The
sequence alignment further indicates that the disulfide bond formed in HMGB1 between
Cys23 and Cys45 cannot be formed in HMGB4 due to the absence of a cysteine at
position 23.
HMGB4:
HMGB1: IAAAKGK A- VVKAEK .4 EEEDEEDEEDEE
HMGB4: -----------------
HMGB1: EEEDEEDEDEEEDDDDE
Chart 5.2. Sequence alignment of human HMGB4 and human HMGB1. Identical residues are highlighted in
black, similar residues are highlighted in grey, and the Phe38, Cys23, and Cys45 residues are underlined.
The last 34 C-terminal residues
associate with the N-terminal A-domain
HMGB1 for DNA is increased if the tail is
acidic tail (Chart 5.2), but seems to bind
preliminary conclusions is based on
chromatin with about the same affinity
of HMGB1 are acidic and wrap around to
of the protein (Chart 5.2).45 The affinity of
removed from the protein.4 6 HMGB4 lacks the
chromatin with less affinity than HMGB1. This
separate observations that HMGB1 binds
as the histone linker H1 protein 47' 48 and that
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HMGB4 binds with less affinity than H1,44 although the differences in binding affinity for
specific DNA structures (cisplatin-modified DNA, cruciform DNA) have yet to be
determined.
Goals of this Chapter
The aim of this work is three-fold. The first goal is to investigate the hypothesis
that androgens, like estrogen and progesterone, will increase the level of HMGB1 in cell
nuclei and potentiate the antitumor activity of cisplatin in cells. If both of these
hypotheses are true, inorganic compounds combining platinum(IV) and a modified
androgen can be synthesized and used to selectively target and kill prostate cancer.
cells The second goal is to show that retinoic acid, an agent already being investigated
as an antitumor agent can increase the level of HMGB1 in tumor cell nuclei and that it
can potentiate the antitumor activity of cisplatin. The third goal is to determine the effect
of reducing or oxidizing conditions on the affinity of HMGB1 for cisplatin-modified DNA.
Experimental
Materials
The prostate cancer cell lines were a gift from the lab of J. M. Essigman (MIT),
who had obtained them from the American Type Culture Collection (ATCC). The MCF-7
cell line was obtained from ATCC. 4,5a-Dihydrotestosterone (DHT),
dehydroepiandrosterone (DHEA), (Scheme 5.1) and all-trans retinoic acid (ATRA)
(Chart 5.1) were obtained from Aldrich. DHT and DHEA were kept in strict accordance
with all US Drug Enforcement Agency requirements. Specifically, one gram of DHT was
stored in a locked cabinet that was permanently built into the wall, usage records were
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kept, and all DHT remaining after the completion of the experiments was incinerated
(Guaranteed Returns, Holbrook, NY). Cisplatin was synthesized from potassium
tetrachloroplatinate as previously reported. 49 Solutions of the androgens and ATRA
were prepared fresh daily in dimethylformamide and diluted 10-fold in sterile PBS before
use. Cisplatin solutions in PBS were prepared daily and quantitated by atomic
absorption spectroscopy (Perkin Elmer, Aanalyst 300, HGA800 graphite furnace).
Highly purified sterile water (Milli-Q) was used for the immunofluorescence assay.
Recombinant HMGBfu and HMGB1AB was prepared by Yongwon Jung of the Lippard
lab.
Cell Culture
LNCaP, a cell line which expresses the androgen receptor (AR+), DU-145 (AR-),
and PC-3 (AR-) prostate cancer cells were incubated at 370C in 5% CO 2 and grown in
RMPI medium supplemented with 1% glucose, 10% fetal bovine serum, 1%
penicillin/streptomycin, 1% 1M Hepes buffer (pH 7.4), 1% sodium pyruvate, and 1% L-
glutamine. MCF-7 cells, which express retinoic acid receptor P (RARP) were grown in
DMEM with 10% FBS and 1% penicillin/streptomycin. Cells were passed every 4 to 5
days and restarted from frozen stock upon reaching pass number 20. Media was
changed every three days.
Immunofluorescence
Cells were plated on day 1 in a 25 cm 2 flask and treated with 500 nM ATRA on
day 2. The medium was replaced with fresh ATRA-containing medium on day 4. On day
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6, cells were treated with trypsin/EDTA and plated in a 24-well plate on microscope
cover slips at 30,000 to 50,000 cells per well in ATRA-containing medium. Cells treated
with either DHT or DHEA were plated directly in a 24-well plate on microscope cover
slips at 30,000 to 50,000 cells per well on day 1. Androgens were added on day 2 to a
concentration of 1 pM at time points of 20, 16, 12, 8, 6, 4, 2, and 0.5 hours prior to
fixation and permeabilization. Cells treated with either ATRA or androgens were fixed
for 10 min in 2% paraformaldehyde/0.1M phosphate buffer (pH 7.4) and washed three
times in fresh PBS. Cells were then permeabilized by incubating for 10 minutes in 0.1%
Triton-X100, a detergent, in PBS (pH 7.4). The samples were washed six times in PBS
and incubated for 15 minutes in a blocking buffer, (PBS, pH 7.4, 0.1% goat serum,
0.075% glycine). The rabbit anti-HMGB1 primary antibody was diluted 1:100 in blocking
buffer and the cover slips were placed in a humid container, covered with 35 pL of the
diluted antibody, and incubated at 37 0C for 1 hr. After washing the samples three times
in blocking buffer, the incubation was repeated with a goat anti-rabbit FITC-conjugated
secondary antibody (1:100 dilution in blocking buffer). The cover slips were washed
twice in blocking buffer and four times in water before mounting with a p-
phenylenediamine anti-bleaching solution (9.2 mM p-phenylenediamine in 1:10 10x
PBS:glycerol) on microscope slides. Slides were imaged on a Nikon Eclipse TS100
Microscope with a Nikon DXM1200 digital camera.
Cytotoxicity Assays
Cells to be treated with retinoic acid were grown in a 25 cm2 flask with medium
containing 500 nM retinoic acid. The medium was replaced with fresh retinoic acid-
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containing medium after two days of growth. After four days of growth, the cells were
plated at 2,000 cells per each well of a 96 well plate and grown for one day before
adding cisplatin to concentrations of 0, 1, 2, 5, 8, 10, 12, 15, and 20 pM cisplatin (in
MCF-7 cells) or 0, 1, 1.5, 2, 2.5, 3, 6, 10, and 15 giM cisplatin (in PC-3 cells).
Cells to be treated with androgen were plated at 2,000 cells per each well of a 96
well plate and grown for one day before adding androgen to a final concentration of 1
pM and cisplatin to concentrations of 0, 1, 2, 5, 8, 10, 12, 15, and 20 pM. Cell survival
was quantified by the MTT assay after five days of growth.
Oxidation and Reduction of HMGB 1
HMGBfull and HMGB1AB were fully reduced with 10 mM DTT. Oxidizing
conditions were produced with diamide (Chart 5.3) (10-500 mM, 4-250C, 0-30 min),
H20 2 (0.1-5 mM), or oxidized and reduced glutathione (GSH:GSSG 1:10).
0 Me
Mes%., N::e  N.. % Me
Me 0
Chart 5.3. Structure of diamide.
Electrophoretic Mobility Shift Assays
EMSAs were performed as diagrammed in Figure 5.2 and as a modification of a
previously reported protocol.50 Radiolabeled, platinated 20mer (-0.5 nM overall) with
the top strand sequence (cDDP site in bold):
5'-CCT CTC CTC TCT GGA TCT TCT CTC C-3'
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was incubated in a buffer (10 mM Hepes, pH 7.5, 50 mM LiC12, 10 mM MgCI 2, 100 mM
NaCI, 2 mg/mL BSA, 0.05% Nonidet P40, 1 mM spermidine, carrier poly dGdC DNA at
a 10:1 ratio with platinated DNA on a per nucleotide basis). HMGB1 pre-incubated in
the same buffer with either 10 mM DTT or 10 mM diamide was added and the reaction
was kept at 40C for 30 minutes. A 10% polyacrylamide gel with a 37.5:1 ratio of
acrylamide:bis-acrylamide was pre-run for at least 30 min in an ice bath with
recirculating chilled water. Non-denaturing loading buffer (overall 0.7% sucrose (w/v),
0.017% xylene cyanol (w/v), 0.5% Ficoll 400 (v/v)) was added to the protein-DNA
reactions and the protein-DNA complexes were electrophoresed at 150 V for 2.67 h.
5 ' - CCTCTCCTCTCTGGATCTTCTCTCC- 3 'radiolabel
3 ' -GGAGAGGAGAGACCTAGAAGAGAGG- 5 add rin
Increasing [protein]
"slow band" .
protein + DNA
"fast band" --
DNA only
Bandshift Buffer Incubate 4*C, 30 min
10 mM Hepes, pH 7.5 Add loading buffer:
50 mM LiCI2,10 mM MgCI 2,100 mM NaCI Sucrose to 0.7% (w/v)
2 mg/mL BSA Xylene cyanol to 0.017% (w/v)
0.05% Nonidet P40 Ficoll 400 to 0.5% (v/v)
1 mM spermidine (fresh daily) Low V gel, 150 V, 2.67 h
10:1 (nt basis) poly dGdC DNA 10% acrylamide, 37.5:1 acrylamide:bis,
+ 10 mM DTT/+ 10 mM diamide ice bath and recirculating chilled water
Figure 5.2. Summary of experimental conditions for the electrophoretic shift mobility assays on
HMGB1.
Results and Discussion
Cytotoxicity of Cisplatin in the Presence of an Androgen
Plots of the cytotoxicity data for cisplatin-treated cells grown in the presence or absence
of an androgen, DHEA, are shown in Figure 5.3. The concentrations of cisplatin
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required for 50% inhibition of cell growth (IC50) are reported in Table 5.1. Percentage
survival was determined separately for cells grown in the presence and absence of
androgen due to slightly decreased survival for DHEA-treated cells and slightly
increased survival for DHT-treated cells. Based on the IC50 values, no statistically
significant difference in cytotoxicity was observed in any of the experiments.
Table 5.1. Summary of cytotoxicity values from the plots
LNCaP (AR+)
cisplatin 2.5 pM
cisplatin+1pM DHT 4.9 pM
cisplatin+1pM DHEA 2.5 pM
in Figure 5.3.
DU-145 (AR-)
2 tM
2.5 ltM
PC-3 (AR-)
2.55 pM
2.75 pM
LNCaP (AR +) with Cisplatin and DHT
- Cisplatin
-U- Cisplatin + 1 pM DHT
0 5 10 15
[Cisplatin] (pM)
PC-3 (AR -) with Cisplatin and DHEA
- Cisplatin
-- Cisplatin + 1 pM DHEA
0 5 10 15 20
LNCaP (AR +) with Cisplatin and DHEA
S- Cisplatin
0 Cisplatin + 1 pM DHEA
0 10 20 30
DU-145 (AR -) with Cisplatin and DHEA
- - Cisplatin
-- Cisplatin + 1 pM DHEA
0 5 10 15 20
Figure 5.3. Cytotoxicity assays indicating the results of co-treatment of cisplatin with either DHEA
or DHT in cells with (LNCaP) and without (DU-145, PC-3) the androgen receptor (AR).
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Cytotoxicity of Cisplatin in the Presence of Retinoic Acid
The results of cytotoxicity assays conducted in both the RARP positive MCF-7
cells and the RARP negative PC-3 cells are plotted in Figure 5.4 and the IC50 values are
reported in Table 5.2. Neither RARP(+) nor RARP(-) cell lines show cisplatin
sensitization after treatment with retinoic acid and cisplatin. An increase of the ATRA
treatment time from seven days to eight days did not affect this result. The lack of
increased cytotoxicity is unsurprising based on the immunofluorescence results showing
the ATRA-upregulated HMGB1 to be localized in the cytosol. Cytosolic HMGB1 would
not be available to participate in repair-shielding of cisplatin-DNA adducts and therefore
is not expected to sensitize cells to cisplatin.
MCF-7 (RARP+) Treated with Cisplatin and ATRA PC-3 (RAR-)Treated with Cisplatin and ATRA
100 100
-- Cisplatin -- Cisplatin
-m- Cisplatin + 500 nM ATRA -"- Cisplatin + 500 nM ATRA
3 50 50
0 0 ,- --'
0 5 10 15 20 0 5 10 15
[Cisplatin] (pM) [Cisplatin] (pM)
Figure 5.4. Cytotoxicity assays indicating the effect of cisplatin after preincubation of cells in
retinoic acid in cells with (MCF-7) and without (PC-3) the retinoic acid receptor (RARP).
Table 5.2. Summary of cytotoxicity values from plots shown in Figure 5.4
MCF-7 (RARP+) PC-3(RAR-)
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cisplatin cisplatin+500M RA cisplatin cisplatin+500iM RA
1.4 pM 2.6 jM 0.7 jiM 0.7 pM
Immunofluorescence-based Detection of HMGB1 in Cells Treated with Androgens
In the androgen experiments, the upregulation of HMGB1 due to the steroid
would have resulted in a marked increase in fluorescence intensity, as was observed in
the previously published work on progesterone and estrogen. 5'4 No intensity difference
between the androgen-treated and untreated cells was observed. In an effort to allow
time for the biosynthetic transformation of DHEA into DHT, the androgen pretreatment
time was varied between 0 and 20 hours. None of the timed experiments showed an
intensity difference between treated and control cells. Representative samples from two
experiments, one with DHEA and one with DHT, in which cells were pretreated with
androgen for 4 h are shown in Figure 5.5.
A.
LNCaP (AR+), Control LNCaP+ 1gm DHT, 4 hr pretreatment
B.
LNCaP (AR+), Control LNCaP+ 1 um DHEA, 4 hr pretreatment
Figure 5.5. Representative immunofluorescence results showing the HMGB1 protein labeled with
a FITC-conjugated secondary antibody. Results were invariant, even with varying durations of
androgen pretreatment. (A): Results from treatment with DHT. (B): Results from treatment with
DHEA.
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Immunofluorescence-based Detection of HMGB 1 in Cells Treated with Retinoic Acid
For the ATRA experiments, the time course for immunofluorescence was based
on the time required for the upregulation of HMGB1 in the P19 (murine embryonal
carcinoma) cell line. Images showing the results of the immunofluorescence assay are
shown in Figures 5.6 and 5.7. A distinct increase in the level of HMGB1 can be seen in
the cells that have been treated with retinoic acid.
(A) Control, MCF-7 cells, RARP(+)
? cAmnloc identirl rnnrlitinnc
(B) +500 nM retinoic acid, MCF-7 cells, RARP(+)
3 samnles identical conditions
Figure 5.6. Immunofluorescence results showing fluorescence due to an anti-HMGB1 primary
antibody and a FITC-conjugated secondary antibody. (A) shows samples photographed in the
absence of retinoic acid. (B) shows samples photographed after addition of 500 nM retinoic acid,
as stated in the Methods section.
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'nntrrll PC'-?PAPR I(-
+ 500 nM RA, MCF-7, RARP (+) + 500 nM RA, PC-3, RARP (-)
Figure 5.7. Samples showing the difference in upregulation between MCF-7 cells (left), which
express the retinoic acid receptor P (RARP), and PC-3 cells (right), which do not express the
receptor.
Oxidation and Reduction of HMGB 1
Examination of the interaction of HMGB1 with platinated DNA has been crucial to
development of the repair-shielding hypothesis. Previous gel mobility shift assays have
been carried out at pH 7.5 with no reducing agent,3 50-54 pH 7.5 with 1 mM DTT, 55 and
pH 7.9 without reducing agent.56 Because the preparation of recombinant HMGB1
involves expression in E. coli, an organism with a reducing cytosol in which disulfide
bonds do not commonly form,57 followed by purification under reducing conditions, 56s '5
the proteins used in these previous experiments were probably completely reduced.
Investigation of the relative binding constants of platinated DNA with oxidized
and reduced forms of HMGB1 has been completed. Recombinant protein as prepared
by Yongwon Jung was 55% oxidized to begin with and could be fully reduced by 10 mM
DTT (Figure 5.8). Despite a variety of oxidation strategies, however, HMGB1 could not
be oxidized in vitro. Diamide concentrations from 10 mM to 500 mM were ineffective.
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Variation of the time (0-30 min) and temperature (40C, 160C, or 250C) of incubation with
diamide produced no further oxidation than the initial 55% (Figure 5.8). Full reduction
with 10 mM DTT followed by treatment with 500 mM diamide yielded only the fully
reduced protein, indicating that whatever bond the DTT reduced could not be reformed.
"Pre-assembly" of the protein by incubation with salmon sperm DNA, followed by
diamide treatment failed to form the disulfide bond. An attempt to oxidize using the
GSH:GSSG molar ratio of 10:1 found in the mammalian endoplasmic reticulum yielded
no disulfide bond, nor did incubation with [H20 2] Of 0.1, 0.2, 0.5, 1, or 10 mM. It was
finally concluded that some cellular component, such as a disulfide isomerase, is
required for the formation of the bond.
250
150
100
1 2 3 4 5 50
Figure 5.8. SDS-PAGE gel showing complete reduction and attempted complete
oxidation of full length HMGB1. A) Lanes: 1) 100 mM diamide, 30 min; 2) 100 mM
diamide, 10 min; 3) 10 mM diamide, 30 min; 4) 10 mM diamide, 10 min; 5) 10 mM DTT.
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Reexpression of HMGB1 in E. coli under oxidizing conditions, such as with the
inclusion of a low concentration of diamide in the expression medium, was determined
to be the next logical step. The protein in the next experiments was used as purified
from E. coli under normal conditions, in a 55% oxidized state, or fully reduced by DTT.
Interaction of Oxidized and Reduced HMGB I with Cisplatin-Modified DNA
The sequence for the bandshift probe was carefully chosen according to previous
investigations of the sequence specificity of HMGB1.5o The 20 bp length is critical. If the
probe were too long, the protein could find multiple binding sites and the EMSA would
be smeared. Conversely, a shorter probe would not have enough length to
accommodate the entire protein footprint. The reduction of voltage and temperature
below that normally used for a native gel was also crucial to obtaining clean bandshift
data.
Bandshifts with HMGB1domAB and full-length HMGB1 have shown that the
reduced form of both the full-length and the AB-truncated protein binds more tightly to
cDDP-modified DNA than the 55% oxidized form (Figure 5.9). The binding constant for
the AB domain shows on the order of a 10-fold increase for the reduced protein (Figure
5.10).
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Titration of HMGBlfull
(0.003, 0.03, 0.06, 0.15, 0.3, 3 pM)
Titration of HMGB1AB
(0.02, 0.1, 0.2, 1, 2, 20 nM)
fully reduced
I I
fully reduced oxidized
Figure 5.9. EMSAs for HMGB1 in the reduced and oxidized forms. Gels are 10% native PAGE as
described in the experimental section. Top gel is full length HMGB1 and bottom gel is for the
combined domain AB polypeptide.
Titration of HMGBlful
(0.003, 0.03, 0.06, 0.15, 0.3, 3 pM)
80%"
70% 70% * 10 mM DTT, full HMGB1
c 60% & * 10 nmM diamide, full HMGB1
50%.
40% -
- 30% *
S20%
10%
0% ..
0 0.1 0.2 0.3 0.4
[full length HMGB1] (uM)
Maximum % shift obtained:
(70.0% at 3 uM HMGB1)
Titration of HMGB1AB
(0.02, 0.1, 0.2, 1, 2, 20 nM)
80%
70%-
60%,
- 50%-
S40%-
a 30%-
' 20%-
10% -
0%-
[ 10 mM DTT, domAB
* 10 mM diamide, domAB
p 0.5 1 1.5
[HMGB1domAB] (nM)
2 2.5
(76.0% at 20 nM domAB)
Figure 5.10. Analysis of EMSA gels shown as percentage of shifted DNA as a function of
increasing HMGB1 concentration. The improvement in binding upon reduction of the full-length
protein was 1.5-fold and the improvement upon reduction of the AB-domain protein was 2.4-fold.
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Conclusions
The Effect of Androgens on HMGB1 Levels and Cisplatin Potency
HMGB1 is not upregulated upon treatment of LNCaP cells with androgens. Our
experiments are not the only evidence for this lack of HMGB1 upregulation. A recent
study59 utilized high-throughput arrays to identify 692 genes upregulated by the
treatment of LNCaP cells with dihydrotestosterone. This study also collected results
from five similar LNCaP-based experiments performed by other labs, bringing the total
of identified upregulated genes to 2118. We obtained this database as a list of mRNA
ascension numbers in a searchable Microsoft Excel format and searched using for
numbers associated with HMGB1 and HMGB2. Because no reference to either of these
high mobility group proteins was found in this extensive database, the conclusion was
made that HMGB1 is not involved in the androgen receptor-DNA interaction in LNCaP
cells. Other proteins containing the high mobility group box binding domain have been
implicated as facilitators in this interaction, including the male sex determining factor
SRY.7
The Effect of Retinoic Acid on HMGB 1 Levels and Cisplatin Potency
All-trans retinoic acid does not sensitize the RAR3(+) MCF-7 cells to cisplatin, but
does induce an increase in the HMGB1 levels. The interaction of the retinoic acid
receptor and HMGB1 is complicated by the observation that the RAR is connected to
the RAGE pathway in murine embryonal carcinoma cells. 15,60 Any increase in the
cytosolic levels of HMGB1 are likely related to the RAGE pathway and the activity of
HMGB1 as a cytokine, although such an increase was not detected by
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immunofluorescence. An increase in HMGB1 localized to the nucleus, such as that
seen upon treatment with ATRA in this work, indicates a mechanism similar to that seen
when cells are treated with either progesterone or estrogen.4 Of interest for future work
would be the study of HMGB1 upregulation in the OVCCR1 or NIH-OVCAR-3 ovarian
cancer cell lines, in which the sensitization of cells to cisplatin by ATRA co-treatment
has already been proven. 18,19 Interestingly, these cell lines only express RARa and
RARy. 19
Reducing Conditions and HMGB 1 Affinity for Cisplatin-Modified DNA
The large increase in binding constant for the reduced form of HMGB1 provides
an exciting chance to expand and develop the theory of repair shielding. The new
member of the HMGB family, HMGB4,44 lacks Cys23 (Chart 5.2). and cannot form the
Cys23-Cys45 disulfide bond. HMGB4 therefore permanently resembles the reduced
form of HMGB1 that has the higher affinity for cisplatin-modified DNA. The RNAi work of
Dong Xu has provided us with a variety of HMGB1 knockdown lines that will allow us to
move beyond the in vitro EMSA result to in vivo proof of concept in human tissue. Using
site-directed mutagenesis, we can transfect C23A and C45A mutants of the HMGB1A
domain protein into HMGB1 knockdown cells and look for the potentiation of cisplatin
activity. These mutants would prevent the formation of a disulfide bond and should yield
a nuclear-bound form of the protein with high affinity for cisplatin-modified DNA.
Additionally, a mimic of the oxidized form of the protein could be generated by
introducing a salt bridge into the protein, such as C23D and C45K. Finally, tryptophan
can be incorporated into the protein as a fluorescent indicator of the folding state of the
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protein. The optimal site for such a modification should be determined by examination of
the Ohndorf-Lippard structure of HMBG1domA on DNA. Computer-assisted modeling of
all of these mutants can be carried out prior to beginning lab work.
In addition to transfection of human cells with plasmids for expression of the
mutant proteins in vivo, recombinant forms of the proteins can also be produced for the
purpose of in vitro studies. EMSAs on the mutant proteins will provide information on
binding constants. Nucleotide excision repair assays in mammalian cell extracts will
yield information on the ability of the mutants to engage in repair shielding of the
cisplatin-DNA adduct. Finally, a crystal structure of the protein mutant that shows the
most promising behavior in human tissue will lend visual images to complement the in
vitro and in vivo data.
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Chapter 6
Preclinical Evaluation of the Antitumor Properties of Pyriplatin
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Introduction
Three platinum compounds in use worldwide, cisplatin, carboplatin, and
oxaliplatin, have been developed with crucial support of the National Cancer Institute
(NCI) of the United States and based on results of screening done with the NCI's 60-cell
line panel.' The use of this screen and the NCI COMPARE program has allowed
identification of clear differences in activity profile and mechanisms of action among
platinum compounds and enabled grouping of platinum compounds according to these
differences.2 The cisplatin activity profile is similar to that of other diammine platinum
compounds and to alkylating agents such as melphalan and camptothecin analogs. The
oxaliplatin activity profile is similar to that of other platinum compounds with the 1,2-
diaminocyclohexane ligand, including the Pt(IV) drug tetraplatin, and also to acridines,
organic compounds currently being developed as anticancer drugs.2
Other classes have also been defined on the basis of the NCI60 screen. The
platinum pyridines are one distinct group, into which the Farrell compounds (including
the clinically tested BBR3464) can be grouped, 3,4 and the platinum-silanes are another
distinct group. Cells resistant to compounds from one group are commonly not cross-
resistant to compounds from another group. Because of the different mechanisms of
action for each type of compound, members of different groups can show synergy when
combined. For example, synergistic effects upon combination occur for the combination
of cisplatin with oxaliplatin.2
The aim of present study is to characterize pyriplatin, a novel monofunctional,
cationic platinum(ll) compound, in vitro with direct comparisons to cisplatin and
oxaliplatin as representative members of the cisplatin and dach platinum groups,
respectively. The devevlopment of pyriplatin as an antitumor drug is a result of the
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structure-activity relationship developed in chapter 2 and explored in chapter 3.
Preliminary mechanistic studies and an x-ray structure of pyriplatin bound to a
dodecamer of DNA were introduced in chapter 4. builds on work introduced in chapters
2, 3, and 4Pyriplatin has previously shown antitumor activity in mice,5 despite the fact
SH2  0
H3N CI HN O N 0
H3N' CI H3N O N O
H2  0
Cisplatin Carboplatin 0 Oxaliplatin
7+ CI ,NH 3
Pt H3N NHPt
H3N C
Pyriplatin
H N  ' NH2 H .4+
PtBBR3464 H3N *CI
Chart 6.1. Platinum compounds from the cisplatin group (cisplatin, carboplatin), the dach group
(oxaliplatin) and, tentatively assigned, the pyridine group (BBR3464, pyriplatin)
that it forms only a single covalent bond with DNA and is cationic. Pyriplatin is similar in
some ways to the polynuclear Farrell compounds, including the trinuclear, cationic
complex that was tested in phase II clinical trials, BBR3464. The two platinum centers of
BBR3464 that bind to DNA each resemble pyriplatin (Chart 6.1), in that they contain
three am(m)ine ligands and a single chloro ligand to form one covalent bond with DNA.
Both the BBR3464 and pyriplatin have an overall cationic charge and the accumulation
of each of these compounds in cells has been attributed to the presence of cell
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membrane transporters. Specifically, pyriplatin is an outstanding substrate for the
organic cation transporters 1 and 2,6 and BBR3464 is a substrate for the copper
transporter CTR1.
Results of Single-Agent Study of Pyriplatin
Single-Agent Study: Antiproliferative effects of pyriplatin given as a single agent in a
panel of human cancer cell lines.
A panel of 10 cancer cell lines of different origins was exposed to pyriplatin for 24
hours and then assessed for cytotoxicity by the MTT assay. Simultaneous assays were
performed in the same manner in the 10 cell lines with cisplatin and oxaliplatin. Table
6.1 represents the concentrations required to achieve 50% growth inhibition (IC5o) in our
panel of cancer cell lines and the standard deviation for at least three experiments, each
done in triplicate. A comparison of cytotoxicity for the three drugs is represented in
Figure 6.1. Figure 6.2 represents the IC50 values in each of the 10 cell lines and Figure
6.3 shows cell survival for the different cell lines at concentrations ranging from 0.1-160
p.M of cisplatin (6.3A), oxaliplatin (6.3B), and 0.46-1000 pM pyriplatin (6.3C).
Pyriplatin had a cytotoxicity profile different from that of either cisplatin -or
oxaliplatin (Figures 6.1 and 6.2).. Pyriplatin is roughly 10- or 20-fold less potent than
cisplatin or oxaliplatin in all cell lines.
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Table 6.1. IC50 values for pyriplatin, cisplatin, and oxaliplatin in the 10-cell line panel. Data reflect
the mean and standard deviation of
triplicate.
results from three separate experiments, each performed in
Cell Line Cancer Type ICso Cisplatin ICso Oxaliplatin ICso Pyriplatin
HT-29 Colorectal 11.9 + 4.1 pM 6.65 + 1.0 pM 443 + 255 pM
MDA-435 Breast /Melanoma 5.81 + 4.0 pM 12.7 + 5.6 pM 401 + 156 pM
HCT-116 Colorectal 4.22 + 2.5 pM 1.10 + 0.28 pM 281 + 50 pM
HCC2998 Colorectal 11.8 + 4.0 pM 7.27 + 2.3 pM 381 + 103 pM
COL0205 Colorectal 16.7 + 7.2 pM 2.84 + 0.64 pM 266 + 57 pM
MCF7 Breast 15.6 + 6.4 pM 1.70 + 0.54 pM 335 + 104 pM
OVCAR3 Ovarian 5.10 + 3.0 pM 1.24 + 0.30 pM 328 + 128 pM
IGROV1 Ovarian 5.64 + 1.3 pM 8.08 + 2.9 pM 230 + 33 pM
HOP92 Non-Small Cell Lung 3.55 + 3.2 pM 2.70 + 0.60 pM 171 + 56 pM
HOP62 Non-Small Cell Lung 3.56 + 1.4 pM 6.86 + 0.39 M 190 + 36 M
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Figure 6.1. Mean graphs for IC50 . Bars depict the deviation of individual cell lines from the overall
mean value for all the cells tested.
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Figure 6.2. IC50 values of pyriplatin, cisplatin and oxaliplatin. Plots reflect the mean and standarddeviation of results from three separate experiments, each performed in triplicate.
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Figure 6.3. Cytotoxicity of cisplatin (A), oxaliplatin (B), and pyriplatin (C) in the studied cancer cell
lines given for 24 hours. Plots reflect the mean and standard deviation of results from three
separate experiments, each performed in triplicate.
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Single-Agent Study: NCI60 Single Dose Study
Pyriplatin was submitted to the National Cancer Institute (USA) for single agent
testing in 2008. Analysis by the online COMPARE algorithm revealed that pyriplatin had
very little correlation with cisplatin or oxaliplatin. The best correlation with a platinum
compound in the NCI database was with an entry titled "(carboxyphthalato) platinum"
(NSC # S748451) and a correlation coefficient of 0.396 was found.
Single-Agent Study: Antiproliferative Effects of Pyriplatin Over Time
The non-small cell lung cancer cell line HOP-62 was chosen for further study
because it is more sensitive to pyriplatin than the other cell lines in the 10-cell line panel.
HOP-62 was treated with pyriplatin, cisplatin, or oxaliplatin for 1, 2, 5, 24, 48, or 72
hours. After the specified time, the plates were washed and the medium replaced with
drug-free medium. The MTT assay was performed after 48 hours of incubation in drug-
free medium. Results in Figure 6.4 are reported as the mean IC50 plus and minus the
standard deviation of at least three separate experiments performed in triplicate.
The cytotoxic effects of pyriplatin increased over the entire time period tested,
meaning cytotoxicity increased even up to 72 h, indicating that the compound, or
biological modifications thereof, retain some cytotoxic characteristics even after
extended incubation in cell medium. Similar results were found for both cisplatin and
oxaliplatin.
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Figure 6.4. Antiproliferative effects of pyriplatin, cisplatin, and oxaliplatin over time.
Single-Agent Study: Cell Cycle
Effects on the cell cycle due to administration of pyriplatin were examined after 24
h incubation with the platinum compound at the IC50o value in the MCF-7 breast cancer
cell line. Cells were stained with propidium iodide and analyzed immediately by flow
cytometry. As shown in Figure 6.5, cisplatin initiates accumulation of cells in the S
phase and cells treated with oxaliplatin accumulate in Go/G 1. The results for pyriplatin
show about 10% of the population in a sub-G 1 phase, which can be indicative of cells
undergoing apoptosis.
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Figure 6.5. Analysis of the effects of platinum drugs on cell cycle progression in MCF-7 cells after
treatment at the IC50 value for 24 h.
Pyriplatin in Combination with Known Antitumor Agents
Combination assay methodology
The antiproliferative effects of pyriplatin in combination with five known anticancer
agents, taxol, gemcitabine, SN38, cisplatin, and 5-fluorouracil, were investigated in two
cell lines, the ovarian cancer line OVCAR-3 and the colon cancer cell line HT-29. The
combination experiments were performed according to three different schedules as
shown in Figure 6.6. Cells were either treated with pyriplatin for 24 h followed by the
192
lo
~L~l~-*l
r
combination drug for 24 h, or treated with the drug combination for 24 h followed by
pyriplatin for 24 h, or treated with both pyriplatin and the combination drug for 24 h.
Antiproliferative effects were evaluated by the MTT assay. Calculation of combinatorial
indices and classification of the effects of combination as either additive, synergistic, or
antagonistic were done according to the method developed by Chou and Talalay.8
combinationA pyriplatin, 24 h drug, 24 h
wash
Figure 6.6. The three schedules used for combination experiments.
Combination assay results
Data were analyzed according to the method developed by Chou and Talalay
using the CalcuSyn program. A combinatorial index (CI) of 1 indicates that the
antiproliferative effects of two drugs are additive. A Cl of less than 1 indicates a
synergistic effect between the two drugs and a Cl of greater than 1 indicates an
antagonistic effect. A synergistic effect suggests that two drugs exert antiproliferative
effects via separate mechanisms of action. Additive effects indicate that two drugs act
via similar mechanisms of action.
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Synergistic effects were observed for taxol, especially when pyriplatin and taxol
were used simultaneously or when cells were treated with taxol prior to pyriplatin.
Synergistic effects were also observed in combination with cisplatin when pyriplatin and
cisplatin were added to cells simultaneously.
Table 6.2. Combination experiments in the HT-29 colon cancer cell line. Data are presented as the
median Cl value and the range represents the 95% confidence interval.
Taxol Gemza SN38 Cisplatin 5-FU
Schedule A 0.87 (0.75-0.98) 1.66 (0.70-2.76) 0.90 (0.72-1.22) 1.11 (0.89-1.23) 0.94 (0.80-1.03)
Schedule B 0.88 (0.69-1.22) 1.09 (0.89-1.38) 2.21 (1.42-3.31) 0.96 (0.94-1.22)
Schedule C 0.96 (0.55-1.21) 0.86 (0.45-1.49) 0.81 (0.62-1.34) 0.84 (0.83-0.85) 1.02 (0.87-1.20)
Table 6.3. Combination experiments in the OVCAR-3 ovarian cancer cell line. Data are presented
as the median Cl value and the range represents the 95% confidence interval.
Taxol Gemza SN38 Cisplatin 5-FU
Schedule A 0.89 (0.63-0.99) 1.13 (0.69-1.91) 1.08 (1.51-0.77) 1.09 (0.96-1.19) 0.99 (0.89-1.22)
Schedule B 1.06 (0.63-1.55) 1.31 (0.60-7.22) 0.95 (0.94-0.97) 0.84 (0.72-1.10)
Schedule C 1.19 (0.87-1.38) 1.21 (1.11-1.44) 1.38 (1.07-1.99) 0.79 (0.74-0.85) 1.32 (1.22-1.55)
Table 6.4. Combinations of pyriplatin and taxol in HT-29, OVCAR-3, HOP 62 and MCF-7 cells.
HT-29 OVCAR-3 HOP 62 MCF-7
Schedule B 0.88 (0.69-1.22) 1.06 (0.63-1.55) 1.30 (1.08-1.49) 1.43 (1.23-1.49)
Schedule C 0.96 (0.55-1.21) 1.19 (0.87-1.38) 1.42 (1.38-1.58) 0.97 (0.83-1.35)
HT-29 Taxol, then Pyriplatin
4-
3-
2-
1-
0-
0.2 0.4 0.6 .0
1- Fraction Affected
OVCAR3 Taxol, then Pyriplatin
SCIl
0.2 0.4 0.6
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Figure 6.7. Combination data for taxollpyriplatin in HT-29 and OVCAR-3 on schedule B.
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Mechanistic Results
Mechanistic Study: Antiproliferative Effects of Pyriplatin and p53 Status
Cells of the HCT-116 colon cancer cell line were obtained from the Mario Negri
Institute for studying the effect of p53 status on pyriplatin cytotoxicity. The p53 status of
HCT-116 is wild-type. HCT-116 cells with disrupted p53, a cell line termed E6, were
produced by stable transfection of HCT-1 16 with the human papillomavirus type 16 E6
gene. As a control, HCT-116 cells transfected with an empty plasmid, termed pcDNA,
were included in the study.
Antiproliferative effects of pyriplatin were evaluated by MTT after 24 h treatment
with the drug, followed by a 48 h incubation period in drug-free medium. Figure 6.8
reports the results of three experiments, each performed in triplicate.
Pyriplatin, pcDNA and p53 -I- (E6)
1 pcDNA
1. 6 E6 p53 --
5-S0.5
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Cisplatin, pcDNA and p53 -- (E6) Oxaliplatin, pcDNA and p53 -/- (E6)
1.0 -e pcDNA 1.0 pcDNA
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Figure 6.8. Effect of p53 status on pyriplatin, cisplatin and oxaliplatin antiproliferative effects.
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Mechanistic Study: Antiproliferative Effects of Pyriplatin and MMR Pathway Status
Cells of the HCT-116 colon cancer cell line were obtained from the Mario Negri
Institute for studying the interaction between the mismatch repair (MMR) pathway and
pyriplatin cytotoxicity. HCT-116 has a homozygous mutation in the mismatch repair
gene hMLH1 on chromosome 3, which renders the MMR pathway inactive. The p53
status of HCT-116 is wild-type. A cell line with an active MMR pathway, HCT-116 + ch3,
was obtained after insertion of a single copy of chromosome 3. HCT-116 cells proficient
in MMR and with disrupted p53, a cell line termed N8, were produced by stable
transfection of HCT-116+ch3 with the human papillomavirus type 16 E6 gene. As a
control, HCT-116 cells transfected with an empty plasmid, termed pcDNA, were
included in the study.
Antiproliferative effects of pyriplatin were evaluated by MTT after 24 h treatment
with the drug, followed by a 48 h incubation period in drug-free medium. Figure 6.9
reports the results of three experiments, each performed in triplicate.
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Figure 6.9. Effect of MMR pathway status on antiproliferative effects of pyriplatin, cisplatin and
oxaliplatin.
Mechanistic Study: Apoptosis Induction by Pyriplatin and Cisplatin
The induction of apoptosis was detected by treating MCF-7 cells at the IC5o and
2*lC5o (cisplatin) or at the IC5o and V/2*IC50 (pyriplatin) for 24 h. Cells were stained with
FITC-conjugated Annexin V for apoptosis detection, propidium iodide to detect necrosis,
and analyzed by flow cytometry. Annexin V binds to phosphatidylserine, which is
present in the cell membrane of apoptotic cells. As shown in Figure 6.10, A higher
percentage of cells treated with pyriplatin undergo apoptosis after 24 h as compared
with cells treated with cisplatin at an equitoxic dose.
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Figure 6.10. Top: Scatter plots of flow cytometry data for cells treated with cisplatin or pyriplatin.
Bottom: Plot of all cells detected that were stained with Annexin V after treatment with cisplatin or
pyriplatin.
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Mechanistic Study: Determination of Factors Predictive of Sensitivity to Pyriplatin
The mRNA expression levels of 21 genes (Table 6.5) in the panel of 10 cell lines
were measured by RT-PCR. Levels of gene expression were plotted versus IC50 values
(Figure 6.11) in order to identify genes that were particularly well-correlated with either
resistance or sensitivity to pyriplatin. Cells with high levels of RAD50 mRNA are more
resistant to pyriplatin (r2 = 0.35), suggesting that double-strand breaks may play a role in
the cellular consequences of pyriplatin-DNA lesions. Cells with high levels of mRNA
coding for GSTP1 are also more resistant to pyriplatin (r2 = 0.38), indicating possible
cellular inactivation of pyriplatin by modification with glutathione.
Table 6.5. Genes analyzed for correlation of mRNA levels with ICso values.
Gene Area/Pathway of Interest
ERCC1
XPA Nucleotide Excision Repair
XPC
PARP1PARP1 Base Excision RepairXRCC1
RAD50 Homologous Recombination
BRCA1
DNA-PK-csXRCC6 (ku7) Non-homologous end-joining (NHEJ)XRCC6 (ku70)
MSH2 Mismatch RepairMLH1
BCL2
PUMA Apoptosis
COX2
Ki67 Cell Growth
CDKN1A (p21) Cell Cycle Regulation
ABCB1
ABCC1 Influx/Export
GSTP1
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Figure 6.11. Correlation of pyriplatin IC50 values and expression levels of genes of interest.
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Mechanistic Study: Evaluation of protein markers of apoptosis in HOP 62 cells
Western blots were performed by Shahin Emami at Saint-Antoine to determine
the effect of pyriplatin treatment on Chk2 and gamma-H2AX phosphorylation. HOP 62
cells were treated at the IC50 values of each drug for 24 hours. The platinum-containing
medium was then removed and protein content was determined 0, 24, 48, or 72 hours
following removal of the platinum. Figure 6.12 shows the appearance of a band at 25
kDa for cisplatin, oxaliplatin and pyriplatin, which corresponds to the phosphorylated
form of y-H2AX, indicating the induction of apoptosis based on DNA double-strand break
formation.
Control Cisplatin Oxaliplatin Pyriplatin
Time elapsed after removal of platinum (h):
0 24 48 72 0 24 48 72 0 24 48 72
I
y-H2AX
4 25 kDa
4 15 kDa
a-Tubulin
4 55 kDa
Figure 6.12. Level of y-H2AX after 24 h treatment at the IC50 values with platinum followed by
incubation in drug-free medium for 0, 24, 48, or 72 h. The a-tubulin blot is used as a loading
control.
Discussion
The antitumor effects of pyriplatin in the 10-cell line panel are significantly
different from the effects seen for cisplatin or oxaliplatin. The cytotoxic effects of
pyriplatin can be measured after 1 h of incubation with the drug and the potency
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increases as the incubation time is increased to 72 h, indicating that pyriplatin or some
cytotoxic biological modification of pyriplatin remains potent for extended periods of time
in cell medium.
The cell cycle effects of pyriplatin are distinct from those of either cisplatin or
oxaliplatin. Pyriplatin does not appear to exert cytotoxic effects by blocking cells in S/G 2
phase, as was observed for cisplatin. Pyriplatin causes a significant, early induction of
sub-Go, or apoptotic, cells that is not seen with either oxaliplatin or cisplatin. This result
was confirmed by Annexin V staining and also by western blot for detection of DNA
double-strand breaks by measurement of y-H2AX phosphorylation. Results obtained by
RT-PCR to detect mRNA levels of RAD50 suggest that some of the DNA double-strand
breaks may be directly due to DNA damage caused by pyriplatin, rather than apoptosis-
induced fragmentation of the DNA. Cells with high levels of RAD50 mRNA are more
resistant to cisplatin, a result that is being pursued by analysis of pyriplatin-treated cells
using the Comet assay.
The effects of treating cells with pyriplatin in combination with other known
anticancer drugs have been investigated for four known drugs and three different
treatment schedules. The treatment of cells with pyriplatin and cisplatin simultaneously
seems to produce a synergistic effect, although these are only preliminary results.
Additionally, preliminary results indicate that the treatment of cells with taxol followed by
pyriplatin may produce synergistic effects.
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Conclusions
Pyriplatin has a unique cytotoxicity profile that is distinct from that of either the
platinum dach class of compounds or cisplatin. The distinct profile may suggest a
significantly different mechanism of action than either oxaliplatin or cisplatin. Pyriplatin is
about 10-fold less potent than either cisplatin or oxaliplatin and shows synergy in
combination with taxol or cisplatin in vitro.
Materials and Methods
Cell Lines and Reagents
Colorectal cancer cell lines HT-29, HCT-1 16, HCC2998, and COLO 205, breast
cancer line MCF-7, melanoma line MDA-435, ovarian cancer lines OVCAR-3 and
IGROV-1, and non-small cell lung cancer line HOP-92 and HOP-62 were obtained from
the American Type Culture Collection (Rockville, MD, USA) and maintained in RPMI
medium supplemented with 10% fetal bovine serum. The p53 (-/-) cell lines and MMR
proficient cell lines had previously been derived from HCT-116 cells as described 9' 10 and
were provided by Massimo Broggini of the Mario Negri Institute, Milan. The HCT116-
pcDNA, HCT116-ch3, HCT116-E6, and HCT-1 16-N8 cell lines were maintained in
medium supplemented with the antibiotics G418 (Sigma) or G418 and Hygromycin B
(HCT1 16-N8 only, Sigma). All cell lines were regularly tested for mycoplasma
contamination by PCR using a Stratagene kit (La Jolla, CA, USA). Cisplatin and
oxaliplatin were obtained from the Beaujon University Hospital Pharmacy.
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In vitro growth inhibition assays
Cells were plated in 96-well plates at 2 x 103 cells per well. Twenty-four hours
after plating, the medium was replaced with platinum-containing medium. Cells were
incubated with platinum for 24 h, or as indicated in the text. After the 24 h incubation
with drug, wells were washed with RPMI and cells were incubated in serum-containing
medium for 72 h. Cell viability was determined either by detection of mitochondrial
cleavage of the tetrazolium ring of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide) by absorption at 562 nm as described11 or by detection of
sulforhodamine B as described. 1 2
Cell Cycle Analysis
Analysis of cell cycle effects of pyriplatin were evaluated after incubation of HOP-
62 cells with either pyriplatin, cisplatin, or oxaliplatin at the IC50 values (Table 6.1) for 24
h. Immediately after the 24 h incubation, cells were collected, stained with propidium
iodide and analyzed by flow cytometry as described.13
RT-PCR
Total RNA was extracted from all cell lines at the same passage used for the
cytotoxicity studies. The Trizol reagent (Invitrogen), composed of guanidinium
thiocyanate, phenol, chloroform, and isoamyl alcohol, was used to facilitate the
extraction. RT-PCR was performed as described14 15 by Ivan Bieche and coworkers to
detect mRNA for the genes listed in Table 6.5.
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Chapter 7
Preclinical Evaluation of the Antitumor Properties of Mitaplatin,
a Novel Platinum-based Drug
209
Introduction
Cancer cells have consistently higher rates of glycolysis than normal cells, a
property first identified by Warburg,' and the glycolytic phenotype has been associated
with suppression of mitochondrial function.2 This difference between solid tumor cells
and cells in healthy tissue offers an appealing target for the design of anticancer drugs,
because of the wide therapeutic window potentially available for a drug that targets only
cells metabolizing glucose by aerobic glycolysis. If the glycolytic phenotype in affected
tumor cells could be reversed, changes in the mitochondria that suppress apoptosis, or
programmed cell death, would probably also be reversed. Such a drug would switch on
apoptosis in cancer cells, a valuable characteristic for an antitumor agent. The design of
such a compound was not previously pursued with much interest because the activation
of aerobic glycolosis in many cancers was thought to be a result of cancer and not a
cause. Furthermore, it was unknown whether reliance on glycolosis for energy
production could be reversed in cancer cells. 3 The connection between the metabolic
change in cancer cells and suppression of apoptosis4 and evidence that apoptosis could
be increased by a small molecule kinase inhibitor5 have recently greatly energized the
search for anticancer therapies that exploit the Warburg effect.
The apoptosis resistance that characterizes many human cancers is regulated by
hyperpolarization of the mitochondrial membrane and downregulation of the K+ channel
Kv1.5.3 Dichloroacetate is an existing generic drug that is a small-molecule inhibitor of
PDK1, a protein kinase that inactivates pyruvate dehydrogenase (PDH), a mitochondrial
enzyme, by phosphorylating its El subunit.6 PDH plays the role of gatekeeper in the
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metabolism of glucose by determining whether glucose will undergo glycolysis in the
cytoplasm or glucose oxidation in mitochondria.
DCA increases the level of pyruvate in the mitochondria, thereby promoting
glucose oxidation and increasing apoptosis in the tumor. 2 The antitumor effect has been
proven in rats,3 and a long-term clinical trial of oral DCA in children with lactic acidosis
suggests that DCA will be safe at the doses required for treatment of cancer.4
The Lippard lab has modified of cisplatin with two molecules of DCA via a
synthetically facile, rapid, high-
yielding method.7 The aim of 0
the work described here has 0 HC
been to characterize this Ci ,NH3ivt Pt
compound, mitaplatin, in vitro CI
and to compare its antitumor H I cisplatin
properties to those of cisplatin O +2 DCA
and oxaliplatin. Mitaplatin has Imitaplatin]
H2  O
the potential for anticancer H 2
activity by acting through two
distinct pathways. Upon H2 O
exposure to a reducing agent, oxaliplatin
mitaplatin is transformed into
Scheme 7.1. Mitaplatin, cisplatin and oxaliplatin.
one molecule of cisplatin plus
two molecules of DCA (Scheme 7.1). Cisplatin is a widely used, clinically effective
platinum(ll) anticancer drug that derives its anticancer activity by forming DNA-platinum
adducts and triggering cellular responses to the DNA damage. The anticancer activity of
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DCA is based on its activity in the mitochondrial of cancerous, but not healthy cells, as
described above.
Results
Single-Agent Study: Antiproliferative effects of mitaplatin given as a single agent in a
panel of human cancer cell lines.
A panel of 10 cancer cell lines of different origins was exposed to mitaplatin for 24
h and then assessed for cytotoxicity by the MTT assay. Simultaneous assays were
performed in the same manner in the 10 cell lines with cisplatin and oxaliplatin. Table
7.1 represents the concentrations required to achieve 50% growth inhibition (IC50) in our
panel of cancer cell lines and the standard deviation for at least three experiments, each
done in triplicate. A comparison of cytotoxicity between the three drugs is represented in
Figure 7.1. Figure 7.2 represents the IC50 values in each of the 10 cell lines and Figure
7.3 shows cell survival for the different cell lines at concentrations ranging from 0.1-160
liM of cisplatin (7.3A), oxaliplatin (7.3B), and mitaplatin (7.3C).
Mitaplatin had a cytotoxicity profile similar to that of cisplatin in all cell lines
(Figures 7.1 and 7.2). The mitochondrial effects of mitaplatin were not apparent in the
cytotoxicity profile generated by comparision of IC50 values (Figure 7.1). Mitaplatin was
at least as potent as cisplatin and oxaliplatin. It is likely that more DCA per molecule is
needed for effect of the mitochondrial activity of the drug to be manifest in IC50 values.
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Cell Line Cancer Type IC50 Cisplatin ICso Oxaliplatin IC5so
Mitaplatin
HT-29 Colorectal 11.9 + 4.1 pM 6.65 + 1.0 pM 10.1 + 4.1 pM
MDA-435 Breast /Melanoma 5.81 + 4.0 pM 12.7 + 5.6 pM 8.86 + 4.2 pM
HCT-116 Colorectal 4.22 + 2.5 pM 1.10 + 0.28 pM 5.57 + 3.4 pM
HCC2998 Colorectal 11.8 + 4.0 pM 7.27 + 2.3 pM 11.8 + 4.8 pM
COL0205 Colorectal 16.7 + 7.2 pM 2.84 + 0.64 pM 26.0 + 6.3 pM
MCF7 Breast 15.6 + 6.4 pM 1.70 + 0.54 pM 12.3 + 6.0 pM
OVCAR3 Ovarian 5.10 + 3.0 pM 1.24 + 0.30 pM 5.67 + 1.7 pM
IGROV1 Ovarian 5.64 + 1.3 pM 8.08 + 2.9 pM 6.03 + 2.3 pM
HOP92 Non-Small Cell 3.55 + 3.2 pM 2.70 + 0.60 pM 7.24 + 4.1 pM
Lung
HOP62 Non-Small Cell 3.56 + 1.4 pM 6.86 + 0.39 pM 2.74 + 0.8 pM
Lung
Table 7.1. IC50 values for mitaplatin, cisplatin and oxaliplatin in the 10-cell line panel. Values
represent the mean of three independent experiments, each performed in triplicate, and the
standard deviation.
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Figure 7.1. Mean graphs for IC50. Bars depict the deviation of individual cell lines from the overall
mean value for all the cells tested.
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Figure 7.3. Cytotoxicity of cisplatin (A), oxaliplatin (B), and mitaplatin (C) in the studied cancer cell
lines given for 24 h. Plots reflect the mean and standard deviation of results from three separate
experiments, each performed in triplicate.
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Single-Agent Study: NCI60 Single Dose and Five-Dose Study
Mitaplatin was submitted to the National Cancer Institute (USA) for single agent
testing in 2008 by Shanta Dhar of the Lippard lab. The compound was tested in a panel
of 60 cell lines at a single dose, 10-5 M as described.8 Analysis by the online COMPARE
algorithm on January 13, 2009 revealed that mitaplatin had a correlation score of 0.719
with cisplatin.
Single-Agent Study: Antiproliferative Effects of Mitaplatin Over Time
A non-small cell lung cancer cell line, HOP-62, was treated with mitaplatin,
cisplatin, or oxaliplatin for 1, 2, 5, 24, 48, or 72 h. After the specified time, the plates
were washed and the medium replaced with drug-free medium. The MTT assay was
performed after 48 h of incubation in drug-free medium. Results in Figure 7.4 are
reported as the mean IC50 plus and minus the standard deviation of at least three
separate experiments performed in triplicate. The cytotoxic effects of mitaplatin
increased over the entire time period tested, meaning cytotoxicity increased even up to
72 h, indicating that the compound or biological modifications thereof, retain some
cytotoxic characteristics even after extended incubation in cell medium. Similar results
were found for both cisplatin and oxaliplatin.
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Figure 7.4. Antiproliferative effects of mitaplatin, cisplatin, and oxaliplatin over time.
Single-Agent Study: Antiproliferative Effects of Mitaplatin Evaluated by Cellular Protein
Content and by Mitochondrial Activity
Two cell lines, the ovarian cancer line OVCAR-3 and the colon cancer line COLO
205, were used to compare the antiproliferative effects of mitaplatin on the basis of
cellular protein content and mitochondrial activity. Cells were treated for 24 h with either
mitaplatin or cisplatin, washed, and incubated for 48 h in drug-free medium. Proliferation
was assayed by either the MTT assay, which measures mitochondrial activity, or by the
SRB assay, which measures cellular protein content. Figure 7.5 shows the similarity of
results obtained for either cisplatin or mitaplatin using either the protein content assay or
the mitochondria-based tetrazolium assay. The results obtained using the two assays
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are very similar. These results suggest that the mitochondrial effect of mitaplatin is not
evident, at least at the time points, concentrations, and conditions studied. Additionally,
the results reinforce the validity of the MTT assay for use in the evaluation of dose-
dependent cell survival after treatment with cisplatin or mitaplatin.
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Figure 7.5. Comparison of results obtained by evaluation of protein content or mitochondrial
activity for cisplatin (top) and mitaplatin (bottom) in OVCAR-3 (left) and COLO 205 (right).
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Mechanism of Action
Mechanistic Study: Cell Cycle
Effects on the cell cycle due to administration of mitaplatin were examined after
24 h incubation with the platinum at the IC50 value in the MCF-7 breast cancer cell line.
Cells were stained with propidium iodide and analyzed immediately by flow cytometry.
As shown in Figure 7.6, both cisplatin and mitaplatin initiate accumulation of cells in the
S phase, with the relative percentages of cells in each phase being nearly identical for
both drugs.
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Figure 7.6. Analysis of the effects
treatment at the IC50 value for 24 h.
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of platinum drugs on cell cycle progression in MCF-7 after
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Mechanistic Study: Antiproliferative Effects of Mitaplatin and p53 Status
Cells of the HCT-116 colon cancer cell line were obtained from the Mario Negri
Institute for studying the effect of p53 status on mitaplatin cytotoxicity. The p53 status of
HCT-116 is wild-type. HCT-116 cells with disrupted p53, a cell line termed E6, were
produced by stable transfection of HCT-116 with the human papillomavirus type 16 E6
gene. As a control, HCT-116 cells transfected with an empty plasmid, termed pcDNA,
were included in the study.
Antiproliferative effects of mitaplatin were evaluated by MTT after 24 h treatment
with the drug, followed by a 48 h incubation period in drug-free medium. Figure 7.7
reports the results of three experiments, each performed in triplicate.
Mitaplatin, pcDNA and p53 -/- (E6)
1.0 -e- pcDNA
-- E6 p53 --
0.5
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Figure 7.7. Effect of p53 status on mitaplatin, cisplatin and oxaliplatin antiproliferative effects.
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Mechanistic Study: Antiproliferative Effects of Mitaplatin and MMR Pathway Status
Cells of the HCT-116 colon cancer cell line were obtained from the Mario Negri
Institute for studying the interaction between the mismatch repair (MMR) pathway and
mitaplatin cytotoxicity. HCT-116 has a homozygous mutation in the mismatch repair
gene hMLH1 on chromosome 3, which renders the MMR pathway inactive. The p53
status of HCT-116 is wild-type. A cell line with an active MMR pathway, HCT-116 + ch3,
was obtained after insertion of a single copy of chromosome 3. HCT-116 cells proficient
in MMR and with disrupted p53, a cell line termed N8, were produced by stable
transfection of HCT-116+ch3 with the human papillomavirus type 16 E6 gene. As a
control, HCT-116 cells transfected with an empty plasmid, termed pcDNA, were
included in the study. Cytotoxicity in these lines was evaluated by MTT after 24 h of
drug treatment and 48 h of incubation in drug-free medium (Figure 7.8).
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UM1
10 20 30 40 0 10 20 30 40
[Cisplatin] (pM) [Oxaliplatin] (pM)
Effect of MMR pathway status on antiproliferative effects of mitaplatin, cisplatin and
Results are the average of three experiments, each performed in triplicate.
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Mechanistic Study: Determination of factors predictive of sensitivity to mitaplatin
We have analyzed the correlation of the mRNA levels of 19 genes (Table 7.2)
with the IC50 values of mitaplatin (Figure 7.9).
Table 7.2. Genes analyzed for correlation of mRNA levels with ICso values.
Gene Area/Pathway of Interest
ERCC1
XPA Nucleotide Excision RepairXPC
(not shown, no correlation)
PARP1
XRCC1 Base Excision Repair
RAD50BRCA1 Homologous Recombination
DNA-PK-csXRCC6 (ku) Non-homologous end-joining (NHEJ)XRCC6 (ku70)
MSH2 Mismatch RepairMLH1
BCL2
PUMA ApoptosisCOX2
(not shown, no correlation)
Ki67 Cell Growth
CDKN1A (p21) Cell Cycle Regulation
ABCB1
(not shown, no correlation) Influx/Export Transporters
ABCC1
GSTP1
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Figure 7.9. Correlation of mitaplatin IC50 values and expression levels of genes of interest.
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Evaluation of protein markers of apoptosis in HOP 62 cells
Western blots were performed by Shahin Emami at Saint-Antoine to determine
the effect of mitaplatin treatment on Chk2 and gamma-H2AX phosphorylation. HOP 62
cells were treated at the IC50 values of each drug for 24 h. The platinum-containing
medium was then removed and protein content was determined 0, 24, 48, or 72 h
following removal of the platinum. The top panel of figure 7.10 tentatively indicates the
appearance of a band at 62 kDa for Chk2 in cells treated with either cisplatin, oxaliplatin,
or mitaplatin. The bottom panel of Figure 7.10 shows the appearance of a band at 25
kDa for cisplatin, oxaliplatin and mitaplatin, which corresponds to the phosphorylated
form of y-H2AX, indicating the induction of apoptosis based on DNA double-strand break
formation.
Control Cisplatin Oxaliplatin Mitaplatin
Time elapsed after removal of platinum (h):
0 24 48 72 0 24 48 72 0 24 48 72 Chk2
I62 kDa
y-H2AX
*5 kDa
a-Tubulin
Figure 7.10. Levels of chk2 (top) and y-H2AX (bottom) after 24 h treatment at the IC50 values with
platinum followed by incubation in drug-free medium for 0, 24, 48, or 72 h. The a-tubulin blot is
used as a loading control.
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Discussion
Mitaplatin is a dual-functional drug designed to affect only the cancer cell
mitochondria, not the mitochondria of healthy cells, and also to cause the cytotoxic,
DNA-damaging, transcription-inhibiting effects of cisplatin. The fact that it is a
platinum(IV)-derivative of cisplatin is both an advantage and a disadvantage. It is at
least as potent as cisplatin in all cell lines studied and mechanistic studies reveal that
the mitaplatin mechanism of action is very similar to that of cisplatin. The disadvantage
is that, because it is an analog of a well-known and well-studied class of drug, mitaplatin
should show significantly improved cytotoxicity over cisplatin and proof of a significantly
different spectrum of activity in order to attract funding for clinical trials. An independent
measure of the difference of activity between mitaplatin and cisplatin was obtained due
to the results of the NCI60 single-dose screen.8 In the NCI's online COMPARE assay,
the correlation between cisplatin and mitaplatin was 0.7, a score that, in this context,
indicates a very high degree of similarity between the two compounds. Future
modifications of mitaplatin should aim to show a correlation of 0.4 or lower in the NCI60
single dose screen to secure interest in funding of clinical trials.
Conclusions
Although it is a promising, intelligently designed dual functional platform for
delivery of both cisplatin and dichloroacetate, the dual functional properties of mitaplatin
are not apparent in data collected using in vitro models. The cytotoxicity profile, cell
cycle results and potential predictive factors (mRNA vs. IC50 correlation results) are very
similar to that of cisplatin. The results suggesting the similarity of mitaplatin and cisplatin
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are supported by the correlation factor between the two compounds of 0.719 found
using the NCI's COMPARE algorithm.
Potential strategies to either deliver more DCA per molecule of cisplatin or to
ensure that the molecule is not reduced prior to entry into the cell will likely yield
compounds of great interest for use in the clinic, especially considering the high potency
of this compound relative to other known Pt(IV) compounds.
Materials and Methods
Cell Lines and Reagents
Colorectal cancer cell lines HT-29, HCT-116, HCC2998, and COLO 205, breast
cancer line MCF-7, melanoma line MDA-435, ovarian cancer lines OVCAR-3 and
IGROV-1, and non-small cell lung cancer line HOP-92 and HOP-62 were obtained from
the American Type Culture Collection (Rockville, MD, USA) and maintained in RPMI
medium supplemented with 10% fetal bovine serum. The p53 (-/-) cell lines and MMR
proficient cell lines had previously been derived from HCT-116 cells as described9'10 and
were provided by Massimo Broggini of the Mario Negri Institute, Milan. The HCT116-
pcDNA, HCT116-ch3, HCT116-E6, and HCT-116-N8 cell lines were maintained in
medium supplemented with the antibiotics G418 (Sigma) or G418 and Hygromycin B
(HCT116-N8 only, Sigma). All cell lines were regularly tested for mycoplasma
contamination by PCR using a Stratagene kit (La Jolla, CA, USA). Cisplatin and
oxaliplatin were obtained from the Beaujon University Hospital Pharmacy.
In vitro growth inhibition assays
Cells were plated in 96-well plates at 2 x 103 cells per well. Twenty-four hours
after plating, the medium was replaced with platinum-containing medium. Cells were
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incubated with platinum for 24 h, or as indicated in the text. After the 24 h incubation
with drug, wells were washed with RPMI and cells were incubated in serum-containing
medium for 72 h. Cell viability was determined either by detection of mitochondrial
cleavage of the tetrazolium ring of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide) by absorption at 562 nm as described11 or by detection of
sulfrhodamine B as described. 12
Cell Cycle Analysis
Analysis of cell cycle effects of mitaplatin were evaluated after incubation of HOP-
62 cells with either mitaplatin, cisplatin, or oxaliplatin at the IC5o values (Table 7.1) for 24
h. Immediately after the 24 h incubation, cells were collected, stained with propidium
iodide and analyzed by flow cytometry as described. 13
RT-PCR
Total RNA was extracted from all cell lines at the same passage used for the
cytotoxicity studies. The Trizol reagent (Invitrogen), composed of guanidinium
thiocyanate, phenol, chloroform, and isoamyl alcohol, was used to facilitate the
extraction. RT-PCR was performed as described 4,15 to detect mRNA for the genes
listed in Table 7.2.
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Appendix A.
Examination of the Platination of Plasmid DNA in Carbonate Buffer
Parts of this material have been published in Todd, R.C.; Lovejoy, K.S.; Lippard, S.J.
"Understanding the effect of carbonate ion on cisplatin binding to DNA." J. Am. Chem.
Soc. 2007, 129, 20, 6370-6371. The work described below is that of the author of this
thesis.
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Introduction
Upon IV introduction of cisplatin into the blood of a cancer patient, the
electrophilic Pt(llI) center is exposed to many nucleophilic species, including
carboxylates, amines, and thiols, that are potential reaction partners.' Sulfur-containing
species such as the tripeptide glutathione and the amino acids cysteine and methionine
have a particularly high affinity for platinum(ll). The species Pt(Met)2 is one of the few
characterized metabolites of cisplatin2' 3 and glutathione, present at mM concentrations
in much of the human body, plays a large role in deactivating cisplatin. Besides
complexes with sulfur-containing small molecules, many other platinum species exist in
the bloodstream and cells of patients receiving cisplatin therapy. Platinum(Il) complexes
of amino acids as the N,O-chelates have been synthesized using combinatorial
synthesis.4' 5 Logically, cisplatin also forms complexes with proteins. Much of the Pt(II)
found in human blood plasma is bound to serum albumin as a Met-S,Nchelate, for
example. 6 Another example of protein-cDDP complexes is with the iron carrier
transferrin, for which a cisplatin binding site has been characterized.7'8
Cisplatin also reacts with buffering agents, including carbonate and phosphate.1
Recent studies on the platinum interaction with carbonate ion should therefore not be of
special interest to the cisplatin scientific community. The assertion, based on two-
dimensional ['H, 15N]HSQC NMR, that the cis-[Pt(NH 3)2CI(OC0 2)] ion is the active
adduct-forming species in biological systems9-11 does require closer scrutiny, however.
We do not propose to have developed a superior method for identifying the
multitude of transient [Pt(NH 3)2CI(X)] species (X= O-coordinating ligand) in complex
biological media. We instead intend to use the basic techniques of HPLC, agarose gel
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electrophoresis, and measurement of rb/rf values to investigate the cisplatin-DNA
interaction in carbonate buffer and to correct some recent literature.
Experimental
Platination of Plasmid DNA
Plasmid pBR322 was purchased from New England Biolabs and amplified in a
100 mL LB culture of e. coli XL1-Blue cells with ampicillin as a selecting agent. The
plasmid was purified on a Maxi-prep column (Qiagen), ethanol precipitated, analyzed by
agarose gel electrophoresis, and used for platination reactions. Platination reactions
were done in 19.2 pM DNA (with respect to bp), 23.8 mM of buffering agent (NaHCO 3,
NaH 2PO 4, or Hepes), pH 7.4, and 5 mM NaCI in a total volume of 120.4 tpL. Cisplatin
concentrations varied from 1.5 jiM to 60 jIM and rf values varied from 0.078 to 3.13.
Reactions were incubated for 24 h at 37 0C in the dark and dialyzed for 24 h against 10
mM Tris-HCI, pH 7.4, 1 mM EDTA to remove excess platinum.
Measurement of rb Values
DNA concentrations were quantified by measuring the absorbance of the
dialyzed solutions at 260 nm on a Cary 50 Bio UV-Visible Spectrometer equipped with a
microprobe (C Technologies Inc.). Platinum concentrations were measured by atomic
absorption spectroscopy using an AAnalyst 300 equipped with an HGA-800 graphite
furnace and operated through the AAWinLab interface, version 3.0 (Perkin Elmer,
Wellesley, MA). A hollow cathode platinum lamp with 265.9 nm emission was used with
a slit width of 0.70 nm. Pyrolysis was performed at 12000 C for 20 s and atomization at
26500C for 5 s. AA samples were measured in duplicate using a calibration range of 20-
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80 pg/L and an r value of > 0.998 for all calibration curves. For samples requiring
dilution, dialysis buffer was used. The dialysis buffer was analyzed by both AA and UV-
Vis and no detectable platinum or DNA signals were observed.
Agarose Gel Analysis of Platination
A portion of 8 gL of each of the above samples was removed immediately
following the 24 h incubation and 1 pL of a loading solution containing 50% glycerol,
0.05% bromophenol blue, and 0.05% xylene cyanol was added. Samples were loaded
in 1% agarose gels prepared with 1x TAE (40 mM Tris-base, pH 8.0, 20 mM acetic acid,
1 mM EDTA) and gels were allowed to run for 4 h at 75 W at room temperature. Gels
were stained in 500 mL of deionized water with 1 pg/mL ethidium bromide for 15 min,
followed by 60 sec of destaining in deionized water. Imaging was done on a Fluor-S
(BioRad) and processed using QuantityOne software (BioRad).
Results and Discussion
Platination of Plasmid DNA
Our measurements of rb values for platination reactions in phosphate, Hepes and
carbonate buffer indicate that significantly less platinum binds to DNA in phosphate or
carbonate as compared with Hepes buffer (Figures 1 and 2). Slightly less platinum
binds in carbonate than in phosphate buffer.
Agarose gel electrophoresis of platinated plasmid DNA indicates a point at which
the unwinding due to platinum has completely removed all supercoils from the DNA
(coalescence point) for the platination in Hepes buffer at rb = 0.138 (Figure 3).
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Figure A.1. Platinum bound per nucleotide (rb) for the platination of plasmid DNA as a function of
platinum added per nucleotide (rf) for reactions at pH 7.4 in Hepes, phosphate, or carbonate
buffer.
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Figure A.2. Plot of (rb) vs. (rf) for low platination levels (expansion of Figure A.1).
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Figure A.3. 1% agarose gels showing DNA platinated at rf values from 0.078 to 3.13 (rf
increases from left to right). Top: platination in carbonate buffer; Middle: platination in
phosphate buffer; Bottom: platination in hepes buffer. Numbers correspond to rf
values: 1, 0.078; 2, 0.091; 3, 0.104; 4, 0.117; 5, 0.13; 6, 0.143; 7, 0.156; 8, 0.26; 9, 0.52; 10,
0.78; 11, 1.04; 12, 1.3; 13, 1.56; 14, 1.82; 15, 2.08; 16, 2.34; 17, 2.6; 18, 2.86; 19, 3.13.
The coalescence point for platination in phosphate and carbonate buffers is not
observed at these rf values and will be > 0.139 in phosphate buffer and > 0.080 in
carbonate buffer. In phosphate buffer, the high rb value of the coalescence point as
compared with Hepes indicates that a greater level of platination is required to achieve
DNA unwinding equal to that seen in Hepes buffer. Monofunctional platinum adducts
unwind the DNA to a lesser extent than do bifunctional adducts. The complete
unwinding of the DNA supercoil, marked by the coalescence point on the agarose gel, is
therefore reached for compounds forming monofunctional adducts at a higher rb value
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than for bifunctional adducts. 1 2 Assuming that only bifunctional cisplatin-DNA adducts
are formed in Hepes buffer, the reduced unwinding-per-Pt seen in phosphate buffer
indicates that some monofunctional adducts are formed. Similar information about
adducts formed in carbonate buffer was not obtained. Despite repeated attempts, the
persistently low level of platination in carbonate buffer always precluded any possibility
of observing a coalescence point.
Conclusions
Numerous side reactions occur upon the introduction of cisplatin into biological
matrices. These side-reactions, which are mostly deactivating, include interactions with
ions such as phosphate and carbonate, as well as interactions with proteins, small
molecules, and RNA.
Recent reports of the interaction of cisplatin with carbonate suggest that platinum
carbonato species are the active species in reactions of cisplatin and carboplatin with
DNA, 9 that carbonate activates carboplatin ([Pt(NH 3)2(CBDCA)] by displacing one side
of the chelating ligand," and that a monocarbonato Pt(ll) species enters Jurkat cells.10
Although carbonate does displace bidentate dicarboxylate ligands from the Pt(ll)
center,13 there is no evidence to support a persistent Pt(ll)-carbonato species in
biological matrices, nor is there evidence suggesting the existence of long-lived
monodentate adducts on DNA in vivo.
Monofunctional adducts on DNA in 0.2 M carbonate have been detected
immunochemically 14 and 195Pt-NMR studies of aquated cisplatin in 10 mM sodium
phosphate buffer shows the presence of a peak at -1736 ppm that does not appear
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when the reaction is done in pure water.15 These and other results suggest that
monofunctional DNA-platinum adducts can exist in various buffers under highly
controlled, in vitro conditions. However, strong evidence exists for the formation of
predominantly bifunctional adducts on DNA under biological conditions 16'17 and for the
facile deactivation of cisplatin by carbonate and phosphate, among other buffering
agents.1 Furthermore, cells grown in 5% CO 2 show the same sensitivity to cisplatin as
cells grown in 10% CO 2 (Hepes-buffered to pH 7.4 in both cases), a preliminary
indication that cytotoxicity is independent of [CO 2] in the culture medium. 18
Also interesting is a review of 15N-NMR and 1H-NMR spectroscopy on cisplatin in
various buffering systems. Plots from three figures in papers spanning 11 years attribute
the peak at (6(1H), 6( 15N)) = -(3.6,-85) in the two-dimensional [1H,15 N]HSQC NMR
spectrum of cisplatin to cis-[Pt(15 NH3)2(OH)CI]19 (Figure 5, in RPMI medium, later
ascribed to the monocarbonato formg), either cis/trans-[Pt(15 NH3)2(OH)CI] or cis/trans-
[Pt(15NH3)2(OH 2)Cl] + (Figure 1, 10 mM sodium phosphate), 20 or cis-[Pt(NH 3)2CI(OCO2)]
(Figure 2, 5 mM sodium bicarbonate).
Our measurements of rb values for platination reactions in phosphate, Hepes and
carbonate buffer indicate that significantly less platinum binds to DNA in phosphate or
carbonate as compared with Hepes buffer. Slightly less platinum binds in carbonate
than in phosphate buffer. Agarose gel electrophoresis of platinated plasmid DNA
suggests that predominantly bifunctional adducts form during platination reactions in
Hepes or phosphate buffers. In carbonate buffer, agarose gels could not yield
information about the mode of binding because the highest platination levels achieved
were too low for observation of supercoil unwinding behavior. It is noted that the
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experiments performed do not directly address the nature of the platinum adducts
formed in biological matrices. The results may instead be useful for researchers
platinating DNA in vitro.
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Appendix B:
Cellular properties of a cell-permeable Zn 2+-sensitive MRI contrast agent and the
Effect of Zinc Chelators on Cisplatin Cytotoxicity.
A portion of this material was published as part of Zhang, X-a., et al. "Water Soluble
Porphyrins as a Dual-Function Molecular Imaging Platform for MRI and Fluorescence
Zinc Sensing," 2006, Proc. Natl. Acad. Sci. USA.
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The Effect of Zn2+ Chelators on Cisplatin Cytotoxicity
Background and Methods
The cytotoxicity of cisplatin in combination with three compounds capable of
coordinating Zn 2 + was evaluated. The calcium salt of EDTA chelates many divalent
metals, including zinc, and is cell membrane-impermeable. TPEN is a cell membrane-
permeable Zn 2+ chelator, and ZX1 is a cell membrane-impermeable Zn 2+ chelator
(Scheme B.1). We wished to test the hypothesis that chelating the zinc released upon
induction of apoptosis would affect the cytotoxicity of the apoptosis-inducing agent
cisplatin. COO- OOC Na2+2
(A) C Ca coo-
Ethylenediaminetetraacetic acid calcium
disodium salt
(Ca-EDTA)
(B)
N N
N,N, N',N'-tetrakis(2-pyridylmethyl)ethylenediamine
(TPEN)
(C) S03
IN
NH N
N
XAZ Cell Impermeable Chelator
(ZX1)
Chart B.1. Zn2+ chelators used in an attempt to potentiate cisplatin cytotoxicity.
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For the cytotoxicity experiments, HeLa ovarian cancer cells were incubated at
37 0C in 5% CO 2 and grown in DMEM supplemented with 10% fetal bovine serum, 1%
penicillin/streptomycin, and 1% 1 M Hepes buffer (pH 7.4). Cells were plated at 300
cells per well of a 96 well plate, reduced from the usual 500 cells per well to allow for
possible acceleration of cell growth. After 24 h, cisplatin was added to concentrations of
0, 0.5, 1, 2, 5, 10, 15, 20, and 50 pM. The platinum-containing medium was removed
after 7 h, Zn 2 + chelators were added at concentrations of 1.5 pM (TPEN) or 150 pM
(XAZ) and cells were incubated for four more days. For the assays done without
cisplatin, Zn2 + chelators were directly added at various concentrations 24 h after cell
plating. In all cases, cell survival was quantified by the MTT assay after a total of five
days of growth.
Results and Conclusions
Plots of the cytotoxicity data are shown in Figure B.1. No statistically significant
difference in cytotoxicity was observed in the experiments in which cisplatin and
chelators were combined. The cytotoxicity data for the zinc chelators is shown in Figure
B.2. TPEN is the most toxic of the Zn2 + chelators, with an IC50 of 3.8 IpM and neither of
the cell membrane-impermeable sensors showed measurable toxicity within the wide
range of concentrations tested.
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Figure B.1.Cytotoxicity assay showing the effect of Zn chelation on cisplatin cytotoxicity.
In conclusion, these experiments have shown that the two cell-impermeable
chelators can be used in cells at high concentrations without worry of toxicity.
Potentiation of cisplatin cytotoxicity due to chelation of extracellular zinc was not
observed in this study.
If this investigation were continued, it is suggested that the amount of zinc in
various batches of fetal bovine serum be quantified, because it may vary widely
between batches. The amount of zinc released during apoptosis should be compared to
the amount already in fetal bovine serum to determine if the difference in [Zn 2+] after
apoptosis is relevant. Finally, a fluorescent zinc detector should be employed to verify
that Zn2 + release actually occurs in the chosen transformed cell line. In general, either
neuronal or pancreatic cell lines may be better choices for the study than HeLa.
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Figure B.2. Cytotoxicity assays showing the cell toxicity of various Zn2+ chelators.
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Cellular properties of a cell-permeable Zn2+-sensitive MRI contrast agent
Background
A molecular platform for dual-function fluorescence/MRI sensing of mobile zinc
was synthesized by Xiao-an Zhang. Zinc-selective binding units were strategically
attached to a water-soluble porphyrin template. The metal-free form, (DPA-C 2)2-TPPS 3
(1), where DPA is dipicolylamine and TPPS 3 is 5-phenyl-10,15,20-tris(4-
sulfonatophenyl)porphine, was found to be an excellent fluorescent sensor for zinc. The
manganese derivative, [(DPA-C 2)2TPPS 3Mn(III)] (2), switches the function of the
molecule to generate an MRI contrast agent (CA). Both metal-free and Mn(lll)-inserted
forms are efficiently taken up by live cells, and the intracellular zinc can be imaged by
either fluorescence or MR, respectively.
Cell Culture
Suspension-adapted HEK-293 cells (Free-Style 293-F cell line; Invitrogen,
Carlsbad, CA) were grown in 125 mL shaker flasks containing FreeStyle 293
Expression Medium (Invitrogen). Cultures were maintained at >90% viability by shaking
at 125 rpm in a 370C incubator with 8% CO 2 and subculturing at a 1:10 ratio upon
reaching a density of 2 x 106 cells/mL. Cell density and viability were evaluated with a
hemocytometer using 0.4% trypan blue staining. Cell pellets for MRI were prepared in 6
mL suspension cultures, to which either 2 or Mn-TPPS 4 was added to a final
concentration of 100 pM, and incubated for 24 h. Where appropriate, zinc carried by the
ionophore pyrithione was subsequently added to 200 pM, followed by incubation for an
additional 10 min. Cell suspensions were thrice pelleted (10 min, 500 x g) and washed
with phosphate-buffered saline (PBS), and the resulting loose pellet was inserted into
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microtiter plates for imaging. Slides of cells growing in adherent monolayers were
prepared by plating the suspension-adapted HEK-293 cells in 25 cm 2 flasks containing
Dulbecco's Modified Eagle's Serum (DMEM; Invitrogen) with 10% fetal bovine serum
(Hyclone, Logan, UT). After subculturing five times, cells were grown to 70% confluence
on poly-D-lysine-coated glass cover slips and incubated with 5 1pM of 1 for 24 h. Cells
were then either incubated with 40 lM zinc carried by pyrithione for 10 min, fixed in 4%
paraformaldehyde, washed with PBS and stained with Hoechst 33258 (0.4 pM, 10 min
incubation in PBS), or directly fixed, stained with Hoechst dye, and imaged.
Fluorescence Microscopy
The cell fluorescence imaging experiments were performed with a Zeiss Axiovert
200M inverted epifluorescence microscope, equipped with a Hamamatsu EM-CCD
digital camera C9100, and a MS200 XY Piezo Z stage (Applied Scientific Instruments,
Inc.). An X-Cite® 120 metal-halide lamp (EXFO) was used as the light source. The
fluorescence images were obtained by using a 63x oil immersion objective lenses and a
customized optical filter (exciter: D425/50, emitter: E600Ip, beamsplitter: 460dcxr,
Chroma Technology Corp.). The microscope was operated with Volocity software
(Improvision).
Manganese Atomic Absorption Spectroscopy
Cell monolayers were grown in 75 cm 2 plates to 70% confluence and treated with
100 jpM of either 2 or Mn-TPPS 4, followed by incubation for 24 h. All fractionation steps
were performed at 40C. After twice pelleting by centrifugation (500 x g) and washing
with PBS, cells were gently resuspended in five packed-cell volumes of ice-cold lysis
buffer (10 mM Hepes, pH 7.9, 10 mM KCI, 1.5 mM MgCI 2, 1 mM dithiothreitol, 2 mM
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phenylmethylsulfonyl fluoride) and incubated on ice for 15 min. After centrifugation (420
x g, 5 min) the pellet was resuspended in 2 packed-cell volumes of lysis buffer. Cell
membranes were disrupted by drawing cells into a syringe with a 27-gauge syringe
needle and ejecting ten times. After centrifugation (11,000 x g, 20 min), the supernatant
was retained (cytosolic fraction) and the pellet was resuspended in 2/3 packed-cell
volume of extraction buffer (20 mM Hepes, pH 7.9, 25% glycerol, 0.42 M NaCI, 1.5 mM
MgCI2 1 mM dithiothreitol, 2 mM phenylmethylsulfonyl fluoride). The nuclei were
disrupted with ten strokes using a fresh syringe and the suspension was shaken at 50
rpm for 30 min at 40C and then centrifuged (20,000 x g, 5 min). The resulting pellet was
retained as the membrane fraction and the supernatant as the nuclear fraction.
Manganese atomic absorption spectroscopic analyses of samples were performed on
an Aanalyst 300 instrument equipped with an HGA-800 graphite furnace and using
AAWinLab, version 3.0 (Perkin Elmer, Wellesley, MA). A hollow cathode manganese
lamp with 279.5 nm emission was used with a slit width of 0.2 nm. Pyrolysis was
performed at 1400 oC for 30 s and atomization at 2200 oC for 5 s.
Results: Intracellular Imaging
Because 1 (the metal free form, (DPA-C 2)2-TPPS3) is membrane-permeable in all cell
lines tested to date, it can be employed in intracellular imaging of zinc by fluorescence
microscopy. In order to use the same cell line for demonstration of both fluorescence
and MR imaging, we selected HEK-293. Suspension cultures of HEK-293 enabled
production of a sufficient number of cells for obtaining a cell pellet suitable for MRI and
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could alternatively be plated as an adherent monolayer for fluorescence imaging
studies. The latter, monolayer cultures were subcultured five times after the initial
plating to allow the cells to adapt fully, after which they were grown to 70% confluence
on glass cover slips and treated with 1 for fluorescence imaging. The cytotoxicity of 1
was evaluated in these adherent HEK-293 cells by incubating them with 5 gM 1 for 24 h.
Fig. B.3.. Fluorescence imaging of intracellular zinc in fixed HEK-293 cells labeled with 1, shown in
red, using a customized optical filter (exciter: D425/50, emitter: E6001p, beamsplitter: 460dcxr).
The cell nucleus was stained with Hoechst 33258, shown in blue. The HEK-293 cells were
incubated with 5 pM of 1 for 24 h prior to fixing. (A): Cells without addition of exogenous zinc; (B):
Cells incubated with 40 pM Zn2* carried by the ionophore pyrithione for 10 min before fixing. The
inlet pictures are the corresponding bright field images. Bars are 25 pm.
These cells were healthy as compared to control, untreated cells according to analysis
by cell counting and evaluation of viability using trypan blue and a hemocytometer.
Fixed cells investigated by fluorescence imaging using a customized optical filter, which
was especially designed to match the unusual excitation and emission profiles of 1. The
cell nuclei were co-stained with the blue fluorescent dye Hoechst 33258 (0.4 jiM). The
treated cells showed faint red fluorescence from 1; a significant increase in the red
fluorescence intensity occurred upon the addition of Zn 2+ (40 1M) carried by the
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ionophore pyrithione (2-mercaptopyridine-N-oxide), as shown in Fig. B.3 (B), indicating
that 1 is taken up by the cell and the intracellular Zn2+ can be detected by fluorescence
turn-on of 1. Thus, (DPA-C 2)2-TPPS3 (1) is a valuable zinc fluorescence sensor and can
be applied for intracellular zinc imaging.
Results: Cellular Uptake of (2)
As mentioned above, we chose to investigate a suspension-adapted HEK-293 cell
line, which tolerates high-density growth and can produce a sufficiently large cell pellet
for performing MRI in a multiwell plate. After a 24-h incubation with 100 pM 2, the cell
density was similar to that of untreated control cells, indicating that 2 has little cytoxicity.
Centrifugation and washing with phosphate-buffered saline (PBS) yielded a dark-green
cell pellet, a color typical of manganese porphyrins. This result indicates that 2 either
accumulated intracellularly or became associated with the cell membrane. By
comparison, the control cell pellet was pale white (Fig. B.4). To confirm the membrane
permeability and further investigate the sub-cellular localization of 2, the cells were
lysed, and nuclear and cytosolic fractions were extracted and analyzed by flameless
AAS (atomic absorption spectroscopy). The Mn absorption signal was calibrated by
using a standard solution of known concentration. The results indicated that 2 is cell
membrane-permeable and preferentially localizes in the nuclear fractions (5.62 mg
Mn/L), rather than in the cytosol (0.78 mg Mn/L). By contrast, no Mn AAS signal was
observed in the control cells under similar experimental conditions.
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To investigate zinc-induced relaxivity changes in 2 inside cells, MR images were
recorded and compared for cell pellets with and without exogenously introduced zinc.
The HEK-293 cell suspension was divided equally into two flasks following a 24-h
treatment with 100 pM 2. A 200 pM portion of zinc pyrithione was then added to one of
the samples and incubated for an additional 10 min. As in the solution studies,
comparisons were made by using Mn-TPPS 4 as a reference compound. In addition, an
untreated cell sample was prepared as a control. The cell suspensions were pelleted by
centrifugation, washed and transferred into a multiwell plate for MRI analysis.
Figure B.4. Photographs of pellets of HeLa cells incubated with 100 pM (DPA-C2)2-MnTPPS 3 (2) for
24 h (left) and the blank control cells (right). The darker-colored pellet indicates cellular uptake of
2. Similar results were obtained for HEK 293 cells.
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